A primary malignant neoplasm of epithelial liver cells. It ranges from a well-differentiated tumor with EPITHELIAL CELLS indistinguishable from normal HEPATOCYTES to a poorly differentiated neoplasm. The cells may be uniform or markedly pleomorphic, or form GIANT CELLS. Several classification schemes have been suggested.
| Excerpt | Reference |
|---|
| "Three cases of hepatocellular carcinoma are reported in young men who had been taking androgenic-anabolic steroids." | ( Baird, PJ; Farrell, GC; Joshua, DE; Kronenberg, H; Perkins, KW; Uren, RF, 1975) |
| "Primary hepatocellular carcinoma is one of the most common and lethal cancers in the world." | ( Groopman, JD; Kensler, TW; Roebuck, BD, 1992) |
| "Hepatocellular carcinoma is not only the leading cause of male cancer death in Taiwan, but also one of the most common cancers in the world." | ( Chi, CW; Liu, TY; Lui, WY; P'eng, FK, 1991) |
| "Hepatocellular carcinoma is the most common cause of cancer death in Thai males." | ( Auethaveekiat, V; Cheirsilpa, A; Kangsumrit, N; Leelasethakul, S; Maoleekulpriroj, S; Phanthumjida, P; Thanakaravit, P, 1989) |
| "Hepatocellular carcinoma is known to have a doubling time of approximately 41 days." | ( Fishman, EK; Guse, C; Klein, JL; Leibel, SA; Leichner, PK; Order, SE; Stillwagon, GB, 1989) |
| "Hepatocellular carcinoma is often an aggressive tumour and, if unresectable, carries a poor prognosis, especially in the presence of jaundice." | ( Blumgart, RL; Krige, JE; Rosen, A; Spence, RA; Temple-Camp, CR; Terblanche, J, 1987) |
| "Hepatocellular carcinoma is a rapidly fatal disease in most patients." | ( Friedman, M; Nerenstone, S, 1987) |
| "Advanced primary hepatocellular carcinoma is a rapidly fatal neoplasm." | ( Lim, F; Tan, YO, 1986) |
| "Primary hepatocellular carcinoma is a very rare disease, especially in association with a pregnancy." | ( Brucker, C; Debus-Thiede, G; Genz, T; Maassen, V; Schweiberer, L; Weiss, M, 1994) |
| "Hepatocellular carcinoma is the leading cause of male cancer death in Taiwan." | ( Chang, TJ; Chang, YF; Hsu, ML; Liu, TY; Lui, WY; P'eng, FK; Su, TS; Tsai, TF; Tsay, SH; Wu, CW, 1993) |
| "Hepatocellular carcinoma is a refractory cancer for the following two reasons: the tumor characteristics, including formation of tumor thrombus in the portal vein, metastasis within the liver and multicentricity of growth; and liver function disturbance due to cirrhotic change by B- or C-type viral infection." | ( Hatsuno, T; Kokuba, Y; Kurumiya, T; Nobuta, T; Suenaga, M; Sugiura, H; Yamanaka, H, 1995) |
| "Hepatocellular carcinoma is the third most common malignancy in Kenyan males occurring with a peak incidence at 40 years of age." | ( Gatei, DG; Mwangi, J, 1993) |
| "Hepatocellular carcinoma is different from other solid tumors." | ( Imamura, M; Kanai, F; Kato, N; Niwa, Y; Obi, S; Okudaira, T; Omata, M; Payawal, DA; Shiina, S; Shiratori, Y; Tateishi, R; Teratani, T, 1996) |
| "Unresectable hepatocellular carcinoma is related to a poor prognosis." | ( Colleoni, M; Liessi, G; Manente, P; Mastrapasqua, G; Nelli, P; Pancheri, F; Sgarbossa, G; Vicario, G, 1997) |
| "The hepatocellular carcinomas are very similar to human well-differentiated hepatocellular carcinoma in histopathological features and on MR images." | ( Fujita, N; Kajiyama, M; Miyasaka, K; Nakakoshi, T; Nakayama, N; Takeichi, N, 1997) |
| "Chemotherapy of hepatocellular carcinomas is hampered by the insufficient accumulation of cytostatic drugs within the tumor cells." | ( Beuers, U; Böker, C; Glasa, J; Grützner, U; Hagenbuch, B; Kramer, W; Kullak-Ublick, GA; Meier, PJ; Oswald, M; Paumgartner, G; Stieger, B; Wess, G, 1997) |
| "Hepatocellular carcinoma is one of the most malignant tumors in the world." | ( Geisen, FH; Graziadei, I; Kelly, T; Konwalinka, G; Schirmer, M; Vogel, W, 1998) |
| "Hepatocellular carcinoma is highly refractory to most chemotherapeutic agents." | ( Chasen, MR; Long, JE; Ruff, P; van Rensburg, CE, 1998) |
| "Since the stroma of hepatocellular carcinoma is composed of sinusoid-like structures, cancer cells are readily released from the primary tumor with possible injurious consequences." | ( Funahashi, S; Ishikawa, H; Iso, Y; Kitamura, M; Maeda, T; Matsumata, T; Nozoe, T; Okamoto, M; Suehiro, T; Yo, R, 1998) |
| "Hepatocellular carcinoma is one of the most common malignancies world wide." | ( Ahmad, S; Alam, A; Butt, AK; Khan, AA; Naqvi, AB; Shafqat, F; Shah, SW, 1998) |
| "Inoperable hepatocellular carcinoma is an incurable malignancy with no accepted standard therapy." | ( Clendennin, N; Johnston, A; Rudy, J; Stuart, K; Tessitore, J, 1999) |
| "Hepatocellular carcinoma is relatively rare in the United States, and the patterns of extrahepatic manifestations are diverse." | ( Beech, DJ; Mikesh, C; Simmons, B; UyBarreta, V, 2000) |
| "Hepatocellular carcinoma is often diagnosed at a late, inoperable stage for which there are no uniformly efficacious treatment available presently." | ( Chow, PK; Findlay, M; Machin, D; Tan, CK; Wong, C, 2000) |
| "Hepatocellular carcinoma is one of the most common cancers in the world." | ( Chau, GY; Chi, CW; Lin, HL; Liu, TY; Lui, WY, 2000) |
| "Hepatocellular carcinoma is similar to an adenoma, but typically occurs in a cirrhotic liver and has earlier washout of contrast." | ( Macdonald, GA; Peduto, AJ, 2000) |
| "Hepatocellular carcinoma is one of the most lethal malignancies and there is no effective preventive measure in this highly malignant disease to date." | ( Jung, MY; Kang, HJ; Moon, A, 2001) |
| "Hepatocellular carcinoma is a common malignancy and a major complication of untreated haemochromatosis." | ( Bridle, KR; Crawford, DH; Powell, LW; Ramm, GA, 2001) |
| "Hepatocellular carcinoma is one of the most common tumors worldwide." | ( Adams, MB; Christians, KK; Franco, J; Pitt, HA; Quebbeman, EJ; Quiroz, FA; Rilling, WS; Wallace, JR, 2001) |
| "The hepatocellular carcinoma is one of the most widely spread malignant tumors in the world." | ( Di Giacomo, P; Felici, G; Maceratini, R; Truemper, K, 2001) |
| "Hepatocellular carcinoma is a lethal disease and methods that develop effective cellular-based immunotherapy are needed." | ( Chen, Y; Dan, Q; Delgado, C; Jadus, MR; Jeffes, EW; Lowell, CA; Morgan, K; Morgan, TR; Sanchez, R; Wepsic, HT, 2001) |
| "The incidence of hepatocellular carcinoma is increasing in many countries." | ( Castagnetta, LA; Cervello, M; Dantona, F; Giannitrapani, L; Montalto, G; Terranova, A, 2002) |
| "Hepatocellular carcinoma is sometimes associated with p53 dysfunction and decreased p21(WAF1) expression." | ( Alric, L; Dubourdeau, M; Matsuura, Y; Miyamura, T; Pipy, B; Rousseau, D, 2002) |
| "Hepatocellular carcinoma is a typical hypervascular tumor." | ( Kim, KR; Kim, KW; Moon, HE, 2002) |
| "Hepatocellular carcinoma is a malignant tumor with a poor prognosis, particularly when it is unresectable." | ( Auriault, ML; Boivin, JF; Chayette, C; Cheaib, S; Deplus, R; Macaigne, G, 2002) |
| "Hepatocellular carcinoma is likely to accompany liver cirrhosis in which the portal pressure increases with portasystemic shunt." | ( Fukuda, Y; Matsuyama, K; Miyake, H; Tashiro, S; Yogita, S, 2004) |
| "Primary hepatocellular carcinoma is one of the most common malignancies worldwide." | ( Alexander, HR; Bartlett, DL; Beresneva, T; Feldman, ED; Helsabeck, C; Libutti, SK; Pingpank, JF; Rodriguez, M; Wu, PC, 2004) |
| "Hepatocellular carcinoma is one of the most common malignant diseases worldwide." | ( Antes, G; Galandi, D, 2004) |
| "Hepatocellular carcinoma is usually preceded by chronic inflammation." | ( Chang, B; Inoue, M; Nishiguchi, S; Nishikawa, M, 2005) |
| "Unresectable hepatocellular carcinoma is extremely difficult to treat." | ( Carr, BI; Geschwind, JF; Goin, JE; Goin, KA; Roberts, CA; Salem, R; Soulen, MC; Thurston, KG; Van Buskirk, M, 2004) |
| "Hepatocellular carcinoma is one of the most common malignancies worldwide." | ( Keeffe, EB; Nguyen, MH, 2005) |
| "Hepatocellular carcinoma is the eighth most frequent cancer in the world, accounting for approximately 500,000 deaths per year." | ( McKillop, IH; Schrum, LW, 2005) |
| "Hepatocellular carcinoma is highly resistant to chemotherapeutic agents, thus the need to discover effective therapeutic molecules to suppress cancer cell growth and to overcome drug resistance is urgent." | ( Alpini, G; Baroni, GS; Benedetti, A; Candelaresi, C; Macarri, G; Marucci, L; Sterpetti, P; Toksoz, D; Ugili, L, 2006) |
| "Hepatocellular carcinoma is known to be associated with underlying liver diseases, such as cirrhosis, hemochromatosis, and chronic viral hepatitis." | ( Chen, SC; Cho, WK; Cummings, OW; Filomena, CA; Hartley, MP, 2006) |
| "Hepatocellular carcinoma is a major cause of cancer-related deaths." | ( Avila, MA; Berasain, C; Castillo, J; Erroba, E; Lee, DC; Perugorría, MJ; Prieto, J; Santamaría, M, 2006) |
| "Hepatocellular carcinoma is a very common malignancy and is chemoresistant to currently available chemotherapeutic agents." | ( Chiang, PC; Guh, JH; Hsu, JL; Li, TK; Lin, CJ; Peng, CY; Wang, SW; Yeh, TC, 2007) |
| "The incidence of hepatocellular carcinoma is increasing in the United States and worldwide." | ( Almhanna, K; Kalmadi, S; Kim, R; Pelley, R, 2007) |
| "Hepatocellular carcinoma is in 90% of cases associated with cirrhosis and to preserve liver function while destroying the tumor is a main issue in these patients justifying the development of local percutaneous ablative therapies." | ( Beaugrand, M; Seror, O, 2007) |
| "Hepatocellular carcinoma is the most common primary tumour of the liver." | ( Achuthan, R; Horgan, KJ; Masannat, YA; McMahon, MJ; Meaney, J; Merchant, W; Munot, K, 2007) |
| "Hepatocellular carcinoma is highly chemoresistant to currently available chemotherapeutic agents." | ( Chiang, PC; Guh, JH; Huang, DY; Huang, YC; Kuo, SC; Lee, KH; Pan, SL; Teng, CM; Wang, SW, 2008) |
| "Hepatocellular carcinoma is a leading cause of global cancer mortality, with standard chemotherapy being minimally effective in prolonging survival." | ( Chow, PK; Goh, BC; Hor, H; Huynh, H; Kalpana, R; Lee, CK; Lee, HS; Lee, MH; Palanisamy, N; Salto-Tellez, M; Somani, A; Soo, KC; Soong, R; Tan, P; Tan, PH; Toh, HC; Wu, J; Yu, K, 2008) |
| "Hepatocellular carcinoma is rare, but increasing in prevalence in the United States." | ( Bekaii-Saab, T; Bloomston, MA; Patel, T; So, BJ, 2008) |
| "Hepatocellular carcinoma is one of the most common cancers in the world." | ( Chi, CW; Ko, PH; Liu, TY; Lui, WY; Uen, YH; Yin, PH, 2008) |
| "The incidence of hepatocellular carcinoma is increasing in many countries." | ( Elmaghraby, TK; Hafez, EE; Ibrahim, SS; Seufi, AM, 2009) |
| "Hepatocellular carcinoma is chemoresistant to many anticancer drugs." | ( Chiang, PC; Guh, JH; Hsu, JL, 2009) |
| "Hepatocellular carcinoma is the leading cause of death in cirrhosis." | ( Cabrera, R; Nelson, DR, 2010) |
| "Hepatocellular carcinoma is dramatically increasing in incidence that is mostly attributed to chronic hepatitis C and non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and its clinical phenotype diabetes and obesity." | ( Cabrera, R; Nelson, DR, 2010) |
| "Hepatocellular carcinoma is the third leading cause of cancer mortality worldwide; current chemotherapeutic interventions for this disease are largely ineffective." | ( Graña, X; Knudsen, ES; Mayhew, CN; Reed, CA; Rivadeneira, DB; Sotillo, E; Thangavel, C, 2010) |
| "Hepatocellular carcinoma is the most common primary cancer of the liver in Asian countries." | ( Gayathri, R; Gunassekaran, GR; Priya, DK; Sakthisekaran, D, 2009) |
| "The hepatocellular carcinoma, is detected sooner due to the progress of the hepatic ultrasound scan allowing an accessibility to curative treatment." | ( Elloumi, H; Gargouri, D; Ghorbel, A; Hefaiedh, R; Kharrat, J; Kilani, A; Kochlef, A; Ouakaa, A; Romani, M, 2009) |
| "The incidence of hepatocellular carcinoma is rising due to alcohol drinking, hepatitis C viral infection and metabolic syndrome." | ( Li, Y; Nie, Y; Wan, YJ; Yang, H, 2010) |
| "Hepatocellular carcinoma is one of the most frequent malignant tumors in general and most common liver malignancy." | ( Bojanović, A; Bosnjaković, P; Marković, M; Mrvić, M; Radić, S; Radovanović, Z; Stojanović, M, 2009) |
| "The occurrence of hepatocellular carcinoma is about 3-15 % in patients with alcoholic liver disease." | ( Fehér, J; Lengyel, G, 2010) |
| "Hepatocellular carcinoma is the most common type of liver cancer and is highly metastatic." | ( Ho, CT; Huang, HW; Weng, CJ; Wu, CF; Yen, GC, 2010) |
| "Hepatocellular carcinoma is a malignant tumor responsible for approximately 600,000-700,000 deaths worldwide, and is becoming more prevalent not only in South-East Asia and Africa, but also in Western countries; therefore, interest in hepatocellular carcinoma has mounted in recent years in the West, where little or no interest was evident 10-20 years ago." | ( Kudo, M, 2010) |
| "Hepatocellular carcinoma is also one of the human cancer types in which aberrant promoter CpG island hypermethylation is frequently found." | ( Jang, JJ; Kang, GH; Kim, BH; Shin, SH; Suh, KS, 2010) |
| "Liver cirrhosis and hepatocellular carcinomas are two major causes of morbidity and mortality worldwide, and can synergistically interact to expedite the tumor progression." | ( Chang, CP; Lei, HY; Yang, MC, 2010) |
| "The incidence of hepatocellular carcinoma is increasing worldwide as well as the associated risk factors, some of which include exposure to aflatoxin B1, Hepatitis B (HBV) virus and hepatitis C (HCV) virus." | ( Azeez, OI; Oyagbemi, AA; Saba, AB, 2010) |
| "Hepatocellular carcinoma is now a major public health concern." | ( Boucher, E; Edeline, J; Garin, E; Pracht, M; Raoul, JL; Rolland, Y, 2011) |
| "As cells of hepatocellular carcinoma are morphologically different from healthy human hepatocytes, we hypothesized that plectin deficiency and cytoskeletal disorganization underlies this pleomorphic transformation." | ( Chao, WT; Cheng, CC; Ho, CC; Hsu, YH; Lai, YS; Liu, YH; Pei, RJ, 2011) |
| "Fibrolamellar hepatocellular carcinoma is a subtype of hepatocellular carcinoma occurring in non-cirrhotic liver at a younger age." | ( Erdélyi-Belle, B; Kiss, A; Korompay, A; Kovalszky, I; Lotz, G; Patonai, A; Schaff, Z; Schirmacher, P; Somorácz, A; Straub, BK, 2011) |
| "The incidence of hepatocellular carcinoma is rising in many countries, including the United States." | ( Aucejo, F; Byrne, MT; Kim, R; Tan, A, 2011) |
| "Hepatocellular carcinoma is mainly associated with viral hepatitis B and C." | ( Ahmad, W; Asad, S; Fouzia, K; Gull, S; Hassan, S; Ijaz, B; Kausar, H; Nazar, N; Nazar, S; Sarwar, MT; Shabbiri, K; Shahid, I, 2011) |
| "Primary hepatocellular carcinoma is the third most common fatal cancer worldwide with more than 500,000 annual deaths." | ( Cuestas, ML; Mathet, VL; Sosnik, A, 2011) |
| "The recurrence of hepatocellular carcinoma is still high even after surgery." | ( Hayami, S; Ozawa, S; Shigekawa, Y; Tani, M; Uchiyama, K; Ueno, M; Yamaue, H, 2011) |
| "Hepatocellular carcinoma is the fifth most common malignant tumour, with a high mortality rate." | ( Iberer, F; Koestenbauer, S; Konrad, K; Leber, B; Mayrhauser, U; Portugaller, RH; Stadlbauer, V; Stiegler, P; Tscheliessnigg, K, 2011) |
| "HCC (hepatocellular carcinoma) is among the most common and lethal cancers worldwide with a poor prognosis mainly due to a high recurrence rate and chemotherapy resistance." | ( Hong, DY; Huang, HS; Liu, ZM; Tseng, JT, 2011) |
| "Hepatocellular carcinoma is a highly chemoresistant tumor with several genetic alterations." | ( Cervera, P; Fléjou, JF, 2011) |
| "Hepatocellular carcinoma is the most common form of primary hepatic carcinoma." | ( Chan, SH; Chang, Y; Kung, HC; Lin, WJ; Lin, WY; Liu, SW; Luo, TY; Peng, CL; Tang, IC, 2011) |
| "Hepatocellular carcinoma is the most common primary hepatic malignancy worldwide." | ( Das, N; Ghosh, A; Ghosh, D; Mandal, AK; Sarkar, S; Thakur Choudhury, S, 2012) |
| "Hepatocellular carcinoma is a common malignancy." | ( Ahn, BC; Cho, JY; Lee, J; Lee, SW; Lee, Y; Lee, YL, 2011) |
| "Hepatocellular carcinoma is becoming one of the most prominent types of cancer in the world." | ( Lee, J; Lim, KT, 2012) |
| "Hepatocellular carcinoma is difficult to diagnose early, and most patients are already in the late stages of the disease when they are admitted to hospital." | ( Chen, QH; Gao, KP; Huang, T; Li, Q; Ma, JW; Qin, JM; Sa, ZQ; Shen, HB; Sheng, X; Yang, L; Yin, PH; Zhang, M, 2012) |
| "Hepatocellular carcinoma is the sixth most prevalent cancer and the third most frequent cause of cancer-related death." | ( Bruix, J; Forner, A; Llovet, JM, 2012) |
| "Hepatocellular carcinoma is one of the most common cancers in worldwide." | ( Dai, XY; Deng, Y; Han, YY; Lin, HJ; Mao, YQ; Peng, F; Xie, G; Xu, YZ; Yang, L; Yu, LT; Zeng, XX; Zhao, YL; Zhou, T, 2012) |
| "Hepatocellular carcinoma is a common type of cancer that is usually associated with poor prognosis." | ( Binh, TV; Chang, HC; Chen, LM; Dung, TD; Huang, CY; Kuo, WW; Lee, MR; Tsai, CH; Tsai, FJ, 2012) |
| "Hepatocellular carcinoma is the third most common cause of cancer-related death." | ( Francis, IR; Krishnamurthy, VN; Novelli, PM; Pandya, A; Vellody, R; Willatt, JM, 2012) |
| "Hepatocellular carcinoma is one of the most common cancers and lethal diseases in the world." | ( Babu, LH; Balasubramanian, MP; Perumal, S, 2012) |
| "Hepatocellular carcinoma is a primary malignant tumor of the liver that accounts for an important health problem worldwide." | ( Al Younis, I; Coenraad, MJ; Defreyne, L; Lam, MG; Lambert, B; Seinstra, BA; van den Bosch, MA; van Erkel, AR; van Erpecum, KJ; van Hoek, B; van Vlierberghe, H; Verkooijen, HM, 2012) |
| "Hepatocellular carcinoma is one of the most malignant human cancers with high metastatic potential." | ( Feng, Y; Man, K; Tsao, SW; Wang, N; Zhang, Z; Zhu, M, 2012) |
| "Annually, hepatocellular carcinoma is diagnosed in approximately a half-million people worldwide." | ( Grewal, P; Viswanathen, VA, 2012) |
| "Hepatocellular carcinoma is one of the most common cancers worldwide." | ( Aizawa, K; Hata, K; Kato, N; Nakabayashi, K; Nakamura, K; Tanoue, A; Yamauchi, J, 2013) |
| "Hepatocellular carcinoma is one of the most common cause of cancer related death." | ( Glodny, B; Henninger, B; Jaschke, W; Petersen, J, 2013) |
| "Screening for hepatocellular carcinoma is reserved for those with hereditary hemochromatosis and cirrhosis." | ( Covey, CJ; Crownover, BK, 2013) |
| "Hepatocellular carcinoma is one of the leading causes of death in cancer and yet no drug has proven to be a successful candidate for its treatment in advanced stages." | ( Afzal, M; Ahmad, A; Al-Abbasi, FA; Anwar, F; Kazmi, I; Narooka, AR; Singh, R, 2013) |
| "Hepatocellular carcinoma is rare in Wilson's disease, especially in the absence of cirrhosis." | ( Dufour, JF; Thattil, R, 2013) |
| "Hepatocellular carcinoma is generally diagnosed at advanced stages, for which only palliative treatments are possible by intra-arterial route or by targeted therapies." | ( Ardisson, V; Audrain, O; Boucher, E; Clement, B; Edeline, J; Garin, E; Lenoir, L; Lepareur, N; Pracht, M; Raoul, JL, 2013) |
| "Hepatocellular carcinoma is the most common type of liver cancer." | ( Li, J; Li, Y; Liu, M; Wei, M; Zhu, W, 2013) |
| "Hepatocellular carcinoma is highly chemoresistant, and ATP-binding cassette subfamily G member 2 (ABCG2) is thought to play a critical role in this drug resistance." | ( Chen, T; Ge, C; Hou, H; Li, H; Li, J; Lu, P; Sun, H; Tian, H; Yao, M; Zhang, L; Zhao, F, 2013) |
| "Hepatocellular carcinoma is the fifth most common cancer and the third leading cause of cancer-related deaths worldwide." | ( Akalın, G; Incesu, Z; Işcan, A; Kutlu, HM; Önder, NI; Özdemir, F; Şen, M, 2014) |
| "Hepatocellular carcinoma is the fifth most common cancer worldwide." | ( Franke, A; Jakobsen, JC; Mössner, J; Schoppmeyer, K; Weis, S, 2013) |
| "Hepatocellular carcinoma is the fifth most common cancer worldwide and the third most common cause of cancer mortality." | ( Abdel-Rahman, O; Fouad, M, 2014) |
| "Hepatocellular carcinoma is a major cause of death among patients with cirrhosis." | ( Behnke, M; Bornstein, K; Cotterell, A; Fisher, RA; Fulcher, A; Lee, DD; Posner, MP; Ramanathan, R; Sharma, A; Stravitz, RT; Sydnor, M, 2014) |
| "Hepatocellular carcinoma is the fifth most common cancer worldwide and shows a complex clinical course, poor response to pharmacological treatment, and a severe prognosis." | ( Capone, F; Castello, G; Colonna, G; Costantini, S; Guerriero, E; Pagliuca, J; Sorice, A; Storti, G, 2014) |
| "Hepatocellular carcinoma is difficult to treat, primarily because the underlying molecular mechanisms driving clinical outcome are still poorly understood." | ( Cao, Y; Fabregat, I; Giannelli, G; Malfettone, A; Rani, B; Tomuleasa, C, 2014) |
| "Hepatocellular carcinoma is a common malignancy with a poor prognosis." | ( Abou-Alfa, GK; Harding, JJ, 2014) |
| "Hepatocellular carcinoma is the third most common cause of cancer death." | ( Bao, X; Chu, QC; Gao, M; Guan, X; Jiang, N; Liu, KX; Tian, Y; Xu, H; Zhang, CH, 2015) |
| "Hepatocellular carcinomas are highly vascular tumors, showing progressive hypervascularity by the process of neoangiogenesis." | ( Bhargava, P; Bhosale, P; Choi, JI; Imagawa, DK; Lall, C; Seery, TE; Tirkes, T, 2014) |
| "Hepatocellular carcinoma is the fifth most common solid cancer worldwide." | ( Chen, IT; Chen, KF; Hsu, CY; Li, YS; Liu, CY; Shiau, CW; Su, JC; Tai, WT; Tseng, PH; Wu, SH, 2014) |
| "Hepatocellular carcinoma is one of the most frequent tumor types worldwide and oxidative stress represents a major risk factor in pathogenesis of liver diseases leading to HCC." | ( Calderon, PB; Dejeans, N; Glorieux, C; Najimi, M; Renard, P; Rommelaere, G; Sid, B; Valenzuela, M; Verrax, J, 2014) |
| "Hepatocellular carcinoma is a difficult-to-treat cancer and, after numerous phase III trials assessing kinase inhibitors have failed to meet their end points, sorafenib is the only accepted treatment for advanced stages of the disease." | ( Llovet, JM, 2014) |
| "Hepatocellular carcinoma is the third cause of cancer related death for which new treatment strategies are needed." | ( Chemin, I; Favaudon, V; Guillot, C; Hall, J; Herceg, Z; Merle, P; Sagne, C; Sauvaigo, S, 2014) |
| "Hepatocellular carcinoma is related to various etiologies including hepatitis B, hepatitis C, high alcohol intake, aflatoxin B1 and metabolic syndrome." | ( Nault, JC, 2014) |
| "Hepatocellular carcinoma is one of the most common malignancies worldwide and drug resistance is a major cause of treatment failure." | ( Qian, J; Wang, C; Wang, D; Ye, Y; Zhang, N; Zhu, Y, 2014) |
| "Hepatocellular carcinoma is one of the most common cancers worldwide, and a leading cause of cancer-related death." | ( Chen, KF; Hung, MH; Shiau, CW; Tai, WT, 2014) |
| "Hepatocellular carcinoma is becoming more common, and numerous treatment algorithms are available for this complex disease." | ( Narang-Master, J; Rizzolo, D, 2015) |
| "Hepatocellular carcinoma is one of the most aggressive cancers with poor prognosis worldwide." | ( Feng, LY; Meng, ZQ; Wang, SY, 2015) |
| "Hepatocellular carcinoma is one of the most common malignancies worldwide and evidence suggests that Ras signaling regulates various hallmarks of cancer via regulating several effector pathways such as ERK and PI3K." | ( Gopal, A; Halagowder, D; Iyer, SC, 2015) |
| "Most patients with hepatocellular carcinoma are still diagnosed at intermediate or advanced disease stages, where curative approaches are often not feasible." | ( Llovet, JM; Torrecilla, S, 2015) |
| "Hepatocellular carcinoma is the third most common cause of cancer-related deaths worldwide." | ( Di Pietro, A; Guterres, FA; Martinez, GR; Rocha, ME; Scoparo, CT; Valdameri, G; Winnischofer, SM; Worfel, PR, 2015) |
| "Hepatocellular carcinoma is one of the most common cancers in adults and develops due to activation of oncogenes and inactivation of tumor suppressor genes." | ( Choi, HG; Choi, JY; Gupta, B; Hiep, TT; Kim, JO; Pathak, S; Poudel, BK; Thapa, RK; Yong, CS, 2015) |
| "Hepatocellular carcinoma is the fifth most common cancer worldwide, with poor prognosis and resistance to chemotherapy." | ( Behmanesh, M; Najafi, F; Sadeghizadeh, M; Zamani, M, 2015) |
| "Hepatocellular carcinoma is the first liver tumor worldwide." | ( Belhadj, N; Ben Nejma, H; Ennaifer, R; Gharbi, L; Hefaiedh, R; Khalfallah, MT; Romdhane, H; Sabbeh, M, 2015) |
| "Hepatocellular carcinoma is a challenging malignancy of global importance." | ( Cabibbo, G; Cammà, C; Maida, M; Petta, S, 2015) |
| "Hepatocellular carcinoma is one of the most common and deadly forms of human malignancies." | ( Liu, L; Wang, D; Wang, J; Wang, S, 2016) |
| "Hepatocellular carcinoma is increasingly important in the United States as the incidence rate rose over the last 30 years." | ( Drinkwater, NR; Hanes, MA; Herbert, DC; Herzig, MC; Hildreth, K; McMahan, CA; Reddick, RL; Reddick, T; Street, K; Walter, CA; Zavadil, JA, 2016) |
| "Hepatocellular carcinoma is a widely prevalent cancer, and hence, the development of radiopharmaceuticals for its management is an important issue." | ( El-Kawy, OA; Talaat, HM, 2016) |
| "Hepatocellular carcinoma is the most common primary hepatic malignant tumor." | ( Kim, JW; Lee, CH; Park, CM; Park, YS; Shin, S, 2016) |
| "Hepatocellular carcinoma is the second deadliest cancer with limited treatment options." | ( Calis, I; Cetin-Atalay, R; Durmaz, I; Ersahin, T; Guven, EB; Ozturk, M, 2016) |
| "Hepatocellular carcinoma is the most common liver neoplasm and the fifth most common cancer worldwide." | ( Abdel-Rahman, OM; Elsayed, Z, 2016) |
| "Hepatocellular carcinomas are frequently nonresponsive to systemically delivered drugs." | ( Exner, AA; Gangolli, M; Hernandez, C; Solorio, L; Wu, H, 2016) |
| "Hepatocellular carcinoma is one of the most common lethal diseases worldwide and there is no effective treatment till date." | ( Ali, N; Ali, R; Hasan, SK; Nafees, S; Rashid, S; Shahid, A; Siddiqi, A; Sultana, S, 2016) |
| "Hepatocellular carcinoma is one of the leading causes of malignancy-related death in China." | ( Jin, FX; Liu, JT; Liu, LJ; Lv, Q; Rong, N; Wang, CM; Xu, XL, 2016) |
| "Hepatocellular carcinoma is the most common primary hepatic tumor in dogs and is amenable to surgical resection in many cases." | ( Cannon, CM; Conklin, GA; Constant, C; Craig, LE; Hecht, S; Lux, CN, 2016) |
| "Hepatocellular carcinoma is among the leading causes of cancer-related deaths worldwide, and the development of new treatment regimens is urgently needed to improve therapeutic approach." | ( Cao, J; Chen, Y; Chen, ZB; Dai, XY; Han, YX; He, QJ; Luo, PH; Ma, J; Peng, Y; Sun, YH; Wang, DD; Yan, FJ; Yang, B; Ying, MD; Zhang, H; Zhu, H, 2016) |
| "Hepatocellular carcinoma is the most prevalent type of tumor among primary tumors affecting the liver." | ( Basso, BS; da Silva, EF; de Oliveira, JR; Haute, GV; Krause, GC; Lima, KG; Mesquita, FC; Nunes, FB; Pedrazza, L; Velasquez, AC, 2016) |
| "Hepatocellular carcinoma is a lethal cancer with high recurrence ratio and lacks effective therapeutics." | ( Chen, K; Chen, L; Huang, Z; Wang, Z; Zhang, H; Zhang, X; Zhou, J, 2016) |
| "Hepatocellular carcinoma is the most common primary liver malignancy, commonly a sequelae of hepatitis C infection, but can complicate cirrhosis of any cause." | ( Kasmari, AJ; Leslie, D; Liu, G; McGarrity, T; Riley, T; Welch, A, 2017) |
| "Hepatocellular carcinoma is the most common liver neoplasm, the sixth most common cancer worldwide, and the third most common cause of cancer mortality." | ( Abdel-Rahman, O; Elsayed, Z, 2017) |
| "Hepatocellular carcinoma is the major form of primary liver cancer, which is the second and sixth leading cause of cancer-related death in men and women, respectively." | ( Ahsani, Z; Karimkhanloo, H; Mohammadi-Yeganeh, S; Paryan, M, 2017) |
| "Hepatocellular carcinoma is one of the conditions in which HSR activation was shown to have the highest clinical significance." | ( Di Ianni, L; Di Stefano, G; Govoni, M; Manerba, M; Recanatini, M; Roberti, M, 2017) |
| "Hepatocellular carcinoma is highly refractory cancer which is resistant to conventional chemotherapy and radiotherapy, carrying a dismal prognosis." | ( Badrinath, N; Heo, J; Woo, HY; Yoo, SY, 2017) |
| "Hepatocellular carcinoma is one of the fastest growing causes of cancer-related mortality worldwide." | ( Ross, P; Srikandarajah, K; Thillai, K, 2017) |
| "Prognosis of hepatocellular carcinoma is measured in months, with median overall survival reaching 10." | ( Abou-Alfa, GK; Dika, IE, 2017) |
| "Hepatocellular carcinoma is known to exhibit highly heterogeneous molecular aberrations across the tumors, including somatic genetic and epigenetic alterations." | ( Bian, CB; Fuchs, BC; Higashi, T; Hirschfield, H; Hoshida, Y; Nair, VD; Nakagawa, S; Zeleke, TZ, 2018) |
| "The hepatocellular carcinoma is one of the most common malignant tumour with high level of mortality rate due to its rapid progression and high resistance to conventional chemotherapies." | ( Basoli, V; Carta, P; Cruciani, S; Delogu, G; Dettori, MA; Fabbri, D; Maioli, M; Serra, PA, 2018) |
| "Hepatocellular carcinoma is the main factor affecting their overall mortality, and is the only factor affecting liver-related mortality in this setting." | ( Berg, T; Buti, M; Calleja, JL; Chi, H; Colombo, M; Dalekos, G; de la Revilla, J; Esteban, R; Galanis, K; Gatselis, N; Goulis, J; Hansen, BE; Idilman, R; Janssen, HLA; Keskın, O; Kourikou, A; Lampertico, P; Lehretz, M; Loglio, A; Manolakopoulos, S; Papatheodoridis, GV; Savvidou, S; Siakavellas, S; Sypsa, V; van Boemmel, F; Vlachogiannakos, I; Yurdaydin, C, 2018) |
| "Hepatocellular carcinoma is a typical hypervascular tumor that relies on angiogenesis." | ( Fathy, M; Nikaido, T, 2018) |
| "Hepatocellular carcinoma is the most common primary malignancy of the liver, with increasing incidence worldwide." | ( Dank, M; Padányi, P, 2018) |
| "Hepatocellular carcinoma is the most frequent primary liver cancer worldwide." | ( Lu, J; Sun, X; Wang, R; Wang, X; Wen, Y; Xu, J; Yang, L; Zhang, M, 2018) |
| "Pedunculated hepatocellular carcinoma is an unusual form of hepatocellular carcinoma protruding from the liver with or without a pedicle." | ( Dong, A; Wang, Y; Zhong, X, 2018) |
| "Hepatocellular carcinoma is emerging as one of the most common forms of cancer resulting in thousands of death worldwide." | ( Afzal, M; Al-Abbasi, FA; Anwar, F; Bhardwaj, DP; Kazmi, I; Khan, R; Saleem, S, 2019) |
| "Hepatocellular carcinoma is highly resistant to chemotherapy." | ( George, J; Patel, T; Yan, IK, 2018) |
| "Hepatocellular carcinoma is a common primary malignancy of hepatocytes that has caused many fatalities globally." | ( Omwandho, C; Wasonga, C, 2018) |
| "Hepatocellular carcinoma is one of most common solid cancers worldwide." | ( Chen, Y; Jiang, R; Lu, S; Shao, Q; Sun, J; Xu, G; Yao, Y; Zhang, Y; Zhou, C, 2018) |
| "Hepatocellular carcinoma is associated with several chronic liver diseases, especially chronic hepatitis B virus, hepatitis C virus, and alcoholism." | ( Carr, BI; Caturelli, E; Farinati, F; Giannelli, G; Giannini, EG; Guerra, V; Marco, MD; Masotto, A; Rapaccini, GL; Sacco, R; Trevisani, F; Virdone, R; Zoli, M, 2018) |
| "HCC (Hepatocellular carcinoma) is a most common type of malignant neoplasms in the digestive system." | ( Duan, X; He, J; He, K; Huang, R; Li, B; Xiang, G; Yang, X; Zhang, J, 2018) |
| "Hepatitis and hepatocellular carcinoma are serious human diseases." | ( Fang, NY; Shen, JJ; Wan, LF; Wang, YH; Xue, BY; Yuan, X; Zhao, W, 2019) |
| "Hepatocellular carcinoma is the most frequent kind of primary liver cancer and occurs mostly in patients with chronic liver disease and cirrhosis." | ( Cui, G; Shang, X; Wang, N; Yang, G; Zhao, H; Zhao, L, 2019) |
| "Hepatocellular carcinoma is a serious health problem worldwide, especially in Asian countries, such as China." | ( Li, N; Liu, Z; Wu, M; Zhang, A, 2019) |
| "Hepatocellular carcinoma is the most frequent primary malignant tumor of the liver and the third most common cause of all cancer-related mortalities." | ( Öcal, S; Özer Etik, D; Selçuk, H; Suna, N, 2019) |
| "Hepatocellular carcinoma is the fourth leading cause of cancer death." | ( Boulin, M; Gehin, S; Guiu, B; Pistre, P, 2020) |
| "Hepatocellular carcinoma is the most frequent and deadliest cancers worldwide." | ( Devaraj, E; Solai Prakash, AK, 2019) |
| "Hepatocellular carcinoma is the most common liver malignancy and the third leading cause of cancer death worldwide." | ( Castronuovo, CC; Cuestas, ML; Davio, C; Gentile, EA; Gómez, N; Mathet, VL; Oubiña, JR, 2019) |
| "Hepatocellular carcinoma is one of the most fatal cancers worldwide." | ( Sun, H; Sun, Y, 2020) |
| "Hepatocellular carcinoma is the most common primary liver cancer and the fourth leading cause of cancer death worldwide." | ( Argentiero, A; Brunetti, O; Delcuratolo, S; Gnoni, A; Licchetta, A; Longo, V; Memeo, R; Solimando, AG, 2019) |
| "Hepatocellular carcinoma is the most common liver neoplasm and the sixth most common cancer worldwide." | ( Abdel-Rahman, O; Elsayed, Z, 2020) |
| "Hepatocellular carcinoma is cancer with many new cases and the highest mortality rate." | ( Du, G; Li, H; Pang, L; Yang, L; Zhan, Y, 2020) |
| "Hepatocellular carcinoma is one of few cancer types that continues to grow in incidence and mortality worldwide." | ( Dewdney, B; George, J; Hebbard, L; Qiao, L; Roberts, A, 2020) |
| "Hepatocellular carcinoma is a major cause of cancer mortality worldwide." | ( Eissa, LA; El-Mesery, ME; Habeeb, MR; Yousef, EH, 2020) |
| "Hepatocellular carcinoma is known to be a common predominant cancer in adults, especially in eastern countries." | ( Guo, W; Huo, J; Liu, Q; Wei, F; Yu, L, 2020) |
| "Hepatocellular carcinoma is one of the most prevalent malignant diseases and causes a third of cancer-related death." | ( Murata, T; Ramos, JW; Yamaguchi, M, 2020) |
| "Hepatocellular carcinoma is the second leading cause of cancer-related mortality worldwide." | ( Devaraj, E; Thakur, RS, 2020) |
| "Liver cancer or hepatocellular carcinoma is considered to be the third leading cause of death among all other cancers." | ( Bolla, SR; Chen, Y; Gong, G; Li, Y; Veeraraghavan, VP; Xu, C; Zhang, C; Zhang, M, 2020) |
| "Hepatocellular carcinoma is a heterogenous group of disease with a spectrum of disease presentations that developed on the setting of liver cirrhosis, although the achievements made in the imaging techniques have enabled the early diagnosis in nearly 60% of the cases in cirrhotic patients." | ( Aydin, C; Yilmaz, S, 2020) |
| "Hepatocellular carcinoma is rapidly becoming one of the leading causes of cancer-related deaths, largely due to the increasing incidence of non-alcoholic fatty liver disease." | ( Alanazy, M; Dewdney, B; George, J; Gillman, R; Hebbard, L; Qiao, L; Roberts, A; Walker, S; Wankell, M, 2020) |
| "Hepatocellular carcinoma is one of the most common malignant tumors in the digestive tract, so it is necessary to find effective preventive and therapeutic measures." | ( Liu, YW; Niu, JQ; Xu, HQ; Zhou, Q, 2020) |
| "HCC (hepatocellular carcinoma) is a major health threat for the Chinese population and has poor prognosis because of strong resistance to chemotherapy in patients." | ( Luo, J; Si, Z; Tan, X; Tong, JS; Yao, H; Zhang, Z, 2020) |
| "Hepatocellular carcinoma is a relevant cause of mortality worldwide, mainly among patients who have a prior liver disease." | ( da Silva Yamashiro, F; Katsuda, L; Kawanami, GH; Pelafsky, L; Qi, X; Rocha, TB; Romeiro, FG, 2021) |
| "Hepatocellular carcinoma is diagnosed in more than half of all cases at unresectable stage when no potentially curative treatments are feasible." | ( Battaglia, S; Busacca, A; Cabibbo, G; Cammà, C; Cannella, R; Celsa, C; Giuffrida, P; Grova, M; Rizzo, GEM; Spatola, F; Stornello, C, 2021) |
| "Hepatocellular carcinoma is one of the most common malignancies and leading cancer-associated deaths worldwide." | ( He, X; Huang, Q; Li, J; Li, X; Tang, S; Zeng, T; Zhong, M, 2021) |
| "Hepatocellular carcinoma is the fourth leading cause of cancer deaths in the world." | ( Abd El Fattah El Sayed, H; Atta, S; Elzayat, E; Hussein, T; Kamel, M; Mahmood, D; Mansour, W; Saber, S, 2022) |
| "Hepatocellular carcinoma is the third-leading cause of cancer-related death worldwide." | ( Bennett, L; Breder, V; Fartoux, L; Hudgens, S; Kudo, M; López, C; Meier, G; Mody, K; Ohtsuka, T; Qin, S; Simon, K; Su, Y; Sung, M; Tamai, T; Vogel, A; Yamashita, T; Yoon, JH, 2021) |
| "Although hepatocellular carcinoma is considered a highly lethal malignancy, recent therapeutic advances have been achieved during the last 10 years." | ( da Fonseca, LG; Piñero, F, 2021) |
| "BACKGROUND Hepatocellular carcinoma is the third leading cause of cancer-associated mortality." | ( Ding, J; Fan, B; Huang, C; Li, J; Li, Y; Qi, C; Zhang, J; Zhang, Y, 2021) |
| "Hepatocellular carcinoma is a well-known internal malignancy with increased worldwide mortality." | ( Balaraman, G; Krishnan, P; Mari, A; Salam, S; Sirajduddin, I; Subramaniam, N; Sundaram, J; Thiruvengadam, D, 2021) |
| "Hepatocellular carcinoma is one of the most common malignant tumors in China and is also a major cause of cancer deaths worldwide." | ( Liu, X; Yi, Y, 2021) |
| "Lay abstract Hepatocellular carcinoma is often found at intermediate or advanced stages and thus often has a poor outcome." | ( Liu, X; Yi, Y, 2021) |
| "Hepatocellular carcinoma is among the leading causes of cancer-related deaths worldwide and needs efficient and feasible approach of treatment." | ( Chaudhary, A; Haque, R; Khan, A; Mishra, AK; Sarkar, A; Singh, P; Srivastava, A, 2022) |
| "Hepatocellular carcinoma is insensitive to many chemotherapeutic agents." | ( Du, YZ; Lu, YF; Wang, XJ; Yang, XY; Yu, JN; Yu, RS; Zhou, JP; Zhou, QM, 2021) |
| "Hepatocellular carcinoma is a malignancy with poor clinical prognosis." | ( Cai, X; He, T; Huang, D; Liu, Y; Lu, D; Luo, L; Tang, W; Wang, X; Wang, Y; Xue, J; Yang, F, 2022) |
| "Hepatocellular carcinoma is one of the major causes of cancer-related deaths worldwide and is associated with several inflammatory mediators, since 90% of HCCs occur based on chronic hepatitis B or C, alcoholism or increasingly metabolic syndrome-associated inflammation." | ( Alotaibi, H; Carr, BI; Sengez, B, 2023) |
| "Hepatocellular carcinoma is the most common primary liver cancer and the fifth most frequently diagnosed cancer worldwide." | ( Cortez, A; Du, Y; Josefsson, A; Krimins, R; Liapi, E; Nedrow, JR; Zarisfi, M, 2022) |
| "Hepatocellular carcinoma is the second most cause of death among the various cancers worldwide." | ( Amudha, P; Jayalakshmi, M; Poojitha, BN; Vidya, R, 2023) |
| "Hepatocellular carcinoma is one of the most common primary hepatic malignancy." | ( Chen, GY; Geng, JJ; Gu, YC; Hai, Y; Hou, XM; Li, PJ; Liu, M; Ma, WP; Shao, CL; Wang, CF; Wei, MY, 2022) |
| "Fibrolamellar hepatocellular carcinoma is a rare type of hepatocellular carcinoma with unclear etiology." | ( Ahmed, A; Ata, F; Gaber, M; Hashim, A; Mahfouz, A; Musa, S; Petkar, M; Schirmacher, P, 2022) |
| "Sarcomatoid hepatocellular carcinoma is a rare subtype of hepatocellular carcinoma." | ( Jiao, J; Yang, T; Zhang, Y; Zou, MH; Zou, Q, 2022) |
| "Hepatocellular carcinoma is one of the most common malignant tumors in the world." | ( Liu, W; Xiong, S, 2022) |
| "Hepatocellular carcinoma is a leading public health concern in sub-Saharan Africa, and it is most prevalent in young adults (median 45 years [IQR 35-57])." | ( Abdo, A; Afihene, M; Cunha, L; Desalegn, H; Dusheiko, G; Jonas, E; Kassianides, C; Katsidzira, L; Kramvis, A; Lam, P; Lesi, OA; Micah, EA; Musabeyezu, E; Ndow, G; Nnabuchi, CV; Ocama, P; Okeke, E; Rwegasha, J; Shewaye, AB; Some, FF; Sonderup, MW; Spearman, CW; Tzeuton, C, 2022) |
| "Hepatocellular carcinoma is a common cancer type, especially among men." | ( Baysar, A; Çiğremiş, Y; Tosun, E; Türköz, Y; Üremiş, MM; Üremiş, N, 2022) |
| "Hepatocellular carcinoma is the most common primary malignancy of the liver." | ( Cao, Z; Deng, X; Ding, W; Dong, F; Han, M; Hao, P; Jin, L; Li, J; Liu, D; Liu, G; Liu, H; Luo, W; Mu, J; Pan, L; Pang, Y; Wang, T; Wei, Y; Zeng, G; Zhang, H; Zhang, Y; Zhen, C, 2022) |
| "Hepatocellular carcinoma is the most prevalent form of primary liver cancer with a multifactorial aetiology comprising genetic, environmental, and behavioural factors." | ( Ajoolabady, A; Kroemer, G; Ren, J; Tang, D, 2023) |
| "Hepatocellular carcinoma is one of the deadliest neoplasms around the world, and a major proportion of patients are diagnosed in an advanced state not amenable to curative treatment." | ( Lu, Z; Wang, H; Yang, X; Zhang, G; Zhao, H, 2023) |
| "Hepatocellular carcinoma is one of the deadliest neoplasms around the world, and a major proportion of patients are diagnosed in an advanced state not amenable to curative treatment." | ( Lu, Z; Wang, H; Yang, X; Zhang, G; Zhao, H, 2023) |
| "Hepatocellular carcinoma is one of the deadliest neoplasms around the world, and a major proportion of patients are diagnosed in an advanced state not amenable to curative treatment." | ( Lu, Z; Wang, H; Yang, X; Zhang, G; Zhao, H, 2023) |
| "Hepatocellular carcinoma is one of the most common types of primary liver cancer in adults and also it is the third leading cause of cancer-related deaths worldwide." | ( Cataklı, D; Dogan, HK; Erzurumlu, Y, 2023) |
| "Hepatocellular carcinoma is the third most deadly malignant tumor in the world with a poor prognosis." | ( Liu, R; Liu, Y; Wei, J; Wu, L; Zhang, F, 2023) |
| "Hepatocellular carcinoma is a primary liver cancer and 6th most common cancer globally." | ( Bibi, K; Fatima, T; Haider, G; Ilyas, A; Sohrab, S; Zarina, S, 2023) |
| "Hepatocellular carcinoma is characterized by a high infiltration of myeloid-derived suppressor cells (MDSC), which are key drivers of maintaining the immunosuppressive tumor microenvironment." | ( Chen, J; Chen, S; Deng, X; Huang, X; Li, X; Luo, X; Wang, C; Wu, H; Zhong, J, 2023) |
| "Hepatocellular carcinoma is a major contributor to cancer-related deaths in China and ranks among the most prevalent malignant tumors." | ( Hu, Y; Huang, L; Xu, Z, 2023) |
| "Hepatocellular carcinoma is a common malignancy with a low survival rate, despite the available treatment options." | ( Bakar-Ates, F; Ozkan, E, 2023) |
| Excerpt | Reference |
|---|
| "Chemoembolization is an effective treatment for hepatocellular carcinoma, giving results equally as good as surgical therapy for T2 tumours." | ( Böhmer, G; Galanski, M; Prokop, M; Reichelt, S; Ringe, B; Schaefer, C; Schmidt, FW; Schmoll, E; Schmoll, HJ; Schüler, A, 1992) |
| "A 64-year-old Japanese female who was treated for hepatocellular carcinoma with doxorubicin developed diffuse blue-gray pigmentation of the face, fading out on the upper trunk." | ( Konohana, A, 1992) |
| "A 64-year-old male was admitted for treatment of hepatocellular carcinoma." | ( Eto, T; Ishinoda, Y; Iwaki, Y; Kawano, T; Kitamura, M; Kitamura, T; Komura, K; Maruyama, T; Shimada, Y; Tamaki, N, 1992) |
| "Hepatectomy has been performed as a treatment for hepatocellular carcinoma (HCC) and metastatic liver carcinoma." | ( Hanawa, S; Hasebe, Y; Kuramoto, S; Maeda, T; Nakazaki, H; Suzuki, Y; Watanabe, M; Yanagita, K; Yoshio, T, 1992) |
| "The tumours treated were hepatocellular carcinoma (n = 35), metastatic adenocarcinoma (n = 14), intrahepatic cholangiocarcinoma (n = 3) and leiomyosarcoma (n = 1)." | ( Dick, R; Dusheiko, G; Hobbs, KE; Markham, NI; Novell, JR; Reddy, K, 1991) |
| "The potential of hormonal therapy for treatment of hepatocellular carcinoma is worthy of further investigation." | ( Chi, CW; Liu, TY; Lui, WY; P'eng, FK, 1991) |
| "For the treatment of small hepatocellular carcinoma, intratumor injection of absolute ethanol under ultrasound guidance was performed in 27 tumors in 23 patients, with a tumor diameter of between 1." | ( Chen, DS; Huang, GT; Lai, MY; Lee, CZ; Sheu, JC; Su, CT; Sung, JL; Tsang, YM; Wei, TC; Yang, PM, 1987) |
| "The surgical treatment for hepatocellular carcinoma must be chosen by considering some factors such as liver function, position and involved area of the tumor." | ( Kato, T; Okamoto, E; Yamanaka, N, 1989) |
| "Our multimodal treatment of hepatocellular carcinoma (HCC) has brought about a significant improvement of the survival rate." | ( Ishii, M; Kitai, Y; Kitaya, T; Shima, Y; Shimamura, Y; Sugai, S; Takashi, A; Takenaka, Y; Taniguchi, H; Watanabe, H, 1989) |
| "Hepatic resection is essential in treating hepatocellular carcinoma." | ( Kojima, K; Mimura, H; Mizukawa, K; Ohkawa, M; Orita, K; Satoh, K; Takashima, H; Tamai, T; Tanabe, M; Tsumura, M, 1989) |
| "A multidisciplinary treatment for hepatocellular carcinoma including preoperative chemo-embolization with resection treatment was introduced." | ( Kuroda, C; Monden, M; Mori, T; Okamura, J; Sakon, M; Sakurai, M; Wakasa, K; Yoshioka, H, 1985) |
| "Adriamycin (ADR) is used in the treatment of hepatocellular carcinoma (HCC)." | ( Ballet, F; Barbare, JC; Poupon, R, 1984) |
| "A patient on hemodialysis treatment developed hepatocellular carcinoma (HCC) after long-term therapy with androgenic anabolic steroids." | ( Cohen, A; Levi, J; Turani, H; Zevin, D, 1981) |
| "Interventional treatment of hepatocellular carcinoma is indicated if surgical treatment is impossible." | ( Duda, SH; Huppert, PE; Lauchart, W; Viebahn, R, 1994) |
| "Its systematic use to treat hepatocellular carcinoma must be proceeded by further comparative studies with PEI." | ( Bonenti, G; Cirillo, S; Dore, D; Fava, C; Grosso, M; Martina, C; Veltri, A, 1995) |
| "Progress in the treatment of hepatocellular carcinoma (HCC), a common tumor worldwide, has been disappointing." | ( Adjei, PN; Gores, GJ; Kaufmann, SH; Leung, WY; Mao, F, 1996) |
| "PLD could serve as a safe and effective treatment for hepatocellular carcinoma even in the presence of impaired liver function." | ( Chang, FH; Hong, RL; Tseng, YL, 2000) |
| "Indeed, pretreatment of human hepatocellular carcinoma HepG2 cells with IL-1beta suppressed IFN-alphabeta-induced antiviral activity and antiviral protein MxA mRNA expression." | ( Feng, H; Gao, B; Shen, X; Tian, Z, 2000) |
| "Recent advances in the treatment of hepatocellular carcinoma (HCC) have prolonged patient survival." | ( Aratani, T; Doi, K; Komori, T; Narabayashi, I; Ogura, Y; Shimidzu, T; Sueyoshi, K; Utsunomiya, K, 2001) |
| "In the treatment of hepatocellular carcinoma, the range of indications for percutaneous ablation techniques is becoming wider than surgery and intra-arterial therapies." | ( Livraghi, T, 2001) |
| "We report the successful treatment of hepatocellular carcinoma (HCC) associated with an intraductal tumor thrombus in a 67-year-old male." | ( Furuse, J; Hasebe, T; Ishikura, S; Ogino, T; Satake, M; Tanizaki, H; Yoshino, M, 2001) |
| "This study suggests that treatment of hepatocellular carcinoma requires multidisciplinary expertise and that ablation and operation can be performed safely." | ( Adams, MB; Christians, KK; Franco, J; Pitt, HA; Quebbeman, EJ; Quiroz, FA; Rilling, WS; Wallace, JR, 2001) |
| "In the treated hepatocellular carcinomas, power Doppler sonography was the same as CO(2)-enhanced sonography in 15 (58%) of 26 tumors and was inferior in 11 (42%) of 26 tumors." | ( Chen, PH; Chen, RC; Chen, WT; Cheng, NY; Liao, LY; Tu, HY; Wang, CK; Wang, CS, 2002) |
| "Effective treatment for hepatocellular carcinoma is urgently needed." | ( Ganslmayer, M; Geerts, A; Hahn, EG; Hermann, M; Herold, C; Ocker, M; Schuppan, D, 2002) |
| "TSA may be a promising agent for treatment of hepatocellular carcinoma in vivo." | ( Ganslmayer, M; Geerts, A; Hahn, EG; Hermann, M; Herold, C; Ocker, M; Schuppan, D, 2002) |
| "Systemic treatment for hepatocellular carcinoma is indicated in locally advanced or metastatic disease." | ( Treiber, G, 2001) |
| "The results of tamoxifen treatment in hepatocellular carcinoma have been disappointing and randomized studies have shown conflicting results." | ( Auriault, ML; Boivin, JF; Chayette, C; Cheaib, S; Deplus, R; Macaigne, G, 2002) |
| "Even after the surgical or medical treatment of hepatocellular carcinoma, tumors frequently develop at new foci, leading to a poor prognosis." | ( Imamura, M; Koike, Y; Obi, S; Omata, M; Sato, S; Shiina, S; Shiratori, Y; Teratani, T; Yoshida, H, 2003) |
| "The optimal treatment for hepatocellular carcinoma (HCC) is surgical resection." | ( Bertolini, E; Bruno, S; Cornalba, GP; Costa, M; Montorsi, M; Podda, M; Santambrogio, R; Zuin, M, 2003) |
| "Its main indication is the treatment of small hepatocellular carcinomas superimposed on liver cirrhosis." | ( Bolog, N; Spârchez, Z, 2003) |
| "In 10 (12%) of the 81 treated hepatocellular carcinomas, contrast-enhanced ultrasonography showed either nodular or crescentic enhancing foci at the margins of ablation zones, suggesting residual unablated tumors." | ( Choi, D; Kim, SH; Kim, YH; Lee, WJ; Lim, HK; Lim, JH, 2003) |
| "Lipiodol-doxorubicin-targeted treatment of hepatocellular carcinoma may improve the intracellular uptake and hence cytotoxicity of doxorubicin in vivo." | ( Al-Mufti, R; Towu, E; Winslet, M, 2004) |
| "A standard treatment for hepatocellular carcinoma with extrahepatic metastasis is not established and chemotherapy is ineffective." | ( Aozasa, S; Fujino, K; Hase, K; Ito, H; Okada, K; Shikina, A; Suganuma, T; Tanaka, M; Terauchi, R; Tsuda, T; Utsunomiya, K, 2004) |
| "To find a new method of treating hepatocellular carcinoma with melittin by way of using the melittin gene." | ( Gu, W; Huang, XQ; Li, B; Li, SX; Ling, CQ; Zhang, C; Zhang, YN, 2004) |
| "To investigate the effects of different treatments for hepatocellular carcinoma (HCC) with tumor thrombus in the portal vein (PVTT)." | ( Chen, H; Cheng, SQ; Cong, WM; Ding, GH; Shen, F; Wang, PJ; Wu, MC; Yang, JH; Zhao, YX, 2005) |
| "Randomized studies on tamoxifen treatment of hepatocellular carcinoma (HCC) produced conflicting results." | ( Abergel, A; Barbare, JC; Bedenne, L; Blanchi, A; Boige, V; Bonnetain, F; Bouché, O; Denis, B; Milan, C; Pariente, A; Raoul, JL; Rougier, P, 2005) |
| "Recent studies of EGFR inhibitors to treat hepatocellular carcinoma have been encouraging and better understanding of EGFR signaling may lead to more effective strategies for inhibiting this key pathway." | ( Kannangai, R; Sahin, F; Torbenson, MS, 2006) |
| "The outcome of surgical treatment of hepatocellular carcinoma (HCC) could be improved by applying patient selection criteria based on tumoral aggressiveness." | ( Fabregat, J; Figueras, A; Figueras, J; Lastra, R; Lladó, L; Rafecas, A; Ramos, E; Serrano, T; Torras, J, 2006) |
| "Percutaneous treatment of hepatocellular carcinoma (HCC) located directly under the diaphragm is problematic because ultrasonic imaging is difficult, and the lung may be injured during the procedure." | ( Fukuno, H; Ito, S; Kohno, N; Nomura, M; Saito, K; Shimizu, I; Tamaki, K; Urata, M, 2007) |
| "Patients receiving LMCT for the treatment of hepatocellular carcinoma associated with compensated cirrhosis were included." | ( Iizawa, K; Miura, Y; Nunokawa, H; Shinzawa, H; Tanaka, H, 2007) |
| "Non-invasive therapies for the treatment of hepatocellular carcinoma (HCC) would be of great benefit to public health." | ( Alpers, CE; Bauer, RL; Campbell, JS; Fausto, N; Gilbertson, DG; Hudkins, KL; Johnson, MM; Riehle, KJ; Yeh, MM, 2007) |
| "Liver transplantation (LT) criteria for treatment of hepatocellular carcinoma (HCC) were refined to improved survival and disease-free rates." | ( Chou, SJ; Chu, CH; Chu, HC; Hsieh, CB; Shih, ML; Yao, NS; Yu, JC, 2008) |
| "Lastly, the first effective medical treatment of hepatocellular carcinoma has been presented." | ( Di Fiore, F; Michel, P, 2008) |
| "There is no standard treatment for hepatocellular carcinoma (HCC) patients with extrahepatic metastases." | ( Aikata, H; Azakami, T; Chayama, K; Jeong, SC; Kawakami, Y; Kawaoka, T; Mori, N; Takahashi, S; Takaki, S; Uka, K, 2008) |
| "We investigated this in vitro by treating hepatocellular carcinoma cells under 1." | ( Fu, Y; Liao, J; Liu, M; Luo, M; Tian, D; Wang, B; Xia, L; Yan, W; Zhu, Q, 2009) |
| "To assess the safety of transarterial treatments of hepatocellular carcinoma (HCC), and the statistical correlation of various patient factors with the frequency of complications, in selected patients with cirrhosis when adhering to well-standardized protocols." | ( Biondo, D; D'Antoni, A; Fili', D; Gridelli, B; Luca, A; Maruzzelli, L; Miraglia, R; Petridis, I; Pietrosi, G; Riccardo, V; Vizzini, GB, 2009) |
| "The proteins extracted from TNBG-treated human hepatocellular carcinoma cell line QGY-7701 were analyzed and compared with control cells by two-dimensional gel electrophoresis." | ( Gu, R; Huang, K; Li, L; Li, W; Liu, H; Yang, X; Yu, Y; Yuan, Y, 2009) |
| "XN05-treatment in human hepatocellular carcinoma cells resulted in the accumulation of G2/M phase cells and finally induced apoptosis assessed by flow cytometry analysis." | ( Ding, W; He, Q; Hu, Y; Liu, T; Wu, R; Yang, B; Zhu, H, 2009) |
| "As clinicians who treat hepatocellular carcinoma move yttrium-90 intra-arterial radiotherapy from the palliative setting to the treatment of patients with potentially curable early stage disease, more intense scrutiny of the safety of that procedure is warranted." | ( Aloia, TA; Barakat, O; Connelly, J; Gaber, AO; Ghobrial, RM; Haykal, N; Michel, D, 2009) |
| "The role of prognostic variables in the treatment of hepatocellular carcinoma (HCC) by transarterial chemoembolisation (TACE) is controversial." | ( Buccellato, A; Cottone, M; Di Piazza, S; Fusco, G; Madonia, S; Marrone, C; Olivo, M; Orlando, A; Scala, L; Sciarrino, E; Valenza, F; Virdone, R, 2010) |
| "To evaluate the effectiveness of treatment of hepatocellular carcinoma (HCC) before liver transplantation (LT) and its influence on survival and tumor recurrence in patients transplanted for HCC." | ( Bañares, R; Clemente, G; Díaz-Sánchez, A; Lo Iacono, O; Matilla, A; Merino, B; Núñez, O; Peligros, I; Rincón, D; Salcedo, M; Vega Catalina, M, 2010) |
| "Due to the ineffective conventional treatment for hepatocellular carcinoma (HCC), the nonviral gene delivery system has been proved to be an attractive alternative to HCC therapy." | ( He, Q; Huang, K; Xiao, X, 2010) |
| "The current curative treatments for hepatocellular carcinoma (HCC) do not effectively prevent tumor recurrence." | ( Kaneko, S; Nakamoto, Y, 2010) |
| "Major burdens in the treatment of hepatocellular carcinoma (HCC) are the high percentage of recurrence and resistance to chemotherapy." | ( Foris, V; Irimie, A; Kacsó, G; Mosteanu, O; Pintea, B; Pop, T; Rus-Ciuca, D; Soritau, O; Susman, S; Todea, D; Tomuleasa, C, 2010) |
| "The impact of diabetes mellitus on the treatment of hepatocellular carcinoma, especially chemotherapy, is uncertain." | ( Fang, JL; Feng, YH; Huang, WT; Lin, CY; Tsao, CJ; Wu, CL, 2011) |
| "There is no standardized treatment for hepatocellular carcinoma (HCC) with portal vein tumor thrombus." | ( Doki, Y; Eguchi, H; Kobayashi, S; Marubashi, S; Mori, M; Murakami, M; Nagano, H; Noda, T; Takeda, Y; Tanemura, M; Tomimaru, Y; Umeshita, K; Wada, H, 2011) |
| "Position of sorafenib in the treatment of hepatocellular carcinoma among hepatic arterial infusion chemotherapy and transcatheter arterial embolization is not yet clear." | ( Arai, K; Kaneko, S; Yamashita, T, 2010) |
| "Despite curative locoregional treatments for hepatocellular carcinoma (HCC), tumour recurrence rates remain high." | ( Arai, K; Arihara, F; Fujita, Y; Kakinoki, K; Kaneko, S; Kitahara, M; Marukawa, Y; Matsui, O; Matsushima, K; Mizukoshi, E; Mukaida, N; Nakamoto, Y; Sakai, Y; Yamashita, T, 2011) |
| "Liver transplant can be a definitive treatment for hepatocellular carcinoma." | ( Busuttil, RW; Finn, RS; McTigue, M; Saab, S, 2010) |
| "Surgical resection is the first-line treatment for hepatocellular carcinoma (HCC) patients with well-preserved liver function." | ( Cheng, SQ; Deng, YZ; Feng, YX; Guan, DX; Li, JJ; Li, N; Qin, Y; Wang, H; Wang, HY; Wang, T; Wang, XF; Wu, MC; Xie, D; Yang, P; Yao, F; Zhu, YQ, 2011) |
| "Zuo-Jin-Wan (ZJW) has been used to treat hepatocellular carcinoma in Asia." | ( Chang, CS; Chao, DC; Ho, TY; Hsiang, CY; Huang, HC; Kao, ST; Liang, JA; Lin, LJ; Wu, SL, 2011) |
| "Sorafenib is an FDA-approved agent for treatment of human hepatocellular carcinoma (HCC), but tumor shrinkage is minor." | ( Carr, BI; Cavallini, A; D'Alessandro, R; Refolo, MG; Wang, M; Wang, Z, 2011) |
| "Despite progress made in the treatment of hepatocellular carcinoma (HCC), there is no curable treatment." | ( Deng, YQ; Guo, ZY; Hu, FY; Huang, WJ; Li, L; Tong, AP; Yang, JL; Yang, L; Zeng, XR; Zhou, R, 2012) |
| "Despite recent advances in the treatment of hepatocellular carcinoma (HCC), the chemotherapy efficacy against HCC is still unsatisfactory." | ( Gao, D; Guo, K; Jiang, K; Jin, G; Kang, X; Li, Y; Liu, Y; Shu, H; Sun, C; Sun, H; Sun, L; Wang, C; Wu, W, 2012) |
| "Sorafenib has been used to treat advanced hepatocellular carcinoma (HCC), but the underlying molecular mechanisms remain controversial and why some patients do not respond to this therapy is poorly understood." | ( Cabrera, R; Cao, M; Liu, C; Nelson, DR; Ogunwobi, OO; Puszyk, WM; Tian, C; Wang, T; Zhao, X, 2013) |
| "Systematic segmentectomy is useful in treating small hepatocellular carcinoma in the cirrhotic liver." | ( Ahn, KS; Kang, KJ; Kim, YH; Kwon, JH; Lim, TJ; Park, TJ, 2013) |
| "The ability to treat hepatocellular carcinoma was measured by comparing biochemical serum markers such as serum alanine aminotransferase, serum aspartate aminotransferase, serum alkaline phosphatase, and the specific marker for hepatocellular carcinoma, alpha fetoprotein." | ( Afzal, M; Ahmad, A; Al-Abbasi, FA; Anwar, F; Kazmi, I; Narooka, AR; Singh, R, 2013) |
| "Chemotherapeutic treatment of hepatocellular carcinoma often leads to chemoresistance during therapy or upon relapse of tumors." | ( Günther, M; Hoehn, M; Marfels, C; Wagner, E, 2013) |
| "Sorafenib is a promising treatment for hepatocellular carcinoma (HCC) but recent toxicity concerns suggest that new strategies for its use are needed." | ( Katano, M; Kiyota, A; Koya, N; Morisaki, T; Onishi, H; Tanaka, H; Umebayashi, M, 2013) |
| "Following treatment of the hepatocellular carcinoma cell lines BEL-7402 and QGY-7703 with EGCG, in vitro, EGCG significantly suppressed cell proliferation as detected by MTT assay, induced apoptosis as detected by flow cytometry, dramatically lowered the expression levels of phosphorylated Stat3 proteins (p-Stat3) as determined by immunoblot detection, and inhibited the expression of multiple genes including Bcl-xL, c-Myc, VEGF and cyclin D1 as demonstrated by RT-PCR analysis." | ( Deng, C; Guo, T; Li, Y; Ren, X; Wang, Y; Xu, MX; Yan, E; Yang, L, 2013) |
| "Six years after the diagnosis of untreatable hepatocellular carcinoma, the patient remains in a good condition." | ( Den Otter, W; Krastev, Z; Popov, D; Tomov, B; Tomova, R; Vladov, N, 2013) |
| "Group-II animals were kept untreated as hepatocellular carcinoma control." | ( Jhala, M; Joseph, JP; Kumar, P; Raval, SK; Sadariya, KA, 2013) |
| "Surgical therapies are the first-line treatments for hepatocellular carcinoma (HCC) patients." | ( Geng, W; Kwok, SY; Lau, SH; Li, CX; Ling, CC; Liu, XB; Lo, CM; Ma, YY; Man, K; Ng, KT; Qi, X; Shao, Y; Tzang, FC; Wei, N; Wong, BL, 2014) |
| "Sorafenib, the drug used as first line treatment for hepatocellular carcinoma (HCC), is metabolized by cytochrome P450 (CYP) 3A4-mediated oxidation and uridine diphosphate glucuronosyl transferase (UGT) 1A9-mediated glucuronidation." | ( Chen, W; Guo, E; Liu, Z; Lu, L; Peng, X; Wang, Y; Yan, T; Yang, X; Ye, L; Zhou, F, 2014) |
| "Multiple modalities for treatment of hepatocellular carcinoma are available, depending on tumor size and number." | ( Imagawa, DK; Reataza, M, 2014) |
| "The study will be helpful for the treatment of hepatocellular carcinoma and to provide theoretical basis for the clinical application of feverfew lactone." | ( Gao, B; Gao, JP; Li, J; Li, YY; Lin, P; Liu, ZP, 2014) |
| "A major obstacle to successful treatment of hepatocellular carcinoma (HCC) is its high resistance to cytotoxic chemotherapy due to overexpression of multidrug resistance genes." | ( Chiang, CL; Ghoshal, K; He, H; Hsu, S; Jacob, ST; Lee, LJ; Lu, Y; Ren, W; Teng, KY; Wang, X; Yang, Z; Yu, B, 2015) |
| "A retrospective analysis of 20 patients treated for hepatocellular carcinoma between 1994 and 2007." | ( Dvorak, J; Ferko, A; Kamaradova, K; Krajina, A; Melichar, B, 2015) |
| "Despite advances in the detection and treatment of hepatocellular carcinoma (HCC), the prognosis remains poor partly due to recurrence or extra/intrahepatic metastasis." | ( Dong, JH; Duan, WD; Leng, JJ; Wang, X; Wang, XD; Xu, YZ; Zhang, AQ; Zhang, N; Zhou, L, 2015) |
| "Few reports are available on LH for the treatment of hepatocellular carcinoma (HCC) in the posterosuperior liver segments (I, IVa, VII, and VIII), especially in association with cirrhosis." | ( Chen, J; Fan, Y; Li, J; Xiang, L; Xiao, L; Zheng, S, 2015) |
| "Sorafenib is the medical reference for treatment of hepatocellular carcinoma (HCC)." | ( Barbare, JC; Barget, N; Bodeau, S; Chauffert, B; Conte, MA; Diouf, M; Galmiche, A; Ganne, N; Godin, C; Louandre, C; Saidak, Z; Trinchet, JC, 2015) |
| "At present, the treatment of hepatocellular carcinoma (HCC) is an international problem." | ( Chen, Q; Li, Y; Liu, W; Tang, H; Yang, X; Zhao, X, 2015) |
| "Despite advances in the treatment of hepatocellular carcinoma (HCC), managing HCC with portal vein thrombosis (PVT) remains challenging." | ( Heo, J; Woo, HY, 2015) |
| "Chemotherapy is one of the most common treatments used for hepatocellular carcinoma (HCC), which effectively improves outcome and reduces tumor recurrence." | ( Guo, R; Lei, X; Ma, J; Pan, X; Peng, C; Tang, H; Wang, T; Xiang, Q; Yang, X; Yin, J; Yu, J; Zu, X, 2015) |
| "Tumors that respond well to antioxidant treatments, such as hepatocellular carcinoma (HCC), may benefit from treatment with selenium as this compound also has antioxidant properties." | ( Kim, HJ; Kim, YM; Lee, YK; Park, OJ; Park, SY, 2016) |
| "Despite progress in diagnostics and treatment of hepatocellular carcinoma (HCC), its prognosis remains poor." | ( Liu, J; Luo, W; Shan, E; Xi, T; Xiong, J; Yang, H; Yang, J; Zhang, F, 2016) |
| "The optimal treatment for hepatocellular carcinoma (HCC) with portal vein tumor thrombus (PVTT) remains controversial." | ( Chen, MS; Cheng, SQ; Cong, WM; Guo, WX; Lau, WY; Mao, YL; Meng, Y; Shi, J; Sun, BC; Wang, K; Wu, MC; Yang, YF; Zhang, YJ, 2016) |
| "Despite the great progress in the treatment of hepatocellular carcinoma, combination chemotherapy is still the main choice of treatment for patients with unresectable metastatic or recurrent hepatocellular cancer." | ( Cheng, F; Cheng, Y; Huang, X; Li, Q; Wang, J; Wang, K; Zhang, Y, 2016) |
| "In summary, DNC-treated hepatocellular carcinoma cells undergo apoptosis by changing the expression of genes involved in the apoptosis and proliferation processes." | ( Khodi, S; Mohaghegh, M; Montazeri, M; Pilehvar-Soltanahmadi, Y; Sadeghizadeh, M; Sadeghzadeh, H; Zarghami, F; Zarghami, N, 2016) |
| "Sorafenib (SOR) is the first-line treatment for hepatocellular carcinoma (HCC)." | ( Abdel-Naim, AB; Badawy, NN; El-Ahwany, E; Khalifa, AE; Liu, AW; Tolba, MF; Youssef, MM; Zada, S, 2016) |
| "Due to the lack of effective treatment, hepatocellular carcinoma (HCC) is one of the malignancies with low survival rates worldwide." | ( Chen, X; He, Y; Huang, Z; Ke, X; Wen, Y; Zhou, X; Zou, F, 2016) |
| "Drug treatments for hepatocellular carcinoma (HCC) often fail because of multidrug resistance (MDR)." | ( Dai, H; Li, J; Ling, S; Liu, J; Lu, D; Shan, Q; Song, P; Wen, X; Xie, H; Xu, X; Zheng, S; Zhou, L, 2017) |
| "The efficacious treatment of hepatocellular carcinoma (HCC) remains a challenge, partially being attributed to intrinsic chemoresistance." | ( Chen, RM; Chen, YJ; Chong, QY; Liu, L; Lobie, PE; Ma, L; Pandey, V; Wu, MM; Wu, ZS; You, ML; Zhu, T, 2017) |
| "In this study, we evaluated XCHT-treated hepatocellular carcinoma (HCC) for anti-proliferative and pro-apoptotic effects." | ( Hong, Z; Liu, L; Wan, Y; Zhang, Y; Zhao, J, 2017) |
| "Radioembolization for the treatment of hepatocellular carcinoma (HCC) induces liver volume changes referred to as "atrophy-hypertrophy complex"." | ( Bellendorf, A; Dechêne, A; Goebel, J; Goebel, T; Lazik-Palm, A; Mueller, S; Sulke, M; Theysohn, J; Umutlu, L, 2017) |
| "Food and Drug Administration for the treatment of hepatocellular carcinoma that has progressed on sorafenib and is expected to become a standard of care for these patients." | ( Bi, Y; Casak, S; Goldberg, KB; Jiang, X; Keegan, P; Lemery, S; Liu, J; McKee, AE; Patel, A; Pazdur, R; Pelosof, L; Pierre, V; Rodriguez, L; Zirkelbach, JF, 2018) |
| "Early identification and treatment of hepatocellular carcinoma is very important for improving the prognosis and survival rate of the patient." | ( Jin, Y; Tian, J; Yang, X, 2018) |
| "Sorafenib (SFB) has improved the treatment of hepatocellular carcinoma (HCC) and has fewer severe side effects than other agents used for that purpose." | ( Cai, S; Chen, L; Jiang, Z; Li, A; Liang, Y; Liu, X; Ma, D; Tang, X; Zhang, Y, 2018) |
| "Sorafenib has been widely used to treat unresectable hepatocellular carcinoma (HCC) but most studies have been done in Child-Pugh A (CP-A) patients with well-preserved liver function." | ( Aquino, D; Balbi, E; Barbosa, D; Carvalho, B; de Tarso Pinto, P; Leal, CRG; Magalhães, C; Pacheco, L; Perez, R; Setubal, S, 2018) |
| "TACE is recognized as the standard treatment of hepatocellular carcinoma patients at an intermediate stage." | ( Boulin, M; Cassinotto, C; Delicque, J; Guiu, B; Piron, L; Schwanz, H, 2018) |
| "Among patients with previously treated advanced hepatocellular carcinoma, treatment with cabozantinib resulted in longer overall survival and progression-free survival than placebo." | ( Abou-Alfa, GK; Blanc, JF; Bolondi, L; Borgman-Hagey, AE; Chan, SL; Chen, Y; Cheng, AL; Cicin, I; El-Khoueiry, AB; Hessel, C; Kelley, RK; Klümpen, HJ; Merle, P; Meyer, T; Park, JW; Pressiani, T; Rimassa, L; Ryoo, BY; Ryu, MH; Schwab, G; Venook, AP; Zagonel, V, 2018) |
| "The most effective treatment of hepatocellular carcinoma is surgical removal of the tumour but there is often recurrence." | ( Berhane, S; Chan, AWH; Chong, CCN; Cucchetti, A; García-Fiñana, M; Johnson, PJ; Kudo, M; Kumada, T; Lai, PBS; Li, LQ; Mazzaferro, V; Roayaie, S; Shi, K; Tada, T; Toyoda, H; Xiang, BD; Zhong, J, 2018) |
| "The principal advancements in the treatment of hepatocellular carcinoma (HCC) are the use of new systemic treatments, such as lenvatinib in first-line treatment and regorafenib, cabozantinib, and ramucirumab in second-line treatment, because of their benefits in terms of overall survival." | ( Díaz-Gonzalez, Á; Reig, M; Sanduzzi-Zamparelli, M, 2019) |
| "Despite being accepted as a mainstay of treatment for hepatocellular carcinoma (HCC), technical aspects of transarterial chemoembolization (TACE) continue to vary by reporting author, leading to heterogeneity in the literature and making meaningful comparisons between treatments difficult." | ( Craig, P; Golzarian, J; Young, S, 2019) |
| "At present, the treatment of hepatocellular carcinoma (HCC) remains to be a problem globally." | ( Chen, XZ; Li, XJ; Li, YS; Shang, HC; Tang, HB; Tian, GH; Zhang, WK, 2018) |
| "Therapeutic attempts to treat hepatocellular carcinoma (HCC) frequently result in a poor response or treatment failure." | ( Chieti, A; Cigliano, A; Dituri, F; Giannelli, G; Mancarella, S, 2019) |
| "Patients receiving sorafenib treatment for hepatocellular carcinoma (HCC) experience different treatment efficacy." | ( Ba, Q; Chen, P; Chen, S; Ge, Y; Li, J; Mu, W; Wang, H; Wang, X, 2019) |
| "Sorafenib is the first-line treatment for hepatocellular carcinoma with portal vein invasion; however, it has shown unsatisfactory survival benefit." | ( Chen, M; Fang, W; Guo, R; Guo, Y; He, M; Le, Y; Li, Q; Shen, J; Shi, M; Tan, G; Wei, W; Wu, X; Xu, L; Zhao, M; Zhou, Y; Zhou, Z; Zou, R, 2019) |
| "Radiation therapy is a major treatment in hepatocellular carcinoma (HCC)." | ( Cao, X; Lin, Y; You, X, 2019) |
| "The clinical treatment of hepatocellular carcinoma has been hindered due to the drug resistance and heterogeneity of tumor cells." | ( Bai, L; Chunyang, Z; Dan, W; Guangliang, H; Huanling, G; Jie, L; Manxia, L; Ming, X; Wei, W; Xiangzi, S; Xiaoyan, X; Yang, T; Zhong, C, 2019) |
| "The first choice of treatment in Hepatocellular Carcinoma (HCC) is 5-fluorouracil (5-FU)." | ( Fard, MM; Hassanzadeh, F; Mirian, M; Varshosaz, J, 2020) |
| "MATERIAL AND METHODS We treated hepatocellular carcinoma (HCC) Huh-7 cells and tumor xenograft mice models with celecoxib to test its effects on the tumor." | ( Dai, H; Ma, R; Pan, L; Zhang, S, 2019) |
| "From 2005 to 2016, a total of 656 treatment-naive hepatocellular carcinoma patients receiving transarterial chemoembolization treatment were recruited." | ( Chen, YC; Hsieh, YC; Huang, CH; Hung, CF; Jeng, WJ; Lin, CC; Lin, CY; Lin, PT; Lin, SM; Lui, KW; Sheen, IS; Teng, W, 2020) |
| "The main curative treatments for hepatocellular carcinoma (HCC) are surgical resection and liver transplantation, which only benefits 15% to 25% of patients." | ( Lin, LS; Liu, TP; Yang, PM, 2020) |
| "Whereas sorafenib is used for the treatment of human hepatocellular carcinoma (HCC), resistance limits its efficacy." | ( Ichimura, Y; Imamura, R; Kojima, H; Komatsu, M; Mashino, T; Nagano, T; Ohe, T; Okabe, T; Takahashi, K; Yamamoto, M; Yasuda, D, 2020) |
| "Potential agents that can effectively treat hepatocellular carcinoma (HCC) are being continuously explored." | ( Chen-Fang, L; Chih-Hsien, C; Hong-Shiue, C; Kun-Ming, C; Ting-Jung, W; Wei-Chen, L, 2020) |
| "There is an urgent need for effective treatments for hepatocellular carcinoma (HCC)." | ( Ba, Q; Gao, Z; Li, J; Li, X; Qiu, L; Sun, M; Wang, F; Wang, H; Wang, W; Yang, C; Yang, Y; Yao, W; You, R, 2020) |
| "Chemotherapy is critical for the treatment of hepatocellular carcinoma (HCC)." | ( Jia, M; Li, M; Mao, Q; Xiong, Y, 2020) |
| "However, the use of solasonine for the treatment of hepatocellular carcinoma (HCC) has not yet been reported." | ( Hu, C; Huang, G; Jin, M; Li, T; Shi, C; Wu, Y, 2020) |
| "The effective treatment of hepatocellular carcinoma (HCC) requires development of novel drug formulations that selectively kill HCC cells while sparing healthy liver cells." | ( Cheng, L; Wang, X; Yuan, J; Zhang, J; Zhong, Z, 2021) |
| "Although sorafenib has been used to treat advanced hepatocellular carcinoma (HCC), the efficacy of sorafenib in patients with recurrent HCCs after liver transplantation (LT) has not been compared with that in patients without LT (non-LT)." | ( Bae, SH; Choi, HJ; Choi, JY; Jang, JW; Kim, CW; Kim, HY; Kwon, JH; Lee, SK; Lee, SW; Nam, H; Song, DS; Song, MJ; Sung, PS; Yoon, SK; You, YK, 2021) |
| "Radical treatments of hepatocellular carcinoma (HCC) with hepatic encephalopathy (HE) can be often difficult due to poor liver function or disturbance of consciousness." | ( Miyasaka, Y; Ohno, T; Okamoto, M; Okazaki, S; Osu, N; Shiba, S; Shibuya, K, 2021) |
| "Triptolide (TPL) has been employed to treat hepatocellular carcinoma (HCC)." | ( Gong, C; Li, Z; Wang, J; Wang, R; Wang, Y; Yang, G; Yang, M; Yuan, Y, 2022) |
| "Sorafenib is mainly used to treat patients with hepatocellular carcinoma (HCC) Barcelona Clinic Liver Cancer (BCLC) stage C, many of whom also have severe cirrhosis." | ( Luo, X; Luo, Z; Wang, C; Wang, Y; Zeng, J; Zhang, Y, 2021) |
| "Various treatments are available for treating hepatocellular carcinoma (HCC)." | ( Aikata, H; Amioka, K; Ando, Y; Arihiro, K; Fujino, H; Imamura, M; Johira, Y; Kawaoka, T; Kobayashi, T; Kodama, K; Kosaka, M; Kosaka, Y; Kuroda, S; Miura, R; Mori, K; Murakami, E; Murakami, S; Nakahara, T; Naruto, K; Ohdan, H; Ohno, A; Okamoto, W; Shirane, Y; Uchikawa, S; Yamaoka, K; Yamauchi, M; Yano, S, 2021) |
| "The surgical treatment for large hepatocellular carcinoma (HCC) remains controversial because of a high risk of recurrence after resection." | ( Cho, EJ; Cho, HJ; Choi, NR; Hong, JH; Hur, MH; Hyun, D; Kim, HC; Kim, J; Kim, JM; Kim, JY; Kim, YJ; Lee, JH; Lee, KW; Lee, YB; Paeng, JC; Park, MK; Sinn, DH; Suh, KS; Yi, NJ; Yoon, JH; Yu, SJ, 2022) |
| "Although there are many options for the treatment of hepatocellular carcinoma, such as surgical resection, interventional therapy, radiotherapy, chemotherapy, targeted therapy and liver transplantation, the poor therapeutic effect seriously reduces the quality of life for patients and also increases the social and economic burden." | ( Liu, W; Xiong, S, 2022) |
| "Locoregional treatments for hepatocellular carcinoma (HCC) induce immunogenic cell death and a tumor-specific immune response, but infiltration and activation of immune cells in the liver have not been clearly described." | ( Chun, HJ; Han, JW; Hur, W; Jin, L; Kang, BY; Kim, SM; Kim, WJ; Roh, PR; Sung, PS; Tak, E; Yoon, SK, 2022) |
| "The current systemic drugs used to treat hepatocellular carcinoma result in low overall survival time." | ( Cao, Z; Deng, X; Ding, W; Dong, F; Han, M; Hao, P; Jin, L; Li, J; Liu, D; Liu, G; Liu, H; Luo, W; Mu, J; Pan, L; Pang, Y; Wang, T; Wei, Y; Zeng, G; Zhang, H; Zhang, Y; Zhen, C, 2022) |
| "At present, the treatment of hepatocellular carcinoma (HCC) is disturbed by the treatment failure and recurrence caused by the residual liver cancer stem cells (CSCs)." | ( Chen, Z; Li, F; Li, Y; Wang, Y; Wang, Z; Xi, X; Xu, L, 2023) |
| "Curative treatment for hepatocellular carcinoma (HCC) is limited to hepatic resection (HR), radiofrequency ablation, and liver transplantation, but the value of particle therapy (PT) as an initial treatment remains unclear." | ( Fukumoto, T; Komatsu, S; Matsuo, Y; Okimoto, T; Omiya, S; Terashima, K; Tokumaru, S; Toyama, H; Yamasaki, N, 2023) |
| "Regorafenib is a standard second-line treatment for hepatocellular carcinoma (HCC)." | ( Chai, J; Liu, K; Lu, D; Lv, W; Wang, L; Xiao, J; Xu, B; Zhang, X; Zhang, Z, 2023) |
| "Sorafenib is the first-line treatment for hepatocellular carcinoma (HCC), but its efficacy is limited by the drug resistance of HCC cells." | ( Wang, D; Yang, J, 2023) |
| "Traditional treatments for hepatocellular carcinoma (HCC) still lack effectiveness." | ( Chen, X; Geng, J; Guo, Y; Kong, G; Li, Z; Shen, H; Sun, J; Tian, H; Wang, F; Wang, H; Yu, S; Zhang, L; Zhao, Y, 2023) |
| "As an innovative technique of treatments for hepatocellular carcinoma (HCC) in recent years, nanocarrier-mediated targeted drug delivery systems can overcome the aforesaid limitations via enhanced permeability and retention effect (EPR) and active targeting." | ( Arya, DK; Deepak, P; Kumar, P; Kumar, S; Narayan, G; Pandey, P; Parida, BP; Rajinikanth, PS; Singh, S, 2023) |
| "So far, there is no gold standard treatment for hepatocellular carcinoma." | ( Badria, F; El Saadany, AA; Elnawasany, S; Haggag, YA; Ibrahim, MAA; Shalaby, SM; Soliman, NA, 2023) |
| "Currently, conventional treatments of hepatocellular carcinoma (HCC) are not selective enough for tumor tissue and lead to multidrug resistance and drug toxicity." | ( Aliberti, A; Buonaguro, L; Caputo, TM; Carriero, MV; Celetti, G; Cicatiello, P; Cusano, A; Cusano, AM; Micco, A; Minopoli, M; Principe, S; Ragone, C; Ruvo, M; Tagliamonte, M, 2023) |
| "Cisplatin (CPT) is one of the standard treatments for hepatocellular carcinoma (HCC)." | ( Cai, W; Chen, Z; Ding, Y; Jiang, H; Song, X; Wu, X; Xu, J; Xu, Q; Ying, H; Ying, K; Yu, F; Zeng, L; Zeng, Y; Zhang, X; Zhao, L; Zhou, R, 2023) |
| "When treating hepatocellular carcinoma with a portal vein tumor thrombus, the computer retrieves eight databases to find controlled trials on the effects of transcatheter arterial chemoembolization combined with apatinib." | ( Hu, Y; Huang, L; Xu, Z, 2023) |
| "The current medical practice in treating Hepatocellular carcinoma (HCC) using Drug Eluting Transarterial chemoembolization (DEB-TACE) technique is limited only to hydrophilic ionizable drugs, that can be attached ionically to the oppositely charged beads." | ( Amer, MS; Borchard, G; Elshafeey, AH; Jordan, O; Qubisi, M; Sakr, OS; Zaitoun, MMA, 2023) |
| "Sorafenib is an oral treatment for hepatocellular carcinoma (HCC)." | ( Cui, M; Fang, Z; Lai, K; Liu, K; Song, M; Yin, M, 2023) |
| "The use of regorafenib in the treatment of hepatocellular carcinoma (HCC) is widespread." | ( Aprile, G; Cao, D; Ge, W; He, A; Samant, H; Satapathy, SK; Shelat, VG; Tang, X; Tustumi, F; Xu, H; Xu, X; Zhao, N; Zhou, D, 2023) |
| Drug | Indicated | Relationship Strength | Studies | Trials |
|---|
| acetylcarnitine | 0 | medium | 5 | 1 |
| dinitrochlorobenzene | 0 | low | 5 | 0 |
| ethylene dichloride | 0 | low | 1 | 0 |
| tartronic acid | 0 | low | 2 | 0 |
| 2,3-diphosphoglycerate | 0 | low | 1 | 0 |
| 2-keto-4-methylvalerate | 0 | medium | 1 | 1 |
| protocatechuic acid | 0 | medium | 6 | 1 |
| 3-hydroxyanthranilic acid | 0 | low | 5 | 0 |
| 3-hydroxykynurenine | 0 | low | 1 | 0 |
| acetoacetic acid | 0 | low | 12 | 0 |
| phosphoserine | 0 | low | 19 | 0 |
| gamma-aminobutyric acid | 0 | low | 5 | 0 |
| 4-hydroxybenzoic acid | 0 | low | 1 | 0 |
| aminolevulinic acid | 0 | low | 29 | 0 |
| 5-hydroxytryptophan | 0 | low | 1 | 0 |
| ethylene glycol | 0 | medium | 1 | 1 |
| acetic acid | 0 | medium | 60 | 12 |
| acetaldehyde | 0 | low | 30 | 0 |
| acetoin | 0 | low | 1 | 0 |
| acetone | 0 | low | 9 | 0 |
| adenine | 0 | medium | 151 | 7 |
| agmatine | 0 | low | 4 | 0 |
| allantoin | 0 | low | 1 | 0 |
| ammonium hydroxide | 0 | medium | 43 | 4 |
| anthranilic acid | 0 | low | 1 | 0 |
| quinacrine | 0 | low | 6 | 0 |
| phycoerythrin | 0 | low | 1 | 0 |
| beta-alanine | 0 | low | 5 | 0 |
| benzaldehyde | 0 | low | 6 | 0 |
| benzene | 0 | medium | 15 | 1 |
| benzoic acid | 0 | low | 1 | 0 |
| betaine | 0 | low | 12 | 0 |
| 1-butanol | 0 | low | 3 | 0 |
| butyric acid | 0 | low | 38 | 0 |
| cadaverine | 0 | low | 3 | 0 |
| carbamates | 0 | low | 50 | 0 |
| carbamyl phosphate | 0 | low | 4 | 0 |
| carbon monoxide | 0 | low | 4 | 0 |
| formic acid | 0 | low | 3 | 0 |
| aminooxyacetic acid | 0 | low | 3 | 0 |
| carnitine | 0 | medium | 30 | 3 |
| catechol | 0 | low | 3 | 0 |
| methane | 0 | medium | 18 | 4 |
| choline | 0 | medium | 105 | 4 |
| aconitic acid | 0 | low | 2 | 0 |
| citric acid, anhydrous | 0 | medium | 11 | 2 |
| chlorine | 0 | medium | 42 | 1 |
| hydrochloric acid | 0 | low | 8 | 0 |
| coumarin | 0 | low | 5 | 0 |
| salicylic acid | 0 | low | 7 | 0 |
| octane | 0 | low | 1 | 0 |
| phloroglucinol | 0 | low | 5 | 0 |
| gallic acid | 0 | low | 15 | 0 |
| 4-nitrophenylphosphate | 0 | low | 1 | 0 |
| octanoic acid | 0 | low | 2 | 0 |
| 2-nitropropane | 0 | low | 1 | 0 |
| hydrogen sulfide | 0 | medium | 18 | 1 |
| trimethylenediamine | 0 | low | 1 | 0 |
| 3-hydroxybutyric acid | 0 | low | 14 | 0 |
| bupropion | 0 | low | 1 | 0 |
| n(1)-methylnicotinamide | 0 | low | 1 | 0 |
| guaiacol | 0 | low | 7 | 0 |
| 4-aminoimidazole | 0 | low | 1 | 0 |
| n(g),n(g')-dimethyl-l-arginine | 0 | low | 1 | 0 |
| 2-methylcitric acid | 0 | low | 2 | 0 |
| malic acid | 0 | low | 2 | 0 |
| propionaldehyde | 0 | low | 3 | 0 |
| phosphonoacetic acid | 0 | low | 1 | 0 |
| 3,4-dihydroxyphenylacetic acid | 0 | low | 1 | 0 |
| aminocaproic acid | 0 | low | 3 | 0 |
| dibenzofuran | 0 | low | 4 | 0 |
| creatine | 0 | low | 4 | 0 |
| cytosine | 0 | low | 34 | 0 |
| lactic acid | 0 | medium | 117 | 1 |
| diacetyl | 0 | low | 1 | 0 |
| dihydroxyacetone | 0 | low | 1 | 0 |
| dimethylglycine | 0 | low | 2 | 0 |
| dimethylamine | 0 | low | 1 | 0 |
| dimethyl sulfoxide | 0 | medium | 49 | 1 |
| ethanolamine | 0 | low | 7 | 0 |
| formaldehyde | 0 | medium | 38 | 1 |
| 3-phosphoglycerate | 0 | low | 1 | 0 |
| gamma-butyrobetaine | 0 | low | 1 | 0 |
| hexachlorocyclohexane | 0 | low | 2 | 0 |
| glycine | 0 | medium | 67 | 1 |
| glyceraldehyde | 0 | low | 5 | 0 |
| glycerol | 0 | medium | 36 | 3 |
| glycolic acid | 0 | low | 4 | 0 |
| hydrogen carbonate | 0 | low | 10 | 0 |
| dalteparin | 0 | medium | 3 | 1 |
| histamine | 0 | medium | 16 | 3 |
| homogentisic acid | 0 | low | 1 | 0 |
| hydrogen | 0 | medium | 7 | 3 |
| hydroquinone | 0 | low | 1 | 0 |
| hydroxylamine | 0 | low | 1 | 0 |
| imidazole | 0 | low | 1 | 0 |
| indole | 0 | low | 2 | 0 |
| indoleacetic acid | 0 | low | 3 | 0 |
| iodine | 0 | medium | 52 | 9 |
| dihydroxyphenylalanine | 0 | low | 5 | 0 |
| kynurenine | 0 | low | 8 | 0 |
| thioctic acid | 0 | low | 17 | 0 |
| malonic acid | 0 | low | 1 | 0 |
| pyruvaldehyde | 0 | low | 4 | 0 |
| methanol | 0 | medium | 41 | 1 |
| phytic acid | 0 | medium | 20 | 1 |
| inositol | 0 | medium | 10 | 1 |
| melatonin | 0 | medium | 48 | 3 |
| croton oil | 0 | low | 7 | 0 |
| naphthalene | 0 | low | 1 | 0 |
| nickel | 0 | medium | 25 | 2 |
| niacinamide | 0 | medium | 1,639 | 174 |
| niacin | 0 | low | 12 | 0 |
| nitrates | 0 | medium | 17 | 4 |
| nitroxyl | 0 | medium | 2 | 1 |
| nitrites | 0 | medium | 23 | 2 |
| nitrous oxide | 0 | low | 2 | 0 |
| hydroxide ion | 0 | low | 1 | 0 |
| orotic acid | 0 | low | 47 | 0 |
| oxaloacetic acid | 0 | low | 1 | 0 |
| oxamic acid | 0 | low | 5 | 0 |
| 4-aminobenzoic acid | 0 | low | 5 | 0 |
| 4-nitrophenol | 0 | low | 3 | 0 |
| triphosphoric acid | 0 | low | 2 | 0 |
| palmitic acid | 0 | low | 48 | 0 |
| pentachlorophenol | 0 | low | 1 | 0 |
| phenanthrene | 0 | low | 1 | 0 |
| phenol | 0 | low | 13 | 0 |
| phenylpyruvic acid | 0 | low | 1 | 0 |
| phenylacetic acid | 0 | low | 3 | 0 |
| phosphoenolpyruvate | 0 | low | 6 | 0 |
| phosphorylcholine | 0 | low | 6 | 0 |
| phosphorylethanolamine | 0 | low | 1 | 0 |
| phthalic acid | 0 | low | 1 | 0 |
| porphobilinogen | 0 | low | 5 | 0 |
| diphosphoric acid | 0 | low | 2 | 0 |
| pqq cofactor | 0 | low | 1 | 0 |
| propylene glycol | 0 | medium | 3 | 2 |
| 1-propanol | 0 | low | 4 | 0 |
| propionic acid | 0 | low | 1 | 0 |
| pteridines | 0 | low | 5 | 0 |
| purine | 0 | low | 13 | 0 |
| putrescine | 0 | low | 16 | 0 |
| pyrazinamide | 0 | low | 2 | 0 |
| pyrazole | 0 | low | 6 | 0 |
| pyridine | 0 | low | 2 | 0 |
| pyridoxal | 0 | low | 33 | 0 |
| pyridoxal phosphate | 0 | medium | 40 | 13 |
| pyridoxamine | 0 | low | 1 | 0 |
| pyridoxine | 0 | low | 18 | 0 |
| pyrogallol | 0 | low | 2 | 0 |
| pyruvic acid | 0 | low | 23 | 0 |
| quinolinic acid | 0 | low | 1 | 0 |
| thiosulfates | 0 | medium | 8 | 1 |
| dithionite | 0 | low | 1 | 0 |
| sarcosine | 0 | low | 4 | 0 |
| sulfites | 0 | medium | 15 | 1 |
| spermidine | 0 | low | 18 | 0 |
| spermine | 0 | medium | 19 | 1 |
| succinic acid | 0 | medium | 9 | 1 |
| sulfur dioxide | 0 | medium | 4 | 2 |
| taurine | 0 | low | 14 | 0 |
| thiamine | 0 | low | 5 | 0 |
| thymine | 0 | low | 24 | 0 |
| toluene | 0 | medium | 25 | 1 |
| trimethyloxamine | 0 | low | 1 | 0 |
| trimethylamine | 0 | low | 2 | 0 |
| uric acid | 0 | medium | 21 | 1 |
| vanillin | 0 | low | 6 | 0 |
| xanthine | 0 | low | 5 | 0 |
| isopentenyl pyrophosphate | 0 | low | 1 | 0 |
| isocitric acid | 0 | low | 1 | 0 |
| vanilmandelic acid | 0 | low | 1 | 0 |
| menthol | 0 | low | 1 | 0 |
| 1,10-phenanthroline | 0 | low | 3 | 0 |
| 1,2-dimethylhydrazine | 0 | low | 3 | 0 |
| pk 11195 | 0 | low | 2 | 0 |
| 1-aminocyclohexanecarboxylic acid | 0 | low | 1 | 0 |
| 1-anilino-8-naphthalenesulfonate | 0 | medium | 102 | 1 |
| edelfosine | 0 | low | 3 | 0 |
| pd 173074 | 0 | low | 3 | 0 |
| 2,2'-dipyridyl | 0 | low | 3 | 0 |
| 2,4,5-trichlorophenoxyacetic acid | 0 | low | 2 | 0 |
| 2,4-dichlorophenoxyacetic acid | 0 | low | 3 | 0 |
| 2,4-dinitrophenol | 0 | low | 3 | 0 |
| 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine | 0 | low | 5 | 0 |
| 2-aminofluorene | 0 | low | 2 | 0 |
| mercaptoethanol | 0 | low | 21 | 0 |
| 2-aminoethoxydiphenyl borate | 0 | low | 3 | 0 |
| 3,4-methylenedioxyamphetamine | 0 | low | 1 | 0 |
| amitrole | 0 | low | 4 | 0 |
| 3-aminobenzamide | 0 | low | 3 | 0 |
| 3-methylcholanthrene | 0 | low | 86 | 0 |
| enprofylline | 0 | low | 1 | 0 |
| 4-(2-aminoethyl)benzenesulfonylfluoride | 0 | low | 3 | 0 |
| 4-amino-1,8-naphthalimide | 0 | low | 3 | 0 |
| 4-nonylphenol | 0 | low | 1 | 0 |
| phenytoin | 0 | low | 7 | 0 |
| 5,8,11,14-eicosatetraynoic acid | 0 | low | 1 | 0 |
| 5-(n,n-hexamethylene)amiloride | 0 | low | 1 | 0 |
| ethylisopropylamiloride | 0 | low | 3 | 0 |
| hydroxyindoleacetic acid | 0 | low | 1 | 0 |
| 5-methoxytryptamine | 0 | low | 1 | 0 |
| 8-cyclopentyl-1,3-dimethylxanthine | 0 | low | 1 | 0 |
| 8-phenyltheophylline | 0 | low | 2 | 0 |
| oxyquinoline | 0 | medium | 7 | 1 |
| tacrine | 0 | low | 6 | 0 |
| 2,2'-azobis(2-amidinopropane) | 0 | low | 2 | 0 |
| acetaminophen | 0 | medium | 47 | 4 |
| acetochlor | 0 | low | 1 | 0 |
| acridone | 0 | low | 1 | 0 |
| beta-aminoethyl isothiourea | 0 | low | 1 | 0 |
| ag 127 | 0 | low | 1 | 0 |
| tyrphostin a23 | 0 | low | 1 | 0 |
| alachlor | 0 | low | 2 | 0 |
| albendazole | 0 | medium | 6 | 2 |
| alendronate | 0 | low | 4 | 0 |
| altretamine | 0 | low | 1 | 0 |
| amantadine | 0 | low | 11 | 0 |
| diatrizoic acid | 0 | low | 2 | 0 |
| amifostine anhydrous | 0 | medium | 1 | 1 |
| p-aminohippuric acid | 0 | low | 2 | 0 |
| theophylline | 0 | low | 27 | 0 |
| amiodarone | 0 | medium | 17 | 2 |
| amitriptyline | 0 | low | 2 | 0 |
| amlodipine | 0 | low | 1 | 0 |
| amobarbital | 0 | low | 5 | 0 |
| amoxapine | 0 | low | 1 | 0 |
| amsacrine | 0 | medium | 5 | 2 |
| antipyrine | 0 | medium | 10 | 1 |
| acetovanillone | 0 | low | 5 | 0 |
| arecoline | 0 | low | 3 | 0 |
| aristolochic acid i | 0 | low | 7 | 0 |
| astemizole | 0 | low | 3 | 0 |
| atrazine | 0 | low | 1 | 0 |
| aurintricarboxylic acid | 0 | low | 1 | 0 |
| azasetron | 0 | medium | 1 | 1 |
| azelastine | 0 | low | 1 | 0 |
| azobenzene | 0 | low | 2 | 0 |
| bay-k-8644 | 0 | low | 6 | 0 |
| benzamidine | 0 | low | 2 | 0 |
| benzbromarone | 0 | low | 1 | 0 |
| benzethonium | 0 | low | 1 | 0 |
| benzo(a)pyrene | 0 | low | 75 | 0 |
| benzothiazide | 0 | medium | 3 | 2 |
| benzyl isothiocyanate | 0 | low | 5 | 0 |
| butylbenzyl phthalate | 0 | low | 2 | 0 |
| berberine | 0 | low | 62 | 0 |
| 5-methoxypsoralen | 0 | low | 1 | 0 |
| beta-naphthoflavone | 0 | low | 17 | 0 |
| 2,5-di-tert-butylhydroquinone | 0 | low | 2 | 0 |
| bicalutamide | 0 | low | 2 | 0 |
| biperiden | 0 | low | 1 | 0 |
| bisbenzimidazole | 0 | low | 7 | 0 |
| bromhexine | 0 | low | 2 | 0 |
| buflomedil | 0 | medium | 1 | 1 |
| bunitrolol | 0 | low | 1 | 0 |
| bupivacaine | 0 | low | 2 | 0 |
| busulfan | 0 | low | 5 | 0 |
| cacodylic acid | 0 | low | 2 | 0 |
| caffeine | 0 | medium | 32 | 1 |
| verapamil | 0 | medium | 40 | 4 |
| beta-glycerophosphoric acid | 0 | low | 1 | 0 |
| calmidazolium | 0 | low | 2 | 0 |
| candesartan | 0 | low | 2 | 0 |
| carbamazepine | 0 | low | 2 | 0 |
| carbazilquinone | 0 | medium | 6 | 1 |
| carmofur | 0 | medium | 15 | 2 |
| carmustine | 0 | low | 15 | 0 |
| carvedilol | 0 | low | 2 | 0 |
| carbonyl cyanide m-chlorophenyl hydrazone | 0 | medium | 6 | 1 |
| cetyltrimethylammonium ion | 0 | low | 1 | 0 |
| cetylpyridinium | 0 | low | 2 | 0 |
| cgp 12177 | 0 | low | 1 | 0 |
| cgs 15943 | 0 | low | 1 | 0 |
| chetomin | 0 | low | 1 | 0 |
| chelerythrine | 0 | low | 8 | 0 |
| chloral hydrate | 0 | low | 2 | 0 |
| chlorambucil | 0 | low | 8 | 0 |
| chlorcyclizine | 0 | low | 1 | 0 |
| chlormezanone | 0 | low | 1 | 0 |
| chloroquine | 0 | medium | 55 | 1 |
| chlorpromazine | 0 | low | 13 | 0 |
| chlorpropamide | 0 | low | 1 | 0 |
| chlorpyrifos | 0 | low | 1 | 0 |
| ciclopirox | 0 | low | 1 | 0 |
| ciglitazone | 0 | low | 3 | 0 |
| cilostazol | 0 | low | 1 | 0 |
| cimetidine | 0 | low | 6 | 0 |
| eucalyptol | 0 | low | 1 | 0 |
| ciprofibrate | 0 | low | 6 | 0 |
| ciprofloxacin | 0 | medium | 5 | 1 |
| citalopram | 0 | low | 1 | 0 |
| clioquinol | 0 | low | 2 | 0 |
| clofazimine | 0 | medium | 5 | 2 |
| clofibrate | 0 | low | 26 | 0 |
| clofibric acid | 0 | low | 9 | 0 |
| clotrimazole | 0 | low | 4 | 0 |
| 2-(2-hydroxyethylsulfanyl)-3-methyl-1,4-naphthoquinone | 0 | low | 4 | 0 |
| cycloleucine | 0 | low | 2 | 0 |
| cyproheptadine | 0 | low | 4 | 0 |
| cystamine | 0 | low | 3 | 0 |
| damnacanthal | 0 | low | 1 | 0 |
| dantrolene | 0 | low | 2 | 0 |
| dapi | 0 | low | 14 | 0 |
| decanoic acid | 0 | low | 1 | 0 |
| deferiprone | 0 | low | 4 | 0 |
| desipramine | 0 | low | 1 | 0 |
| eflornithine | 0 | low | 5 | 0 |
| diazepam | 0 | low | 5 | 0 |
| diazoxide | 0 | low | 3 | 0 |
| dibucaine | 0 | low | 1 | 0 |
| dibutyl phthalate | 0 | low | 2 | 0 |
| diclofenac | 0 | low | 7 | 0 |
| dichlorodiphenyl dichloroethylene | 0 | low | 1 | 0 |
| ddt | 0 | low | 19 | 0 |
| diethylcarbamazine | 0 | low | 1 | 0 |
| pentetic acid | 0 | medium | 52 | 4 |
| diflunisal | 0 | low | 1 | 0 |
| 3,3'-diindolylmethane | 0 | low | 8 | 0 |
| dimercaprol | 0 | low | 2 | 0 |
| dimethadione | 0 | low | 1 | 0 |
| dimethoate | 0 | low | 1 | 0 |
| diphenhydramine | 0 | medium | 3 | 1 |
| diphenyleneiodonium | 0 | low | 4 | 0 |
| dipyridamole | 0 | low | 18 | 0 |
| disopyramide | 0 | low | 1 | 0 |
| disulfiram | 0 | low | 13 | 0 |
| valproic acid | 0 | low | 33 | 0 |
| p-chloroamphetamine | 0 | low | 1 | 0 |
| 2,3-dimethoxy-1,4-naphthoquinone | 0 | low | 1 | 0 |
| domperidone | 0 | low | 1 | 0 |
| doxazosin | 0 | low | 1 | 0 |
| ebselen | 0 | low | 3 | 0 |
| econazole | 0 | low | 1 | 0 |
| 9-(2-hydroxy-3-nonyl)adenine | 0 | low | 1 | 0 |
| ellipticine | 0 | low | 3 | 0 |
| embelin | 0 | low | 2 | 0 |
| emodin | 0 | low | 35 | 0 |
| endosulfan | 0 | low | 2 | 0 |
| endothall | 0 | low | 1 | 0 |
| enflurane | 0 | low | 1 | 0 |
| enoxacin | 0 | low | 3 | 0 |
| erythrosine | 0 | medium | 32 | 1 |
| etanidazole | 0 | low | 1 | 0 |
| ethacrynic acid | 0 | low | 4 | 0 |
| ether | 0 | low | 2 | 0 |
| ethoxyquin | 0 | low | 1 | 0 |
| ethoxyresorufin | 0 | low | 5 | 0 |
| brl 42810 | 0 | low | 5 | 0 |
| famotidine | 0 | medium | 2 | 1 |
| felodipine | 0 | low | 1 | 0 |
| fenbendazole | 0 | low | 2 | 0 |
| fendiline | 0 | low | 1 | 0 |
| fenofibrate | 0 | low | 12 | 0 |
| berotek | 0 | low | 2 | 0 |
| fentanyl | 0 | medium | 7 | 1 |
| fluconazole | 0 | low | 4 | 0 |
| flufenamic acid | 0 | low | 3 | 0 |
| fluphenazine | 0 | low | 1 | 0 |
| flunitrazepam | 0 | low | 1 | 0 |
| fluoxetine | 0 | low | 5 | 0 |
| flurbiprofen | 0 | low | 1 | 0 |
| fluspirilene | 0 | low | 1 | 0 |
| flutamide | 0 | medium | 9 | 3 |
| fomepizole | 0 | low | 2 | 0 |
| furosemide | 0 | low | 5 | 0 |
| fusaric acid | 0 | low | 3 | 0 |
| gabapentin | 0 | low | 1 | 0 |
| gabexate | 0 | medium | 4 | 2 |
| vanoxerine | 0 | low | 1 | 0 |
| gemfibrozil | 0 | low | 5 | 0 |
| gentamicin | 0 | low | 6 | 0 |
| 2,5-dihydroxybenzoic acid | 0 | low | 1 | 0 |
| gliclazide | 0 | medium | 2 | 1 |
| glimepiride | 0 | medium | 2 | 1 |
| glutaral | 0 | low | 9 | 0 |
| glutethimide | 0 | low | 1 | 0 |
| glyburide | 0 | low | 3 | 0 |
| glyphosate | 0 | low | 4 | 0 |
| gö6983 | 0 | low | 1 | 0 |
| go 6976 | 0 | medium | 5 | 1 |
| gossypol | 0 | low | 11 | 0 |
| guaifenesin | 0 | low | 4 | 0 |
| guanidine | 0 | low | 3 | 0 |
| n-(2-(methylamino)ethyl)-5-isoquinolinesulfonamide | 0 | low | 2 | 0 |
| 1-(5-isoquinolinesulfonyl)-2-methylpiperazine | 0 | low | 23 | 0 |
| ha 1004 | 0 | low | 1 | 0 |
| fasudil | 0 | low | 6 | 0 |
| ha14-1 | 0 | low | 2 | 0 |
| haloperidol | 0 | low | 4 | 0 |
| halothane | 0 | low | 8 | 0 |
| heptachlor | 0 | low | 1 | 0 |
| miltefosine | 0 | low | 1 | 0 |
| hexamethonium | 0 | low | 1 | 0 |
| hexestrol | 0 | low | 1 | 0 |
| hexobarbital | 0 | low | 4 | 0 |
| beta-thujaplicin | 0 | low | 1 | 0 |
| hexamethylene bisacetamide | 0 | medium | 8 | 1 |
| ethidium | 0 | low | 11 | 0 |
| hycanthone | 0 | low | 2 | 0 |
| hydralazine | 0 | low | 2 | 0 |
| velnacrine | 0 | low | 1 | 0 |
| hydroxyurea | 0 | low | 28 | 0 |
| hydroxyzine | 0 | medium | 1 | 1 |
| hypericin | 0 | low | 3 | 0 |
| ibuprofen | 0 | low | 4 | 0 |
| lidocaine | 0 | medium | 22 | 1 |
| ifenprodil | 0 | low | 1 | 0 |
| ifosfamide | 0 | medium | 6 | 2 |
| imipramine | 0 | low | 2 | 0 |
| indirubin-3'-monoxime | 0 | low | 2 | 0 |
| indole-3-carbinol | 0 | low | 12 | 0 |
| indomethacin | 0 | medium | 29 | 1 |
| iodamide | 0 | low | 6 | 0 |
| iodixanol | 0 | medium | 15 | 2 |
| iodoacetamide | 0 | low | 4 | 0 |
| iofetamine | 0 | low | 8 | 0 |
| iohexol | 0 | medium | 85 | 8 |
| iomeprol | 0 | medium | 20 | 1 |
| iopanoic acid | 0 | low | 1 | 0 |
| iopromide | 0 | medium | 41 | 3 |
| iothalamic acid | 0 | low | 4 | 0 |
| ioversol | 0 | low | 4 | 0 |
| avapro | 0 | low | 1 | 0 |
| 1-methyl-3-isobutylxanthine | 0 | low | 8 | 0 |
| isoflurane | 0 | medium | 5 | 2 |
| isoniazid | 0 | low | 14 | 0 |
| isoproterenol | 0 | low | 11 | 0 |
| juglone | 0 | low | 3 | 0 |
| staurosporine aglycone | 0 | low | 2 | 0 |
| ketamine | 0 | medium | 6 | 3 |
| ketoconazole | 0 | low | 17 | 0 |
| ketoprofen | 0 | low | 2 | 0 |
| kinetin | 0 | low | 1 | 0 |
| kojic acid | 0 | low | 2 | 0 |
| kynurenic acid | 0 | low | 1 | 0 |
| mimosine | 0 | low | 1 | 0 |
| labetalol | 0 | low | 1 | 0 |
| lansoprazole | 0 | low | 1 | 0 |
| lapachol | 0 | low | 1 | 0 |
| beta-lapachone | 0 | low | 5 | 0 |
| leflunomide | 0 | low | 3 | 0 |
| letrozole | 0 | medium | 1 | 1 |
| lg 100268 | 0 | low | 3 | 0 |
| lomustine | 0 | low | 6 | 0 |
| losartan | 0 | low | 5 | 0 |
| 2-(4-morpholinyl)-8-phenyl-4h-1-benzopyran-4-one | 0 | low | 49 | 0 |
| 6-anilino-5,8-quinolinedione | 0 | low | 2 | 0 |
| edaravone | 0 | low | 1 | 0 |
| mebendazole | 0 | low | 3 | 0 |
| mecamylamine | 0 | low | 1 | 0 |
| mechlorethamine | 0 | low | 37 | 0 |
| medazepam | 0 | low | 1 | 0 |
| memantine | 0 | medium | 2 | 2 |
| vitamin k 3 | 0 | medium | 11 | 1 |
| mepivacaine | 0 | low | 1 | 0 |
| metaproterenol | 0 | low | 1 | 0 |
| methacrylic acid | 0 | low | 1 | 0 |
| methadone | 0 | medium | 5 | 3 |
| methapyrilene | 0 | low | 2 | 0 |
| methenamine | 0 | low | 2 | 0 |
| methoxsalen | 0 | low | 4 | 0 |
| methoxychlor | 0 | low | 3 | 0 |
| methoxyflurane | 0 | low | 2 | 0 |
| nocodazole | 0 | low | 13 | 0 |
| methyl salicylate | 0 | medium | 2 | 2 |
| methyl methanesulfonate | 0 | low | 5 | 0 |
| methylphenidate | 0 | low | 1 | 0 |
| metolachlor | 0 | low | 1 | 0 |
| metoprolol | 0 | low | 2 | 0 |
| metronidazole | 0 | medium | 5 | 1 |
| metyrapone | 0 | low | 2 | 0 |
| n-methyl-d-glucamine dithiocarbamate | 0 | low | 1 | 0 |
| mianserin | 0 | low | 1 | 0 |
| midazolam | 0 | low | 4 | 0 |
| mitoxantrone | 0 | medium | 48 | 11 |
| moclobemide | 0 | low | 1 | 0 |
| molsidomine | 0 | low | 4 | 0 |
| monodansylcadaverine | 0 | low | 1 | 0 |
| entinostat | 0 | low | 6 | 0 |
| muscimol | 0 | low | 1 | 0 |
| myristicin | 0 | low | 1 | 0 |
| n(1),n(11)-diethylnorspermine | 0 | medium | 1 | 1 |
| ethylmaleimide | 0 | low | 16 | 0 |
| nafamostat | 0 | low | 2 | 0 |
| activins | 0 | low | 22 | 0 |
| ubiquinone q1 | 0 | low | 1 | 0 |
| nevirapine | 0 | low | 1 | 0 |
| nicardipine | 0 | low | 2 | 0 |
| niclosamide | 0 | low | 5 | 0 |
| nifedipine | 0 | low | 5 | 0 |
| niflumic acid | 0 | low | 1 | 0 |
| nilutamide | 0 | medium | 1 | 1 |
| nimesulide | 0 | low | 6 | 0 |
| nitidine | 0 | low | 8 | 0 |
| nitroglycerin | 0 | medium | 4 | 1 |
| norfloxacin | 0 | low | 1 | 0 |
| n-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide | 0 | low | 21 | 0 |
| o(6)-benzylguanine | 0 | low | 1 | 0 |
| octopamine | 0 | low | 2 | 0 |
| ofloxacin | 0 | medium | 4 | 2 |
| olprinone | 0 | medium | 1 | 1 |
| omeprazole | 0 | low | 11 | 0 |
| ondansetron | 0 | low | 2 | 0 |
| orphenadrine | 0 | low | 1 | 0 |
| osalmide | 0 | low | 1 | 0 |
| 1,2-cyclohexanediamine | 0 | low | 2 | 0 |
| oxamniquine | 0 | low | 1 | 0 |
| oxazepam | 0 | low | 1 | 0 |
| aminosalicylic acid | 0 | low | 3 | 0 |
| quinone | 0 | low | 3 | 0 |
| fenclonine | 0 | low | 3 | 0 |
| pamidronate | 0 | low | 2 | 0 |
| pantoprazole | 0 | low | 2 | 0 |
| papaverine | 0 | low | 4 | 0 |
| 1,7-dimethylxanthine | 0 | low | 1 | 0 |
| pargyline | 0 | low | 2 | 0 |
| patulin | 0 | low | 1 | 0 |
| pd 153035 | 0 | low | 3 | 0 |
| pd 98059 | 0 | low | 44 | 0 |
| pentobarbital | 0 | low | 4 | 0 |
| pentoxifylline | 0 | low | 7 | 0 |
| perhexiline | 0 | low | 2 | 0 |
| phenacetin | 0 | medium | 5 | 2 |
| phenobarbital | 0 | low | 106 | 0 |
| phenolsulfonphthalein | 0 | low | 5 | 0 |
| phenoxybenzamine | 0 | low | 1 | 0 |
| 4-phenylbutyric acid | 0 | low | 10 | 0 |
| oxophenylarsine | 0 | low | 2 | 0 |
| phenylbutazone | 0 | low | 3 | 0 |
| phenylmethylsulfonyl fluoride | 0 | low | 2 | 0 |
| phloretin | 0 | low | 5 | 0 |
| pifithrin | 0 | low | 5 | 0 |
| pindolol | 0 | low | 1 | 0 |
| pioglitazone | 0 | medium | 16 | 1 |
| potassium chloride | 0 | low | 17 | 0 |
| potassium iodide | 0 | medium | 3 | 2 |
| 4-aminobenzoic acid | 0 | low | 4 | 0 |
| ag 1879 | 0 | low | 3 | 0 |
| praziquantel | 0 | low | 2 | 0 |
| prazosin | 0 | low | 1 | 0 |
| prilocaine | 0 | low | 1 | 0 |
| primaquine | 0 | low | 12 | 0 |
| proadifen | 0 | low | 6 | 0 |
| probenecid | 0 | low | 3 | 0 |
| probucol | 0 | low | 5 | 0 |
| procaine | 0 | low | 1 | 0 |
| procarbazine | 0 | low | 1 | 0 |
| proglumide | 0 | low | 3 | 0 |
| promazine | 0 | low | 1 | 0 |
| propachlor | 0 | low | 1 | 0 |
| propidium | 0 | low | 16 | 0 |
| propofol | 0 | medium | 24 | 2 |
| propyl gallate | 0 | low | 2 | 0 |
| protoporphyrin ix | 0 | low | 17 | 0 |
| pyrilamine | 0 | low | 1 | 0 |
| pyrimethamine | 0 | medium | 2 | 1 |
| opc 12759 | 0 | medium | 1 | 1 |
| riluzole | 0 | low | 1 | 0 |
| rimantadine | 0 | low | 1 | 0 |
| ro 31-8220 | 0 | low | 2 | 0 |
| rofecoxib | 0 | medium | 6 | 3 |
| rolipram | 0 | low | 1 | 0 |
| s-methylisothiopseudouronium | 0 | low | 1 | 0 |
| saccharin | 0 | low | 2 | 0 |
| safrole | 0 | low | 6 | 0 |
| salicyl alcohol | 0 | low | 1 | 0 |
| salicylamide | 0 | low | 1 | 0 |
| sanguinarine | 0 | low | 6 | 0 |
| sb 239063 | 0 | low | 1 | 0 |
| sb 202190 | 0 | low | 5 | 0 |
| scriptaid | 0 | low | 2 | 0 |
| semustine | 0 | medium | 7 | 4 |
| sevoflurane | 0 | medium | 9 | 1 |
| sulfadiazine | 0 | medium | 1 | 1 |
| linsidomine | 0 | low | 4 | 0 |
| sodium fluoride | 0 | medium | 4 | 2 |
| fluoroacetic acid | 0 | low | 1 | 0 |
| stearic acid | 0 | low | 9 | 0 |
| streptonigrin | 0 | low | 4 | 0 |
| vorinostat | 0 | medium | 36 | 1 |
| succinylacetone | 0 | low | 8 | 0 |
| succinylcholine | 0 | low | 1 | 0 |
| sulfadimethoxine | 0 | low | 1 | 0 |
| sulfamonomethoxine | 0 | low | 1 | 0 |
| sulfanilamide | 0 | low | 1 | 0 |
| sulfaphenazole | 0 | low | 1 | 0 |
| sulfapyridine | 0 | low | 1 | 0 |
| sulfasalazine | 0 | low | 8 | 0 |
| sulfinpyrazone | 0 | low | 2 | 0 |
| sulfisoxazole | 0 | low | 2 | 0 |
| sulfobromophthalein | 0 | low | 9 | 0 |
| sulforaphane | 0 | low | 28 | 0 |
| suramin | 0 | low | 9 | 0 |
| tazarotene | 0 | low | 1 | 0 |
| 1,4-bis(2-(3,5-dichloropyridyloxy))benzene | 0 | low | 5 | 0 |
| terbutaline | 0 | low | 1 | 0 |
| terfenadine | 0 | low | 3 | 0 |
| tetraethylammonium | 0 | low | 2 | 0 |
| krypton | 0 | low | 2 | 0 |
| thiabendazole | 0 | low | 1 | 0 |
| 2,4-thiazolidinedione | 0 | low | 3 | 0 |
| thioridazine | 0 | low | 1 | 0 |
| thiotepa | 0 | low | 7 | 0 |
| ticlopidine | 0 | low | 7 | 0 |
| tinidazole | 0 | low | 1 | 0 |
| tiopronin | 0 | medium | 2 | 1 |
| 8-(n,n-diethylamino)octyl-3,4,5-trimethoxybenzoate | 0 | low | 2 | 0 |
| tolazoline | 0 | low | 1 | 0 |
| tolbutamide | 0 | low | 8 | 0 |
| n,n,n',n'-tetrakis(2-pyridylmethyl)ethylenediamine | 0 | low | 2 | 0 |
| tranexamic acid | 0 | low | 1 | 0 |
| trapidil | 0 | low | 1 | 0 |
| triamterene | 0 | low | 1 | 0 |
| triclosan | 0 | medium | 3 | 1 |
| trientine | 0 | medium | 3 | 1 |
| trifluoperazine | 0 | low | 10 | 0 |
| trigonelline | 0 | low | 1 | 0 |
| trimethadione | 0 | low | 1 | 0 |
| trimethoprim | 0 | low | 1 | 0 |
| trimetrexate | 0 | medium | 2 | 1 |
| troglitazone | 0 | low | 24 | 0 |
| tyramine | 0 | low | 3 | 0 |
| urethane | 0 | low | 40 | 0 |
| usnic acid | 0 | low | 4 | 0 |
| vesnarinone | 0 | low | 1 | 0 |
| w 7 | 0 | low | 4 | 0 |
| pirinixic acid | 0 | low | 10 | 0 |
| 3-(5'-hydroxymethyl-2'-furyl)-1-benzylindazole | 0 | low | 10 | 0 |
| ici 204,219 | 0 | low | 2 | 0 |
| zardaverine | 0 | low | 1 | 0 |
| zinc chloride | 0 | low | 6 | 0 |
| zm 336372 | 0 | low | 1 | 0 |
| hydrocortisone acetate | 0 | low | 1 | 0 |
| corticosterone | 0 | low | 21 | 0 |
| estriol | 0 | low | 5 | 0 |
| reserpine | 0 | low | 1 | 0 |
| phentolamine | 0 | low | 1 | 0 |
| sorbitol | 0 | low | 7 | 0 |
| alloxan | 0 | low | 1 | 0 |
| thymidine | 0 | medium | 275 | 2 |
| piperonyl butoxide | 0 | low | 4 | 0 |
| benzimidazole | 0 | low | 5 | 0 |
| triethylenemelamine | 0 | low | 5 | 0 |
| 3,3',5-triiodothyroacetic acid | 0 | low | 1 | 0 |
| hydroxyproline | 0 | low | 7 | 0 |
| thyroxine | 0 | low | 40 | 0 |
| methacetin | 0 | medium | 5 | 2 |
| norethindrone acetate | 0 | low | 3 | 0 |
| spironolactone | 0 | low | 4 | 0 |
| aldosterone | 0 | low | 14 | 0 |
| penicillamine | 0 | low | 15 | 0 |
| trichlorfon | 0 | low | 1 | 0 |
| lynestrenol | 0 | low | 6 | 0 |
| norethandrolone | 0 | low | 4 | 0 |
| tetrahydrocortisol | 0 | low | 3 | 0 |
| estrone | 0 | medium | 20 | 1 |
| androsterone | 0 | low | 4 | 0 |
| dehydroepiandrosterone | 0 | medium | 25 | 1 |
| hydroxyacetylaminofluorene | 0 | low | 2 | 0 |
| 2-acetylaminofluorene | 0 | low | 108 | 0 |
| azauridine | 0 | low | 4 | 0 |
| penicillin g | 0 | low | 1 | 0 |
| idoxuridine | 0 | low | 14 | 0 |
| triiodothyronine | 0 | low | 83 | 0 |
| diethylnitrosamine | 0 | medium | 663 | 1 |
| methyldimethylaminoazobenzene | 0 | low | 38 | 0 |
| isoflurophate | 0 | low | 4 | 0 |
| biguanides | 0 | low | 1 | 0 |
| carbon tetrachloride | 0 | medium | 98 | 1 |
| cantharidin | 0 | medium | 30 | 1 |
| alanine | 0 | medium | 69 | 8 |
| serine | 0 | low | 101 | 0 |
| desoxycorticosterone acetate | 0 | low | 1 | 0 |
| benz(a)anthracene | 0 | low | 9 | 0 |
| 4-nitroquinoline-1-oxide | 0 | low | 4 | 0 |
| chloramphenicol | 0 | low | 15 | 0 |
| aspartic acid | 0 | low | 44 | 0 |
| glutamine | 0 | medium | 112 | 2 |
| allyl isothiocyanate | 0 | low | 5 | 0 |
| cyanides | 0 | low | 20 | 0 |
| sucrose | 0 | low | 35 | 0 |
| ethinyl estradiol | 0 | medium | 42 | 1 |
| chlordan | 0 | low | 3 | 0 |
| testosterone propionate | 0 | low | 1 | 0 |
| 9,10-dimethyl-1,2-benzanthracene | 0 | low | 22 | 0 |
| aminopyrine | 0 | low | 11 | 0 |
| methyltestosterone | 0 | low | 19 | 0 |
| puromycin aminonucleoside | 0 | low | 2 | 0 |
| adenosine diphosphate | 0 | low | 29 | 0 |
| uridine | 0 | low | 127 | 0 |
| uridine monophosphate | 0 | medium | 16 | 3 |
| uridine diphosphate | 0 | low | 5 | 0 |
| bromodeoxyuridine | 0 | medium | 67 | 1 |
| galactose | 0 | medium | 123 | 3 |
| carbostyril | 0 | medium | 24 | 4 |
| phenylephrine | 0 | medium | 3 | 1 |
| n-nitrosomorpholine | 0 | low | 21 | 0 |
| levodopa | 0 | low | 1 | 0 |
| edetic acid | 0 | medium | 106 | 13 |
| tributyrin | 0 | low | 4 | 0 |
| p-aminoazobenzene | 0 | low | 2 | 0 |
| p-dimethylaminoazobenzene | 0 | low | 312 | 0 |
| phenylethyl alcohol | 0 | low | 12 | 0 |
| tyrosine | 0 | medium | 176 | 3 |
| cysteamine | 0 | low | 5 | 0 |
| phlorhizin | 0 | low | 4 | 0 |
| adenosine monophosphate | 0 | low | 33 | 0 |
| methylene blue | 0 | low | 6 | 0 |
| 4-toluenesulfonic acid | 0 | low | 1 | 0 |
| zoxazolamine | 0 | low | 1 | 0 |
| leucine | 0 | low | 142 | 0 |
| aniline | 0 | low | 3 | 0 |
| 2-aminoisobutyric acid | 0 | low | 3 | 0 |
| dimethylnitrosamine | 0 | low | 47 | 0 |
| androstenedione | 0 | low | 9 | 0 |
| cytidine monophosphate | 0 | medium | 3 | 2 |
| cytidine diphosphate | 0 | low | 2 | 0 |
| uridine triphosphate | 0 | low | 3 | 0 |
| lactose | 0 | low | 22 | 0 |
| 1,2-dipalmitoylphosphatidylcholine | 0 | low | 1 | 0 |
| phenylalanine | 0 | medium | 65 | 1 |
| desoxycorticosterone | 0 | low | 8 | 0 |
| colchicine | 0 | medium | 37 | 1 |
| cytidine | 0 | low | 19 | 0 |
| cytidine triphosphate | 0 | low | 4 | 0 |
| uracil mustard | 0 | low | 1 | 0 |
| oxacillin | 0 | low | 2 | 0 |
| cycloheximide | 0 | low | 205 | 0 |
| ficusin | 0 | low | 3 | 0 |
| egtazic acid | 0 | low | 10 | 0 |
| barbituric acid | 0 | low | 1 | 0 |
| chloroform | 0 | low | 8 | 0 |
| dimethyl sulfone | 0 | low | 1 | 0 |
| hexachloroethane | 0 | low | 1 | 0 |
| gliotoxin | 0 | low | 2 | 0 |
| sodium citrate, anhydrous | 0 | low | 1 | 0 |
| dimethylformamide | 0 | low | 4 | 0 |
| norethindrone | 0 | low | 18 | 0 |
| norethynodrel | 0 | low | 10 | 0 |
| cycloserine | 0 | low | 2 | 0 |
| triaziquone | 0 | low | 1 | 0 |
| tubercidin | 0 | low | 3 | 0 |
| ampicillin | 0 | low | 3 | 0 |
| mannitol | 0 | low | 8 | 0 |
| cytarabine | 0 | low | 33 | 0 |
| dithionitrobenzoic acid | 0 | low | 1 | 0 |
| trifluridine | 0 | medium | 2 | 1 |
| ornithine | 0 | low | 34 | 0 |
| asparagine | 0 | low | 27 | 0 |
| 4-hydroxypropiophenone | 0 | low | 3 | 0 |
| histidine | 0 | medium | 46 | 2 |
| 1,1,1-trichloroethane | 0 | low | 1 | 0 |
| medroxyprogesterone acetate | 0 | medium | 5 | 1 |
| valine | 0 | medium | 52 | 1 |
| threonine | 0 | low | 19 | 0 |
| mestranol | 0 | low | 34 | 0 |
| methaqualone | 0 | low | 1 | 0 |
| alizarin | 0 | low | 1 | 0 |
| dichlorodiphenyldichloroethane | 0 | medium | 2 | 1 |
| methandrostenolone | 0 | low | 2 | 0 |
| chlorquinaldol | 0 | medium | 1 | 1 |
| cordycepin | 0 | low | 8 | 0 |
| tryptophan | 0 | low | 84 | 0 |
| isoleucine | 0 | low | 16 | 0 |
| n,n'-diphenyl-4-phenylenediamine | 0 | low | 2 | 0 |
| ethane | 0 | low | 2 | 0 |
| ethylene | 0 | medium | 4 | 2 |
| acetylene | 0 | low | 2 | 0 |
| methylamine | 0 | low | 2 | 0 |
| boranes | 0 | low | 3 | 0 |
| propane | 0 | low | 5 | 0 |
| ethyl chloride | 0 | low | 2 | 0 |
| vinyl chloride | 0 | low | 43 | 0 |
| vinyl fluoride | 0 | low | 1 | 0 |
| acetonitrile | 0 | low | 1 | 0 |
| methylene chloride | 0 | low | 2 | 0 |
| ethylene oxide | 0 | low | 2 | 0 |
| phosgene | 0 | low | 1 | 0 |
| propylene oxide | 0 | low | 1 | 0 |
| tetramethylsilane | 0 | low | 1 | 0 |
| tert-butylhydroperoxide | 0 | low | 17 | 0 |
| trichloroacetic acid | 0 | low | 13 | 0 |
| perflutren | 0 | medium | 7 | 1 |
| triamcinolone acetonide | 0 | low | 5 | 0 |
| fluoxymesterone | 0 | low | 1 | 0 |
| bromcresol green | 0 | low | 1 | 0 |
| phencyclidine | 0 | medium | 3 | 1 |
| butobarbital | 0 | low | 1 | 0 |
| dimethyl sulfate | 0 | low | 1 | 0 |
| tromethamine | 0 | medium | 3 | 1 |
| quinic acid | 0 | low | 2 | 0 |
| tetraethoxysilane | 0 | low | 1 | 0 |
| triparanol | 0 | low | 4 | 0 |
| isoprene | 0 | low | 2 | 0 |
| trichloroethylene | 0 | low | 4 | 0 |
| dichloroacetaldehyde | 0 | low | 1 | 0 |
| acrylamide | 0 | low | 6 | 0 |
| acrylic acid | 0 | medium | 3 | 1 |
| isobutyric acid | 0 | low | 1 | 0 |
| methacrylamide | 0 | low | 1 | 0 |
| dichloroacetic acid | 0 | low | 5 | 0 |
| dimethisterone | 0 | low | 2 | 0 |
| tetrabromobisphenol a | 0 | low | 3 | 0 |
| bisphenol a | 0 | low | 5 | 0 |
| bis(4-hydroxyphenyl)sulfone | 0 | low | 1 | 0 |
| cumene hydroperoxide | 0 | low | 1 | 0 |
| alpha-pinene | 0 | low | 4 | 0 |
| musk ketone | 0 | low | 2 | 0 |
| taurocholic acid | 0 | low | 15 | 0 |
| rhodamine b | 0 | medium | 6 | 1 |
| cyclizine | 0 | low | 1 | 0 |
| methylprednisolone | 0 | medium | 16 | 2 |
| musk ambrette (artificial) | 0 | low | 1 | 0 |
| vitamin k5 | 0 | low | 1 | 0 |
| rotenone | 0 | low | 17 | 0 |
| 2-methylanthraquinone | 0 | low | 1 | 0 |
| 9,10-anthraquinone | 0 | low | 2 | 0 |
| diethyl phthalate | 0 | low | 1 | 0 |
| phthalimide | 0 | low | 1 | 0 |
| pyocyanine | 0 | low | 1 | 0 |
| fluorene | 0 | low | 7 | 0 |
| carbazole | 0 | low | 1 | 0 |
| isosorbide dinitrate | 0 | low | 1 | 0 |
| penicillanic acid | 0 | low | 1 | 0 |
| xylitol | 0 | low | 1 | 0 |
| n-vinyl-2-pyrrolidinone | 0 | medium | 6 | 1 |
| 2,3,5-triiodobenzoic acid | 0 | low | 1 | 0 |
| picryl chloride | 0 | low | 1 | 0 |
| thymol | 0 | low | 4 | 0 |
| 1-naphthol | 0 | low | 2 | 0 |
| 2-aminodiphenyl | 0 | low | 1 | 0 |
| 2-phenylphenol | 0 | low | 1 | 0 |
| aminacrine | 0 | low | 2 | 0 |
| xanthone | 0 | low | 1 | 0 |
| beta-glucono-1,5-lactone | 0 | low | 1 | 0 |
| quinoxalines | 0 | medium | 30 | 2 |
| quinoline | 0 | low | 1 | 0 |
| isatin | 0 | low | 2 | 0 |
| 2-naphthylamine | 0 | medium | 11 | 1 |
| 2-methylquinoline | 0 | low | 1 | 0 |
| 3,3'-dichlorobenzidine | 0 | low | 1 | 0 |
| tolonium chloride | 0 | low | 4 | 0 |
| diphenyl | 0 | low | 1 | 0 |
| 4-biphenylamine | 0 | low | 4 | 0 |
| xanthenes | 0 | low | 23 | 0 |
| benzidine | 0 | low | 3 | 0 |
| methyl benzoate | 0 | low | 1 | 0 |
| cdaa | 0 | low | 3 | 0 |
| propylparaben | 0 | low | 2 | 0 |
| benzotriazole | 0 | low | 1 | 0 |
| benzothiophene | 0 | low | 1 | 0 |
| 2-toluidine | 0 | low | 1 | 0 |
| 1,2-diaminobenzene | 0 | low | 2 | 0 |
| 2,4-diaminotoluene | 0 | low | 1 | 0 |
| diethyl ketone | 0 | low | 1 | 0 |
| 4-butyrolactone | 0 | low | 6 | 0 |
| lactobionic acid | 0 | low | 13 | 0 |
| phosphoribosyl pyrophosphate | 0 | low | 4 | 0 |
| o-aminoazotoluene | 0 | low | 9 | 0 |
| ethylene dimethacrylate | 0 | low | 1 | 0 |
| furaldehyde | 0 | low | 2 | 0 |
| benzenearsonic acid | 0 | low | 1 | 0 |
| pyrrolidonecarboxylic acid | 0 | low | 3 | 0 |
| trehalose | 0 | low | 8 | 0 |
| methyl gallate | 0 | low | 1 | 0 |
| 4-bromophenacyl bromide | 0 | low | 1 | 0 |
| alpha phellandrene | 0 | low | 1 | 0 |
| 4-cymene | 0 | low | 1 | 0 |
| dimethyl-4-toluidine | 0 | low | 1 | 0 |
| 4-(dimethylamino)benzaldehyde | 0 | low | 1 | 0 |
| ethylbenzene | 0 | medium | 2 | 1 |
| styrene | 0 | low | 1 | 0 |
| n-nitrosopiperidine | 0 | low | 7 | 0 |
| quinuclidines | 0 | low | 1 | 0 |
| cyclamic acid | 0 | low | 3 | 0 |
| 4-bromophenyl phenyl ether | 0 | low | 1 | 0 |
| 4,4'-diphenylmethane diisocyanate | 0 | low | 1 | 0 |
| boric acid | 0 | low | 8 | 0 |
| caprolactam | 0 | medium | 3 | 2 |
| 4-toluidine | 0 | low | 1 | 0 |
| 4-phenylenediamine | 0 | low | 1 | 0 |
| 1,3-butadiene | 0 | low | 1 | 0 |
| acrolein | 0 | low | 11 | 0 |
| allylamine | 0 | low | 1 | 0 |
| acrylonitrile | 0 | low | 3 | 0 |
| allyl alcohol | 0 | low | 1 | 0 |
| glyoxal | 0 | low | 1 | 0 |
| 2-methylpentane | 0 | low | 5 | 0 |
| succinic anhydride | 0 | low | 1 | 0 |
| maleic anhydride | 0 | medium | 77 | 10 |
| bromobenzene | 0 | low | 1 | 0 |
| thiophenol | 0 | low | 2 | 0 |
| 2-aminopyrimidine | 0 | low | 2 | 0 |
| pentane | 0 | low | 2 | 0 |
| pyrroles | 0 | medium | 124 | 20 |
| furan | 0 | low | 1 | 0 |
| thiophenes | 0 | medium | 52 | 11 |
| di-tert-butyl peroxide | 0 | low | 2 | 0 |
| 2,5-hexanedione | 0 | low | 1 | 0 |
| isopropyl myristate | 0 | medium | 2 | 2 |
| n-hexane | 0 | low | 3 | 0 |
| pentanal | 0 | low | 1 | 0 |
| 1,4-butanediol | 0 | low | 1 | 0 |
| diethanolamine | 0 | low | 1 | 0 |
| n-butoxyethanol | 0 | low | 1 | 0 |
| methyl palmitate | 0 | low | 1 | 0 |
| dodecanol | 0 | low | 1 | 0 |
| tetraethylenepentamine | 0 | low | 1 | 0 |
| behenic acid | 0 | low | 1 | 0 |
| stearyl alcohol | 0 | low | 1 | 0 |
| phenformin | 0 | low | 3 | 0 |
| oxyphenisatin acetate | 0 | low | 2 | 0 |
| bromcresol purple | 0 | low | 1 | 0 |
| triphenyl phosphate | 0 | low | 1 | 0 |
| diethylhexyl phthalate | 0 | low | 4 | 0 |
| hexachlorobenzene | 0 | low | 7 | 0 |
| 2-toluic acid | 0 | low | 1 | 0 |
| trinitrotoluene | 0 | low | 1 | 0 |
| framycetin | 0 | medium | 12 | 1 |
| 1-hydroxyphthalazine | 0 | low | 1 | 0 |
| 2,2'-methylenebis(4-methyl-6-tert-butylphenol) | 0 | low | 1 | 0 |
| isoquinoline | 0 | low | 1 | 0 |
| anthracene | 0 | low | 1 | 0 |
| cyclopentanone | 0 | low | 1 | 0 |
| 2,4-dinitrotoluene | 0 | low | 3 | 0 |
| triethylamine | 0 | low | 1 | 0 |
| cyclonite | 0 | low | 1 | 0 |
| sulfan blue | 0 | low | 1 | 0 |
| 1-hydroxyanthraquinone | 0 | low | 1 | 0 |
| pyrazolanthrone | 0 | low | 30 | 0 |
| 1,4-naphthoquinone | 0 | low | 2 | 0 |
| dimethyl phthalate | 0 | low | 1 | 0 |
| diatrizoate meglumine | 0 | low | 8 | 0 |
| meglumine | 0 | medium | 87 | 9 |
| monobutyl phthalate | 0 | low | 1 | 0 |
| iodohippuric acid | 0 | low | 3 | 0 |
| uridine diphosphate glucose | 0 | low | 4 | 0 |
| 1-naphthylamine | 0 | low | 5 | 0 |
| fluorodeoxyuridylate | 0 | low | 3 | 0 |
| 2-naphthol | 0 | low | 12 | 0 |
| dextrothyroxine | 0 | low | 1 | 0 |
| n-butyl lactate | 0 | low | 1 | 0 |
| shikimic acid | 0 | medium | 1 | 1 |
| nitrilotriacetic acid | 0 | low | 5 | 0 |
| estragole | 0 | low | 2 | 0 |
| ethyl acetate | 0 | low | 16 | 0 |
| iminodiacetic acid | 0 | low | 1 | 0 |
| monomethylarsonic acid | 0 | low | 2 | 0 |
| pregnenolone | 0 | low | 3 | 0 |
| 3-o-methylglucose | 0 | low | 2 | 0 |
| 2-chloroadenosine | 0 | low | 2 | 0 |
| ditiocarb | 0 | low | 7 | 0 |
| 1,2-dihydroxybenzene-3,5-disulfonic acid disodium salt | 0 | low | 1 | 0 |
| potassium cyanide | 0 | low | 4 | 0 |
| methohexital | 0 | low | 2 | 0 |
| dydrogesterone | 0 | low | 1 | 0 |
| catechin | 0 | low | 84 | 0 |
| thiamine pyrophosphate | 0 | low | 1 | 0 |
| diazooxonorleucine | 0 | low | 2 | 0 |
| dibenzo(a,i)pyrene | 0 | low | 1 | 0 |
| dibenzo(a,l)pyrene | 0 | low | 2 | 0 |
| benzo(e)pyrene | 0 | low | 2 | 0 |
| 7h-dibenzo(c,g)carbazole | 0 | low | 2 | 0 |
| benzo(c)phenanthrene | 0 | low | 1 | 0 |
| perylene | 0 | low | 8 | 0 |
| fluoranthene | 0 | low | 1 | 0 |
| benzo(k)fluoranthene | 0 | low | 2 | 0 |
| chrysene | 0 | low | 1 | 0 |
| quinazolines | 0 | medium | 158 | 24 |
| acridines | 0 | low | 13 | 0 |
| indazoles | 0 | medium | 37 | 8 |
| benzoxazoles | 0 | medium | 11 | 2 |
| adamantane | 0 | low | 2 | 0 |
| cyclopentane | 0 | low | 23 | 0 |
| isoxazoles | 0 | medium | 27 | 5 |
| oxazoles | 0 | low | 13 | 0 |
| thiazoles | 0 | medium | 151 | 6 |
| 1,2,4-triazole | 0 | low | 1 | 0 |
| pyrimidine | 0 | low | 9 | 0 |
| pyrazines | 0 | medium | 57 | 8 |
| ethynodiol diacetate | 0 | low | 4 | 0 |
| nitroblue tetrazolium | 0 | low | 2 | 0 |
| triphenyltetrazolium | 0 | low | 1 | 0 |
| allylisopropylacetamide | 0 | low | 1 | 0 |
| hydrazine | 0 | medium | 31 | 2 |
| chlormadinone acetate | 0 | low | 3 | 0 |
| 2,2-dichloro-1,1,1-trifluoroethane | 0 | low | 1 | 0 |
| paraoxon | 0 | low | 1 | 0 |
| hemicholinium 3 | 0 | low | 1 | 0 |
| evans blue | 0 | low | 3 | 0 |
| monocrotaline | 0 | low | 2 | 0 |
| testosterone enanthate | 0 | low | 2 | 0 |
| 5-fluorouridine | 0 | low | 3 | 0 |
| azacitidine | 0 | medium | 117 | 1 |
| perfluorooctanoic acid | 0 | low | 9 | 0 |
| methylthioinosine | 0 | low | 1 | 0 |
| perfluorobutane | 0 | medium | 112 | 5 |
| perflexane | 0 | low | 4 | 0 |
| aminoimidazole carboxamide | 0 | low | 18 | 0 |
| phenylbenzoquinone | 0 | low | 1 | 0 |
| thymidine monophosphate | 0 | low | 6 | 0 |
| citrulline | 0 | low | 8 | 0 |
| betamethasone | 0 | low | 3 | 0 |
| cyanamide | 0 | low | 1 | 0 |
| perflubron | 0 | low | 1 | 0 |
| cyproterone acetate | 0 | medium | 14 | 1 |
| beta-cyclocitral | 0 | low | 1 | 0 |
| lithocholic acid | 0 | low | 3 | 0 |
| nandrolone | 0 | low | 1 | 0 |
| thiazolidine-4-carboxylic acid | 0 | low | 1 | 0 |
| 2-aminopurine | 0 | low | 9 | 0 |
| 4-fluorobenzoic acid | 0 | low | 1 | 0 |
| hydantoins | 0 | medium | 4 | 1 |
| fluorobenzenes | 0 | low | 2 | 0 |
| homocystine | 0 | low | 1 | 0 |
| n-pentyl nitrite | 0 | low | 1 | 0 |
| limestone | 0 | low | 2 | 0 |
| oxamide | 0 | low | 1 | 0 |
| glycyrrhetinic acid | 0 | low | 1 | 0 |
| chenodeoxycholic acid | 0 | low | 30 | 0 |
| glycocholic acid | 0 | low | 6 | 0 |
| isocorydine | 0 | low | 4 | 0 |
| liriodenine | 0 | low | 2 | 0 |
| fusarium | 0 | low | 5 | 0 |
| funiculosin (anthraquinone) | 0 | low | 1 | 0 |
| boldine | 0 | low | 3 | 0 |
| rhein | 0 | low | 5 | 0 |
| berbamine | 0 | low | 2 | 0 |
| indirubin | 0 | low | 4 | 0 |
| lucanthone | 0 | low | 3 | 0 |
| epitestosterone | 0 | low | 1 | 0 |
| plumbagin | 0 | low | 10 | 0 |
| cepharanthine | 0 | low | 5 | 0 |
| aloe emodin | 0 | low | 1 | 0 |
| chrysophanic acid | 0 | low | 1 | 0 |
| 9-(2,3-dihydroxy-3-methylbutoxy)-4-methoxy-7h-furo(3,2-g)(1)benzopyran-7-one | 0 | low | 1 | 0 |
| imperatorin | 0 | low | 4 | 0 |
| emetine | 0 | low | 2 | 0 |
| osthol | 0 | low | 8 | 0 |
| reticulin | 0 | low | 12 | 0 |
| cytisine | 0 | low | 1 | 0 |
| thymoquinone | 0 | low | 13 | 0 |
| melarsoprol | 0 | low | 1 | 0 |
| carvacrol | 0 | low | 4 | 0 |
| 4-hydroxyphenylethanol | 0 | low | 1 | 0 |
| caprolactone | 0 | low | 2 | 0 |
| alpha-aminopyridine | 0 | low | 21 | 0 |
| thiazolidines | 0 | low | 9 | 0 |
| cyanogen bromide | 0 | low | 3 | 0 |
| oleanolic acid | 0 | low | 69 | 0 |
| elemene | 0 | low | 1 | 0 |
| hematoxylin | 0 | low | 5 | 0 |
| podophyllotoxin | 0 | medium | 24 | 3 |
| hesperidin | 0 | low | 8 | 0 |
| medroxyprogesterone | 0 | low | 2 | 0 |
| dihydrotestosterone | 0 | low | 23 | 0 |
| luminol | 0 | medium | 4 | 1 |
| physcione | 0 | low | 4 | 0 |
| flavone | 0 | low | 1 | 0 |
| copper gluconate | 0 | low | 4 | 0 |
| thiophene-2-carboxylate | 0 | low | 2 | 0 |
| azomycin | 0 | low | 6 | 0 |
| uridine diphosphate n-acetylglucosamine | 0 | low | 2 | 0 |
| 3',5'-dichloromethotrexate | 0 | low | 5 | 0 |
| herniarin | 0 | low | 1 | 0 |
| chrysoidine | 0 | low | 1 | 0 |
| tropolone | 0 | low | 1 | 0 |
| 4,6-dinitro-o-cresol | 0 | low | 1 | 0 |
| perillyl alcohol | 0 | low | 1 | 0 |
| methamphetamine | 0 | low | 1 | 0 |
| dicyclohexylcarbodiimide | 0 | low | 1 | 0 |
| 1,2-ethanedithiol | 0 | low | 1 | 0 |
| uranyl acetate | 0 | low | 1 | 0 |
| maleimide | 0 | low | 1 | 0 |
| muscone | 0 | medium | 3 | 2 |
| malondialdehyde | 0 | medium | 63 | 2 |
| myristic acid | 0 | low | 7 | 0 |
| trinitrobenzenesulfonic acid | 0 | low | 1 | 0 |
| eosine yellowish-(ys) | 0 | low | 5 | 0 |
| violacein | 0 | low | 2 | 0 |
| lucanthone hydrochloride | 0 | low | 4 | 0 |
| resazurin | 0 | low | 3 | 0 |
| paeonol | 0 | low | 4 | 0 |
| hematoporphyrin | 0 | low | 10 | 0 |
| neutral red | 0 | low | 14 | 0 |
| aniline mustard | 0 | low | 2 | 0 |
| lithium carbonate | 0 | low | 6 | 0 |
| linamarin | 0 | low | 2 | 0 |
| 4-chloromercuribenzenesulfonate | 0 | low | 3 | 0 |
| beta-phellandrene | 0 | low | 1 | 0 |
| tristearin | 0 | low | 1 | 0 |
| glycyl-glycyl-glycine | 0 | low | 1 | 0 |
| glycylglycine | 0 | low | 2 | 0 |
| methyl isothiocyanate | 0 | low | 1 | 0 |
| glycerylphosphorylcholine | 0 | low | 2 | 0 |
| formestane | 0 | low | 2 | 0 |
| malachite green | 0 | low | 1 | 0 |
| 3-hydroxyflavone | 0 | low | 24 | 0 |
| diphenylamine | 0 | medium | 8 | 2 |
| allyl sulfide | 0 | low | 10 | 0 |
| megestrol acetate | 0 | medium | 5 | 2 |
| alpha-naphthoflavone | 0 | low | 10 | 0 |
| 2,6-dinitrotoluene | 0 | low | 2 | 0 |
| toyocamycin | 0 | low | 1 | 0 |
| galactitol | 0 | low | 1 | 0 |
| 2,4-dichloro-1-nitrobenzene | 0 | low | 1 | 0 |
| 2-anthramine | 0 | low | 1 | 0 |
| benzoylhydrazine | 0 | low | 1 | 0 |
| 2-benzylmalonate | 0 | low | 1 | 0 |
| acetylcysteine | 0 | medium | 100 | 2 |
| ethyl pyruvate | 0 | low | 1 | 0 |
| 2-chloro-4-nitrophenol | 0 | low | 1 | 0 |
| 4-hydrazinobenzoic acid | 0 | low | 1 | 0 |
| 3-hydroxybenzeneacetic acid | 0 | low | 1 | 0 |
| ethyl palmitate | 0 | low | 1 | 0 |
| hexamethylene glycol | 0 | low | 1 | 0 |
| n-propyl disulfide | 0 | low | 1 | 0 |
| dicarbethoxydihydrocollidine | 0 | low | 3 | 0 |
| c.i. 42510 | 0 | low | 9 | 0 |
| brilliant green | 0 | low | 1 | 0 |
| Berberine chloride (TN) | 0 | low | 1 | 0 |
| glycochenodeoxycholic acid | 0 | low | 13 | 0 |
| erythromycin | 0 | low | 1 | 0 |
| dehydroepiandrosterone sulfate | 0 | low | 5 | 0 |
| nitrosoguanidines | 0 | low | 4 | 0 |
| 2-piperidone | 0 | medium | 15 | 1 |
| perfluoropentane | 0 | medium | 3 | 1 |
| hempa | 0 | low | 1 | 0 |
| methylnitrosourea | 0 | low | 11 | 0 |
| ethylnitrosourea | 0 | low | 6 | 0 |
| 4,4'-biphenyldicarboxylic acid | 0 | low | 1 | 0 |
| o,p'-ddt | 0 | low | 1 | 0 |
| levonorgestrel | 0 | medium | 2 | 1 |
| porfiromycin | 0 | low | 1 | 0 |
| 1,6-hexamethylene diisocyanate | 0 | low | 1 | 0 |
| 1-methylphenanthrene | 0 | low | 1 | 0 |
| 1-phenylazo-2-naphthol | 0 | low | 2 | 0 |
| boldenone | 0 | low | 1 | 0 |
| norgestrienone | 0 | low | 1 | 0 |
| turinabol | 0 | low | 1 | 0 |
| vinblastine | 0 | low | 1 | 0 |
| 2-hydroxypropyl methacrylate | 0 | low | 1 | 0 |
| dibutylnitrosamine | 0 | low | 5 | 0 |
| cyclopentenone | 0 | low | 1 | 0 |
| n-nitrosopyrrolidine | 0 | low | 2 | 0 |
| 1-methylpyridinium | 0 | low | 1 | 0 |
| n-nitrosoperhydroazepine | 0 | low | 1 | 0 |
| 5-aminobenzimidazole | 0 | low | 1 | 0 |
| nitrosobenzylmethylamine | 0 | low | 1 | 0 |
| deoxycytidine | 0 | medium | 152 | 33 |
| deoxyuridine | 0 | low | 24 | 0 |
| 2,6-dichloroindophenol | 0 | low | 1 | 0 |
| testolactone | 0 | low | 1 | 0 |
| heptachlor epoxide | 0 | low | 3 | 0 |
| deoxycytidine monophosphate | 0 | low | 3 | 0 |
| trimethyltin chloride | 0 | low | 1 | 0 |
| bucrylate | 0 | low | 3 | 0 |
| 1,3-diphenylpropane | 0 | low | 1 | 0 |
| nicotinamide mononucleotide | 0 | low | 4 | 0 |
| pyridine-2-carboxaldehyde | 0 | low | 1 | 0 |
| tetramethylpyrazine | 0 | low | 4 | 0 |
| decabromobiphenyl ether | 0 | low | 1 | 0 |
| ethidium bromide | 0 | low | 1 | 0 |
| carmine | 0 | medium | 1 | 1 |
| calcium peroxide | 0 | medium | 1 | 1 |
| durapatite | 0 | medium | 13 | 1 |
| cadmium sulfide | 0 | low | 2 | 0 |
| sodium hydroxide | 0 | low | 3 | 0 |
| manganese dioxide | 0 | medium | 3 | 1 |
| zinc oxide | 0 | medium | 6 | 2 |
| thorium dioxide | 0 | low | 72 | 0 |
| molybdenum disulfide | 0 | low | 2 | 0 |
| cupric sulfide | 0 | low | 2 | 0 |
| arsenic trioxide | 0 | medium | 103 | 7 |
| glycyrrhizic acid | 0 | medium | 33 | 1 |
| d-alpha tocopherol | 0 | medium | 93 | 4 |
| tocopherols | 0 | low | 9 | 0 |
| pregnenolone carbonitrile | 0 | low | 1 | 0 |
| 1,2-epoxyhexane | 0 | medium | 2 | 2 |
| pseudouridine | 0 | low | 8 | 0 |
| selenomethionine | 0 | low | 6 | 0 |
| selenocystine | 0 | low | 2 | 0 |
| digoxigenin | 0 | low | 5 | 0 |
| 1,1-dichloro-1-fluoroethane | 0 | low | 1 | 0 |
| decane | 0 | low | 2 | 0 |
| nitrofen | 0 | low | 1 | 0 |
| stearylamine | 0 | low | 1 | 0 |
| ethyldimethylaminopropyl carbodiimide | 0 | low | 1 | 0 |
| paraquat | 0 | low | 7 | 0 |
| nitrapyrin | 0 | low | 1 | 0 |
| 2-tert-butylhydroquinone | 0 | low | 8 | 0 |
| dronabinol | 0 | low | 2 | 0 |
| methionine sulfoximine | 0 | low | 3 | 0 |
| amiloride | 0 | low | 9 | 0 |
| diallyl trisulfide | 0 | low | 1 | 0 |
| 3'-methyl-4-methylaminoazobenzene | 0 | low | 2 | 0 |
| pimozide | 0 | low | 3 | 0 |
| azetidyl-2-carboxylic acid | 0 | low | 1 | 0 |
| diallyl disulfide | 0 | low | 6 | 0 |
| n-isopropylacrylamide | 0 | low | 3 | 0 |
| phenethyl isothiocyanate | 0 | low | 6 | 0 |
| fluorescein | 0 | low | 9 | 0 |
| methylprednisolone hemisuccinate | 0 | medium | 1 | 1 |
| nile blue | 0 | low | 1 | 0 |
| mirex | 0 | low | 1 | 0 |
| fucose | 0 | medium | 103 | 1 |
| benzophenoneidum | 0 | low | 1 | 0 |
| sulfur hexafluoride | 0 | medium | 130 | 11 |
| victoria blue b | 0 | low | 2 | 0 |
| c.i. direct blue 1 | 0 | low | 1 | 0 |
| uridine diphosphate glucuronic acid | 0 | low | 2 | 0 |
| acadesine | 0 | low | 2 | 0 |
| aviprin | 0 | low | 1 | 0 |
| thiocholchicine | 0 | low | 1 | 0 |
| 2-(dimethylamino)ethyl methacrylate | 0 | low | 1 | 0 |
| uridine diphosphate galactose | 0 | low | 1 | 0 |
| stavudine | 0 | low | 1 | 0 |
| doxifluridine | 0 | medium | 10 | 3 |
| fluorescein-5-isothiocyanate | 0 | low | 32 | 0 |
| sabinene | 0 | low | 10 | 0 |
| mannose | 0 | low | 26 | 0 |
| thiamine triphosphate | 0 | medium | 2 | 2 |
| dithiothreitol | 0 | medium | 31 | 1 |
| megestrol | 0 | medium | 10 | 3 |
| cyclic cmp | 0 | low | 3 | 0 |
| chlorophacinone | 0 | low | 1 | 0 |
| tranylcypromine | 0 | low | 1 | 0 |
| nafenopin | 0 | low | 6 | 0 |
| streptomycin | 0 | low | 3 | 0 |
| carbonates | 0 | low | 4 | 0 |
| butylhydroxybutylnitrosamine | 0 | low | 2 | 0 |
| 2,3-hexanedione | 0 | low | 1 | 0 |
| 2-amino-1,3,4-thiadiazole | 0 | low | 1 | 0 |
| nitroxoline | 0 | low | 1 | 0 |
| pentaethylenehexamine | 0 | low | 2 | 0 |
| 4-acetylaminobiphenyl | 0 | low | 1 | 0 |
| dideoxyadenosine | 0 | low | 2 | 0 |
| dimethylnitramine | 0 | low | 1 | 0 |
| cladribine | 0 | low | 2 | 0 |
| hyaluronoglucosaminidase | 0 | low | 1 | 0 |
| mono-(2-ethylhexyl)phthalate | 0 | low | 2 | 0 |
| chlorophenol red | 0 | low | 1 | 0 |
| diphenylarsinic acid | 0 | low | 4 | 0 |
| metanephrine | 0 | low | 1 | 0 |
| buthionine sulfoximine | 0 | low | 23 | 0 |
| norleucine | 0 | low | 2 | 0 |
| 1'-hydroxysafrole | 0 | low | 1 | 0 |
| floxacillin | 0 | low | 1 | 0 |
| 1-hydroxypyrene | 0 | low | 1 | 0 |
| 1-nitropyrene | 0 | low | 6 | 0 |
| vidarabine | 0 | low | 11 | 0 |
| diadenosine tetraphosphate | 0 | low | 1 | 0 |
| iodinated glycerol | 0 | low | 11 | 0 |
| limonene | 0 | low | 3 | 0 |
| acetoxyacetylaminofluorene | 0 | low | 1 | 0 |
| diazoline | 0 | low | 1 | 0 |
| 4-(4-dimethylaminophenylazo)benzoic acid | 0 | low | 1 | 0 |
| enbucrilate | 0 | medium | 22 | 2 |
| 3-deazaadenosine | 0 | low | 1 | 0 |
| helenalin | 0 | low | 1 | 0 |
| n-nitrodiethylamine | 0 | low | 4 | 0 |
| 1-phenyl-3,3-dimethyltriazene | 0 | low | 1 | 0 |
| hepes | 0 | low | 1 | 0 |
| einsteinium | 0 | low | 1 | 0 |
| iridium | 0 | medium | 4 | 1 |
| lanthanum | 0 | low | 3 | 0 |
| lutetium | 0 | low | 4 | 0 |
| manganese | 0 | medium | 65 | 7 |
| mercury | 0 | medium | 20 | 1 |
| molybdenum | 0 | medium | 9 | 1 |
| neodymium | 0 | low | 1 | 0 |
| neon | 0 | low | 2 | 0 |
| osmium | 0 | low | 1 | 0 |
| palladium | 0 | low | 8 | 0 |
| platinum | 0 | medium | 30 | 2 |
| plutonium | 0 | low | 3 | 0 |
| praseodymium | 0 | low | 1 | 0 |
| rhenium | 0 | medium | 41 | 7 |
| rhodium | 0 | low | 4 | 0 |
| ruthenium | 0 | low | 12 | 0 |
| samarium | 0 | low | 1 | 0 |
| scandium | 0 | low | 2 | 0 |
| silver | 0 | medium | 50 | 5 |
| tantalum | 0 | low | 4 | 0 |
| technetium | 0 | medium | 165 | 1 |
| terbium | 0 | low | 1 | 0 |
| thorium | 0 | low | 6 | 0 |
| thulium | 0 | medium | 2 | 2 |
| titanium | 0 | medium | 15 | 3 |
| actinium | 0 | low | 1 | 0 |
| argon | 0 | low | 10 | 0 |
| cadmium | 0 | low | 45 | 0 |
| cerium | 0 | low | 8 | 0 |
| chromium | 0 | medium | 10 | 1 |
| erbium | 0 | low | 1 | 0 |
| europium | 0 | medium | 2 | 1 |
| gadolinium | 0 | medium | 112 | 11 |
| gold | 0 | medium | 108 | 3 |
| helium | 0 | low | 13 | 0 |
| holmium | 0 | medium | 9 | 3 |
| uranium | 0 | medium | 3 | 2 |
| vanadium | 0 | low | 3 | 0 |
| xenon | 0 | low | 3 | 0 |
| ytterbium | 0 | low | 4 | 0 |
| yttrium | 0 | medium | 15 | 2 |
| zirconium | 0 | low | 7 | 0 |
| aluminum chloride | 0 | low | 1 | 0 |
| cupric chloride | 0 | low | 4 | 0 |
| zalcitabine | 0 | low | 8 | 0 |
| mercuric chloride | 0 | low | 3 | 0 |
| selenium disulfide | 0 | low | 1 | 0 |
| 6-nitrochrysene | 0 | low | 2 | 0 |
| acetylglucosamine | 0 | low | 23 | 0 |
| meladrazine | 0 | low | 1 | 0 |
| galactosamine | 0 | medium | 30 | 2 |
| perchloric acid | 0 | low | 2 | 0 |
| cesium chloride | 0 | low | 1 | 0 |
| hypochlorous acid | 0 | low | 8 | 0 |
| camptothecin | 0 | medium | 100 | 5 |
| nickel chloride | 0 | low | 4 | 0 |
| ferrous sulfate | 0 | low | 3 | 0 |
| phosphine | 0 | low | 1 | 0 |
| isopentenyladenosine | 0 | low | 1 | 0 |
| bromine | 0 | low | 4 | 0 |
| barium sulfate | 0 | low | 5 | 0 |
| monoethylglycinexylidide | 0 | low | 6 | 0 |
| zinc sulfate | 0 | medium | 3 | 1 |
| potassium nitrate | 0 | low | 1 | 0 |
| sodium sulfate | 0 | medium | 2 | 1 |
| calcium phosphate, dibasic, anhydrous | 0 | low | 1 | 0 |
| calcium phosphate, monobasic, anhydrous | 0 | low | 1 | 0 |
| tricalcium phosphate | 0 | medium | 12 | 1 |
| copper sulfate | 0 | low | 3 | 0 |
| tungstate | 0 | low | 1 | 0 |
| silver nitrate | 0 | low | 8 | 0 |
| sodium thiosulfate | 0 | medium | 6 | 1 |
| calcium sulfate | 0 | low | 1 | 0 |
| deuterium | 0 | low | 6 | 0 |
| fluorine | 0 | low | 14 | 0 |
| chlorine | 0 | low | 7 | 0 |
| fluorosulfonic acid | 0 | low | 1 | 0 |
| thallium chloride | 0 | low | 3 | 0 |
| glycerol 1-stearate | 0 | low | 1 | 0 |
| ethinyl estradiol-norgestrel combination | 0 | low | 3 | 0 |
| galactose | 0 | medium | 31 | 3 |
| poloxalene | 0 | low | 2 | 0 |
| sizofiran | 0 | low | 1 | 0 |
| antimony trichloride | 0 | low | 1 | 0 |
| ozone | 0 | medium | 6 | 2 |
| aluminum sulfate | 0 | low | 1 | 0 |
| sodium selenite | 0 | low | 17 | 0 |
| tellurous acid | 0 | low | 1 | 0 |
| cadmium chloride | 0 | low | 15 | 0 |
| 4-chloro-7-nitrobenzofurazan | 0 | low | 6 | 0 |
| ancitabine | 0 | low | 1 | 0 |
| chlormerodrin | 0 | low | 1 | 0 |
| trolamine salicylate | 0 | low | 10 | 0 |
| stanozolol | 0 | low | 1 | 0 |
| rhamnose | 0 | low | 5 | 0 |
| clodronic acid | 0 | low | 4 | 0 |
| coformycin | 0 | low | 1 | 0 |
| ammonium chloride | 0 | low | 16 | 0 |
| chloropeptide | 0 | low | 1 | 0 |
| ethionine | 0 | low | 52 | 0 |
| n-ethyl-n-hydroxyethylnitrosamine | 0 | low | 4 | 0 |
| arabinofuranosylcytosine triphosphate | 0 | low | 2 | 0 |
| benzo(a)pyrene 7,8-dihydrodiol | 0 | low | 4 | 0 |
| 2',3-dimethyl-4-aminobiphenyl | 0 | low | 1 | 0 |
| titanium dioxide | 0 | medium | 8 | 2 |
| tri-(2-chloroisopropyl)phosphate | 0 | low | 1 | 0 |
| dimyristoylphosphatidylcholine | 0 | low | 1 | 0 |
| tetrathionic acid | 0 | low | 1 | 0 |
| salen | 0 | low | 1 | 0 |
| tiletamine hydrochloride | 0 | low | 31 | 0 |
| selegiline | 0 | low | 1 | 0 |
| cycasin | 0 | low | 3 | 0 |
| 1-methyladenosine | 0 | low | 2 | 0 |
| vinyl carbamate | 0 | low | 1 | 0 |
| isosorbide-5-mononitrate | 0 | low | 1 | 0 |
| ferric nitrilotriacetate | 0 | low | 2 | 0 |
| tetradecanoylphorbol acetate | 0 | low | 141 | 0 |
| tocopheryl nicotinate | 0 | low | 1 | 0 |
| sodium bisulfide | 0 | low | 1 | 0 |
| showdomycin | 0 | low | 1 | 0 |
| fluorides | 0 | medium | 24 | 1 |
| danazol | 0 | low | 13 | 0 |
| tomatine | 0 | low | 1 | 0 |
| stannic oxide | 0 | low | 1 | 0 |
| chromium | 0 | low | 3 | 0 |
| keracyanin | 0 | low | 1 | 0 |
| molybdenum dioxide | 0 | low | 1 | 0 |
| 1-deoxynojirimycin | 0 | low | 13 | 0 |
| taurolidine | 0 | low | 1 | 0 |
| isoamyl 2-cyanoacrylate | 0 | low | 1 | 0 |
| geosmin | 0 | low | 1 | 0 |
| iodine | 0 | low | 4 | 0 |
| osmium tetroxide | 0 | low | 1 | 0 |
| daunorubicin | 0 | medium | 36 | 2 |
| razoxane | 0 | low | 1 | 0 |
| phosphotyrosine | 0 | low | 30 | 0 |
| 2,6-diaminopurine | 0 | low | 1 | 0 |
| bromocriptine | 0 | low | 2 | 0 |
| indium phosphide | 0 | low | 1 | 0 |
| fenitrothion | 0 | low | 2 | 0 |
| zingerone | 0 | low | 3 | 0 |
| phenyl acetate | 0 | medium | 152 | 5 |
| cetylpyridinium chloride anhydrous | 0 | low | 4 | 0 |
| myrcene | 0 | low | 1 | 0 |
| pyrrolidine | 0 | low | 2 | 0 |
| 1,4-dioxane | 0 | low | 1 | 0 |
| chlorodibromomethane | 0 | low | 1 | 0 |
| triamcinolone | 0 | low | 6 | 0 |
| tributyl phosphate | 0 | low | 1 | 0 |
| methacrylonitrile | 0 | low | 1 | 0 |
| ursodeoxycholic acid | 0 | medium | 50 | 2 |
| pyrene | 0 | low | 2 | 0 |
| isothiuronium | 0 | low | 1 | 0 |
| rafoxanide | 0 | low | 1 | 0 |
| benzonidazole | 0 | low | 1 | 0 |
| 4-methoxyamphetamine | 0 | low | 14 | 0 |
| prospidium | 0 | low | 1 | 0 |
| 8-bromo cyclic adenosine monophosphate | 0 | low | 18 | 0 |
| transferrin | 0 | medium | 150 | 2 |
| tridemorph | 0 | low | 11 | 0 |
| alkenes | 0 | low | 6 | 0 |
| calcium oxalate | 0 | low | 1 | 0 |
| glutamic acid | 0 | low | 21 | 0 |
| glucaric acid | 0 | low | 3 | 0 |
| alovudine | 0 | low | 4 | 0 |
| adenylyl imidodiphosphate | 0 | low | 1 | 0 |
| azoxymethane | 0 | low | 2 | 0 |
| cefazolin | 0 | medium | 2 | 2 |
| sodium azide | 0 | low | 3 | 0 |
| azides | 0 | low | 11 | 0 |
| adenosine diphosphate ribose | 0 | low | 7 | 0 |
| amoxicillin | 0 | low | 1 | 0 |
| timolol | 0 | low | 1 | 0 |
| tramadol | 0 | low | 2 | 0 |
| vanadyl sulfate | 0 | low | 1 | 0 |
| oxovanadium iv | 0 | low | 1 | 0 |
| gallium citrate | 0 | low | 2 | 0 |
| 4-acetylaminofluorene | 0 | low | 1 | 0 |
| nigericin | 0 | low | 1 | 0 |
| prednimustine | 0 | low | 1 | 0 |
| octachlorostyrene | 0 | low | 1 | 0 |
| ioxitalamic acid | 0 | low | 2 | 0 |
| s-adenosylmethionine | 0 | low | 9 | 0 |
| vidarabine phosphate | 0 | low | 5 | 0 |
| zidovudine | 0 | medium | 12 | 1 |
| 7-ethoxycoumarin | 0 | low | 2 | 0 |
| acetylgalactosamine | 0 | low | 11 | 0 |
| b 10610 | 0 | low | 1 | 0 |
| flubendazole | 0 | low | 1 | 0 |
| pcb 118 | 0 | low | 2 | 0 |
| 3,4,3',4'-tetrachlorobiphenyl | 0 | low | 2 | 0 |
| 2,3,3',4,4'-pentachlorobiphenyl | 0 | low | 1 | 0 |
| 3,4,5,3',4',5'-hexachlorobiphenyl | 0 | low | 1 | 0 |
| 4-ipomeanol | 0 | medium | 3 | 1 |
| 2,3,4,5-tetrachlorobiphenyl | 0 | low | 1 | 0 |
| substance p | 0 | low | 4 | 0 |
| promegestone | 0 | low | 1 | 0 |
| dobutamine | 0 | low | 3 | 0 |
| ticarcillin | 0 | low | 1 | 0 |
| 5,6-dihydroxy-2-dimethylaminotetralin | 0 | low | 1 | 0 |
| 2,4,5,2',4',5'-hexachlorobiphenyl | 0 | low | 1 | 0 |
| diflubenzuron | 0 | low | 1 | 0 |
| 2,5,2',5'-tetrachlorobiphenyl | 0 | low | 1 | 0 |
| iprodione | 0 | low | 1 | 0 |
| ribavirin | 0 | medium | 258 | 19 |
| lentinan | 0 | medium | 9 | 2 |
| amikacin | 0 | medium | 1 | 1 |
| phorbol 12,13-dibutyrate | 0 | low | 3 | 0 |
| 2,3,4,2',3',4'-hexachlorobiphenyl | 0 | low | 1 | 0 |
| agent orange | 0 | low | 2 | 0 |
| 1,2,3,7,8-pentachlorodibenzo-p-dioxin | 0 | low | 1 | 0 |
| n-(2-hydroxypropyl)methacrylamide | 0 | low | 5 | 0 |
| methyldopa | 0 | low | 1 | 0 |
| bezafibrate | 0 | medium | 5 | 1 |
| 1,6-dinitropyrene | 0 | low | 3 | 0 |
| 1,8-dinitropyrene | 0 | low | 2 | 0 |
| diltiazem | 0 | low | 4 | 0 |
| nimustine | 0 | low | 1 | 0 |
| triadimefon | 0 | low | 1 | 0 |
| lonidamine | 0 | low | 1 | 0 |
| vinclozolin | 0 | low | 1 | 0 |
| 2,3,7,8-tetrabromodibenzo-4-dioxin | 0 | low | 1 | 0 |
| n-acetyl-4-benzoquinoneimine | 0 | low | 1 | 0 |
| vx | 0 | low | 1 | 0 |
| ng-nitroarginine methyl ester | 0 | low | 8 | 0 |
| 2,3,7,8-tetrachlorodibenzofuran | 0 | low | 1 | 0 |
| buthiobate | 0 | low | 1 | 0 |
| 1'-hydroxyestragole | 0 | low | 2 | 0 |
| deoxynivalenol | 0 | low | 2 | 0 |
| chlorodiphenyl (54% chlorine) | 0 | low | 1 | 0 |
| pirfenidone | 0 | low | 5 | 0 |
| 6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid | 0 | low | 5 | 0 |
| 1-carboxyglutamic acid | 0 | low | 5 | 0 |
| dh 990 | 0 | low | 1 | 0 |
| diisopropanolnitrosamine | 0 | low | 2 | 0 |
| vindesine | 0 | low | 1 | 0 |
| 3,3',5,5'-tetramethylbenzidine | 0 | low | 1 | 0 |
| meglitinide | 0 | low | 1 | 0 |
| 7,8-dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide | 0 | low | 6 | 0 |
| nitazoxanide | 0 | low | 1 | 0 |
| sufentanil | 0 | low | 1 | 0 |
| eg 626 | 0 | low | 1 | 0 |
| cefmetazole | 0 | low | 1 | 0 |
| desflurane | 0 | low | 1 | 0 |
| 2,3,4,7,8-pentachlorodibenzofuran | 0 | low | 1 | 0 |
| elliptinium | 0 | medium | 4 | 2 |
| eniluracil | 0 | medium | 3 | 3 |
| propiconazole | 0 | low | 11 | 0 |
| nitrosobis(2-oxopropyl)amine | 0 | low | 3 | 0 |
| piperacillin | 0 | medium | 2 | 1 |
| paroxetine | 0 | low | 1 | 0 |
| captopril | 0 | low | 3 | 0 |
| cefoperazone | 0 | low | 1 | 0 |
| staurosporine | 0 | low | 5 | 0 |
| acetyl hexamethyl indan | 0 | low | 1 | 0 |
| cetaben | 0 | low | 3 | 0 |
| 4-(n-methyl-n-nitrosamino)-1-(3-pyridyl)-1-butanone | 0 | low | 1 | 0 |
| oltipraz | 0 | medium | 11 | 5 |
| atracurium | 0 | low | 2 | 0 |
| colforsin | 0 | low | 29 | 0 |
| buserelin | 0 | low | 1 | 0 |
| fialuridine | 0 | low | 1 | 0 |
| amonafide | 0 | low | 2 | 0 |
| 1-nitrobenzo(a)pyrene | 0 | low | 1 | 0 |
| 3-nitrobenzo(a)pyrene | 0 | low | 1 | 0 |
| pimonidazole | 0 | low | 1 | 0 |
| daurisoline | 0 | low | 2 | 0 |
| n-3-methylbutyl-n-1-methylacetonylnitrosamine | 0 | low | 1 | 0 |
| alfentanil | 0 | medium | 1 | 1 |
| bisantrene | 0 | low | 3 | 0 |
| fomesafen | 0 | low | 2 | 0 |
| fenoxycarb | 0 | low | 2 | 0 |
| miglustat | 0 | low | 2 | 0 |
| swainsonine | 0 | low | 6 | 0 |
| 1,3-dinitropyrene | 0 | low | 2 | 0 |
| lovastatin | 0 | low | 41 | 0 |
| 2-amino-3-methylimidazo(4,5-f)quinoline | 0 | low | 12 | 0 |
| mebrofenin | 0 | low | 1 | 0 |
| castanospermine | 0 | low | 2 | 0 |
| simvastatin | 0 | low | 36 | 0 |
| idazoxan | 0 | low | 1 | 0 |
| raloxifene hydrochloride | 0 | low | 5 | 0 |
| ilmofosine | 0 | low | 1 | 0 |
| mifepristone | 0 | low | 13 | 0 |
| itraconazole | 0 | low | 4 | 0 |
| antineoplaston a10 | 0 | low | 3 | 0 |
| fluorodopa f 18 | 0 | low | 1 | 0 |
| salmeterol xinafoate | 0 | medium | 1 | 1 |
| bmy 25067 | 0 | low | 1 | 0 |
| atamestane | 0 | low | 1 | 0 |
| fura-2 | 0 | low | 6 | 0 |
| crisnatol | 0 | low | 1 | 0 |
| n 0437, (-)-isomer | 0 | low | 1 | 0 |
| fadrozole | 0 | low | 1 | 0 |
| esmolol | 0 | medium | 1 | 1 |
| adapalene | 0 | low | 1 | 0 |
| adefovir | 0 | medium | 36 | 3 |
| clopidogrel | 0 | low | 10 | 0 |
| mibefradil | 0 | low | 1 | 0 |
| risotilide | 0 | low | 1 | 0 |
| topotecan | 0 | medium | 11 | 3 |
| tenidap | 0 | low | 1 | 0 |
| temoporfin | 0 | low | 2 | 0 |
| lufironil | 0 | low | 1 | 0 |
| remifentanil | 0 | medium | 4 | 3 |
| atorvastatin | 0 | medium | 23 | 1 |
| duloxetine hydrochloride | 0 | low | 2 | 0 |
| zolmitriptan | 0 | low | 1 | 0 |
| 3-iodobenzylguanidine | 0 | low | 9 | 0 |
| adefovir dipivoxil | 0 | medium | 16 | 2 |
| emtricitabine | 0 | low | 5 | 0 |
| adenosine | 0 | medium | 113 | 2 |
| safranal | 0 | low | 1 | 0 |
| myrtenal | 0 | low | 1 | 0 |
| octyl gallate | 0 | low | 1 | 0 |
| ferric citrate | 0 | low | 2 | 0 |
| 3-n-butylphthalide | 0 | low | 1 | 0 |
| coomassie brilliant blue r | 0 | low | 1 | 0 |
| gadolinium chloride | 0 | low | 5 | 0 |
| acetyl tert-butyl dimethylindan | 0 | low | 1 | 0 |
| vanadates | 0 | low | 15 | 0 |
| dimethylhydrazines | 0 | low | 3 | 0 |
| edda | 0 | low | 1 | 0 |
| dehydroabietylamine | 0 | low | 2 | 0 |
| 2-amino-3,4-dimethylimidazo(4,5-f)quinoline | 0 | low | 5 | 0 |
| 2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline | 0 | low | 8 | 0 |
| musk xylene | 0 | low | 1 | 0 |
| scarlet red | 0 | low | 1 | 0 |
| sudan iii | 0 | low | 2 | 0 |
| acridine orange | 0 | low | 6 | 0 |
| isothiocyanic acid | 0 | low | 4 | 0 |
| cuprous chloride | 0 | low | 1 | 0 |
| chromic phosphate | 0 | medium | 1 | 1 |
| carbogen | 0 | low | 4 | 0 |
| caloreen | 0 | low | 1 | 0 |
| 2-amino-9h-pyrido(2,3-b)indole | 0 | low | 2 | 0 |
| octyl glucoside | 0 | low | 1 | 0 |
| cisatracurium | 0 | low | 1 | 0 |
| halofuginone | 0 | low | 3 | 0 |
| trazodone hydrochloride | 0 | low | 11 | 0 |
| dexamethasone 21-methanesulfonate | 0 | low | 1 | 0 |
| 3,4,5,3',4'-pentachlorobiphenyl | 0 | low | 9 | 0 |
| efavirenz | 0 | low | 2 | 0 |
| nelfinavir | 0 | low | 3 | 0 |
| methionine methyl ester | 0 | low | 1 | 0 |
| glucose, (beta-d)-isomer | 0 | medium | 53 | 2 |
| anisodamine | 0 | low | 1 | 0 |
| mevastatin | 0 | low | 9 | 0 |
| simvastatin acid | 0 | low | 3 | 0 |
| chloroquine diphosphate | 0 | low | 1 | 0 |
| fenofibric acid | 0 | low | 1 | 0 |
| 2',7'-dichlorofluorescein | 0 | low | 3 | 0 |
| ursolic acid | 0 | low | 32 | 0 |
| norharman | 0 | low | 3 | 0 |
| thiazolyl blue | 0 | medium | 72 | 1 |
| thymidine 5'-triphosphate | 0 | low | 2 | 0 |
| betulinic acid | 0 | low | 11 | 0 |
| dexelvucitabine | 0 | low | 2 | 0 |
| arctigenin | 0 | low | 5 | 0 |
| baicalin | 0 | medium | 12 | 2 |
| plerixafor | 0 | low | 8 | 0 |
| amprenavir | 0 | low | 1 | 0 |
| oseltamivir | 0 | low | 2 | 0 |
| allicin | 0 | low | 4 | 0 |
| 5-methylcytosine | 0 | low | 26 | 0 |
| guanidine thiocyanate | 0 | low | 1 | 0 |
| diacetylfluorescein | 0 | low | 1 | 0 |
| ibacitabine | 0 | low | 1 | 0 |
| 2'-deoxyuridylic acid | 0 | low | 1 | 0 |
| epigallocatechin gallate | 0 | low | 66 | 0 |
| cholesteryl sulfate | 0 | low | 1 | 0 |
| fluorexon | 0 | low | 1 | 0 |
| cholesteryl succinate | 0 | low | 1 | 0 |
| gallocatechol | 0 | low | 3 | 0 |
| 2'-deoxycytidine 5'-triphosphate | 0 | low | 1 | 0 |
| 25-hydroxycholesterol | 0 | low | 21 | 0 |
| 10,10'-dimethyl-9,9'-biacridinium | 0 | low | 1 | 0 |
| aica ribonucleotide | 0 | low | 14 | 0 |
| thomsen-friedenreich antigen | 0 | low | 3 | 0 |
| salvin | 0 | low | 3 | 0 |
| 1,2-dipalmitoylphosphatidylglycerol | 0 | low | 1 | 0 |
| 1-beta-d-arabinofuranosylcytosine 5'-monophosphate | 0 | low | 1 | 0 |
| 5-bromo-4-chloro-3-indolyl beta-galactoside | 0 | low | 3 | 0 |
| metaperiodate | 0 | low | 7 | 0 |
| lissamine rhodamine b | 0 | low | 2 | 0 |
| 1,2,3,4,6-pentakis-O-galloyl-beta-D-glucose | 0 | low | 3 | 0 |
| fructose-1-phosphate | 0 | low | 1 | 0 |
| n-acetylserine | 0 | low | 1 | 0 |
| bis(1,10-phenanthroline)copper(1+) ion | 0 | low | 1 | 0 |
| aspartate-beta-hydroxamate | 0 | low | 1 | 0 |
| o-(6)-methylguanine | 0 | low | 4 | 0 |
| pyrrolidine dithiocarbamate | 0 | medium | 10 | 1 |
| glutathione disulfide | 0 | low | 10 | 0 |
| bathophenanthroline disulfonic acid | 0 | low | 1 | 0 |
| hypusine | 0 | low | 1 | 0 |
| 4-nitrobenzylthioinosine | 0 | low | 1 | 0 |
| 5-bromo-4-chloro-3-indoxyl phosphate | 0 | low | 1 | 0 |
| triptonide | 0 | low | 1 | 0 |
| iopamidol | 0 | medium | 75 | 12 |
| cephalosporin c | 0 | medium | 5 | 2 |
| tetraiodothyroacetic acid | 0 | low | 1 | 0 |
| 5-dihydrocortisone | 0 | low | 1 | 0 |
| 3'-deoxyadenosine 5'-triphosphate | 0 | low | 1 | 0 |
| lathosterol | 0 | low | 1 | 0 |
| milnacipran | 0 | low | 1 | 0 |
| flomoxef | 0 | medium | 2 | 2 |
| methoxy-morpholinyl-doxorubicin | 0 | low | 2 | 0 |
| iobitridol | 0 | low | 3 | 0 |
| telmisartan | 0 | low | 6 | 0 |
| lumiflavin | 0 | low | 1 | 0 |
| iridium radioisotopes | 0 | medium | 7 | 1 |
| xenon radioisotopes | 0 | low | 3 | 0 |
| 2-methoxyestradiol | 0 | low | 12 | 0 |
| ovosiston | 0 | low | 2 | 0 |
| naphthalimides | 0 | low | 15 | 0 |
| toxoflavin | 0 | low | 1 | 0 |
| benzeneboronic acid | 0 | low | 1 | 0 |
| moskene | 0 | low | 1 | 0 |
| bromosuccinimide | 0 | low | 1 | 0 |
| musk tibetine | 0 | low | 1 | 0 |
| 1,7-phenanthroline | 0 | low | 12 | 0 |
| pyrazolo(3,4-d)pyrimidine | 0 | low | 1 | 0 |
| triazoles | 0 | medium | 54 | 3 |
| perfluorododecanoic acid | 0 | low | 1 | 0 |
| dabi | 0 | low | 1 | 0 |
| 6-methyladenine | 0 | low | 7 | 0 |
| lupulon | 0 | low | 1 | 0 |
| atranorin | 0 | low | 1 | 0 |
| tangeretin | 0 | low | 5 | 0 |
| isoimperatorin | 0 | low | 3 | 0 |
| isocoumarins | 0 | low | 2 | 0 |
| 1-piperideine | 0 | low | 1 | 0 |
| delphinidin | 0 | low | 19 | 0 |
| 2,6-dimethoxy-1,4-benzoquinone | 0 | low | 1 | 0 |
| sesamol | 0 | low | 1 | 0 |
| 1,2-dithiol-3-thione | 0 | low | 1 | 0 |
| 4-aminoquinoline | 0 | low | 1 | 0 |
| fluorodeoxyglucose f18 | 0 | medium | 338 | 14 |
| sertraline | 0 | low | 3 | 0 |
| artemisinin | 0 | low | 6 | 0 |
| propacetamol | 0 | medium | 1 | 1 |
| tianeptine | 0 | low | 1 | 0 |
| artemether | 0 | low | 2 | 0 |
| 1,2,3,4-tetrahydroquinoline | 0 | low | 1 | 0 |
| fructose-6-phosphate | 0 | low | 2 | 0 |
| 5-fluoropyrimidine | 0 | low | 1 | 0 |
| 5-hydroxymethylcytosine | 0 | low | 21 | 0 |
| acamprosate | 0 | low | 1 | 0 |
| dapoxetine | 0 | medium | 2 | 2 |
| dexrazoxane | 0 | low | 1 | 0 |
| masoprocol | 0 | low | 2 | 0 |
| tocophersolan | 0 | low | 17 | 0 |
| 7-methyladenine | 0 | low | 1 | 0 |
| voriconazole | 0 | medium | 2 | 2 |
| tazolol | 0 | low | 1 | 0 |
| aceclofenac | 0 | low | 1 | 0 |
| olaquindox | 0 | low | 2 | 0 |
| nipradilol | 0 | low | 1 | 0 |
| terlipressin | 0 | medium | 2 | 1 |
| ubenimex | 0 | low | 3 | 0 |
| oxetanocin a | 0 | low | 1 | 0 |
| 7-hydroxystaurosporine | 0 | low | 1 | 0 |
| hesperetin | 0 | low | 2 | 0 |
| 4-o-methyl-12-o-tetradecanoylphorbol 13-acetate | 0 | low | 1 | 0 |
| magnolol | 0 | low | 3 | 0 |
| honokiol | 0 | low | 8 | 0 |
| sesamin | 0 | low | 2 | 0 |
| columbamine | 0 | low | 2 | 0 |
| coptisine | 0 | low | 2 | 0 |
| jatrorrhizine | 0 | low | 1 | 0 |
| betulin | 0 | low | 5 | 0 |
| hernandezine | 0 | low | 1 | 0 |
| nobiletin | 0 | low | 5 | 0 |
| narciclasine | 0 | low | 1 | 0 |
| lycorine | 0 | low | 1 | 0 |
| neamine | 0 | low | 1 | 0 |
| teleocidin b-4 | 0 | low | 7 | 0 |
| leupeptin | 0 | low | 4 | 0 |
| picropodophyllin | 0 | low | 5 | 0 |
| alkannin | 0 | low | 2 | 0 |
| zaluzanin C | 0 | low | 1 | 0 |
| pacein | 0 | medium | 13 | 1 |
| berberrubine | 0 | low | 1 | 0 |
| alantolactone | 0 | low | 1 | 0 |
| 3-aminophenoxazone | 0 | low | 1 | 0 |
| 2-(4'-methylpiperazino-1-methyl)-1,3-diazafluoranthene 1-oxide | 0 | low | 1 | 0 |
| 7-bromobenzanthracene | 0 | low | 1 | 0 |
| tetrandrine | 0 | low | 12 | 0 |
| 3-deazaneplanocin | 0 | low | 4 | 0 |
| tosyllysine chloromethyl ketone | 0 | low | 1 | 0 |
| dehydrocostus lactone | 0 | low | 4 | 0 |
| pinostrobin | 0 | low | 1 | 0 |
| xanthomicrol | 0 | low | 1 | 0 |
| fascaplysine | 0 | low | 1 | 0 |
| pulsatilla saponin a | 0 | low | 1 | 0 |
| hederagenin | 0 | low | 1 | 0 |
| fr 109615 | 0 | low | 1 | 0 |
| jacaranone | 0 | low | 1 | 0 |
| o(6)-methyl-2'-deoxyguanosine | 0 | low | 1 | 0 |
| calpeptin | 0 | low | 1 | 0 |
| gliclazide | 0 | low | 5 | 0 |
| dauricine | 0 | low | 1 | 0 |
| brusatol | 0 | low | 3 | 0 |
| panaxadiol | 0 | low | 3 | 0 |
| corilagin | 0 | low | 4 | 0 |
| glycyl-histidyl-lysine | 0 | low | 1 | 0 |
| maslinic acid | 0 | low | 1 | 0 |
| carbohydrazide | 0 | low | 2 | 0 |
| oxazolidin-2-one | 0 | low | 2 | 0 |
| ceric oxide | 0 | low | 6 | 0 |
| bis(diphenylphosphine)ethane | 0 | low | 1 | 0 |
| perfluorooctane sulfonic acid | 0 | low | 6 | 0 |
| triphenylmethylphosphonium | 0 | low | 1 | 0 |
| atovaquone | 0 | low | 2 | 0 |
| 1-(2-chloroethyl)-1-nitrosourea | 0 | low | 1 | 0 |
| 2-(methylamino)isobutyric acid | 0 | low | 1 | 0 |
| 2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane | 0 | low | 1 | 0 |
| 6-carboxyfluorescein | 0 | low | 2 | 0 |
| bendamustine hydrochloride | 0 | low | 1 | 0 |
| sofosbuvir | 0 | low | 1 | 0 |
| atherospermidine | 0 | low | 1 | 0 |
| 2',7'-dichlorodihydrofluorescein diacetate | 0 | low | 2 | 0 |
| ribose-5-phosphate | 0 | low | 1 | 0 |
| rosiglitazone | 0 | low | 28 | 0 |
| erucin | 0 | low | 3 | 0 |
| 3,7-diazanonane-1,9-diamine | 0 | low | 1 | 0 |
| 3,7-dimethyl-7-octen-1-ol | 0 | low | 1 | 0 |
| gamma-glutamine-4-nitroanilide | 0 | low | 1 | 0 |
| cryptolepine | 0 | low | 1 | 0 |
| 2-bromopalmitate | 0 | low | 1 | 0 |
| bexarotene | 0 | medium | 2 | 1 |
| noracycline | 0 | low | 1 | 0 |
| 3,4-dihydroxyphenylethanol | 0 | low | 5 | 0 |
| 4-phenylbutylamine | 0 | low | 2 | 0 |
| eriocitrin | 0 | low | 2 | 0 |
| n-acryloyl-tris(hydroxymethyl)aminomethane | 0 | low | 1 | 0 |
| biotinyl-n-hydroxysulfosuccinimide ester | 0 | low | 1 | 0 |
| 5-(biotinamido)pentylamine | 0 | low | 1 | 0 |
| adriamycinol | 0 | low | 4 | 0 |
| clarithromycin | 0 | medium | 2 | 1 |
| ferroin | 0 | low | 1 | 0 |
| tebuconazole | 0 | low | 2 | 0 |
| difenoconazole | 0 | low | 1 | 0 |
| cp094 | 0 | low | 1 | 0 |
| cyprodinil | 0 | low | 1 | 0 |
| fludioxonil | 0 | low | 1 | 0 |
| coenzyme a | 0 | low | 17 | 0 |
| 5-aminoindazole | 0 | low | 1 | 0 |
| 7-chlorobenz(a)anthracene | 0 | low | 1 | 0 |
| gentiopicroside | 0 | low | 1 | 0 |
| 5,7-dimethoxyflavone | 0 | low | 3 | 0 |
| acetyl methyl tetramethyl tetralin | 0 | low | 1 | 0 |
| mebeverine | 0 | low | 2 | 0 |
| o-desmethylangolensin | 0 | low | 1 | 0 |
| nicotine | 0 | medium | 4 | 2 |
| nsc-172755 | 0 | low | 1 | 0 |
| loganic acid | 0 | low | 1 | 0 |
| 1-aminocyclobutanecarboxylic acid | 0 | low | 2 | 0 |
| fibrinogen | 0 | medium | 168 | 8 |
| tandospirone | 0 | low | 1 | 0 |
| terreic acid | 0 | low | 1 | 0 |
| 17-alpha-hydroxypregnenolone | 0 | low | 1 | 0 |
| beta-eudesmol | 0 | low | 1 | 0 |
| matrine | 0 | low | 1 | 0 |
| equol | 0 | low | 5 | 0 |
| 7-ketocholesterol | 0 | low | 1 | 0 |
| galaxolide | 0 | low | 1 | 0 |
| cadmium telluride | 0 | low | 11 | 0 |
| glycidamide | 0 | low | 1 | 0 |
| homocysteine | 0 | medium | 33 | 1 |
| 4-methylumbelliferyl glucuronide | 0 | low | 1 | 0 |
| 4-hydroxypropranolol | 0 | low | 2 | 0 |
| 1-cyano-2-hydroxy-3-butene | 0 | low | 1 | 0 |
| 8-((4-chlorophenyl)thio)cyclic-3',5'-amp | 0 | low | 2 | 0 |
| 2-methylhippuric acid | 0 | low | 1 | 0 |
| hydroxyflutamide | 0 | low | 2 | 0 |
| 2,2',4,6,6'-pentachlorobiphenyl | 0 | low | 1 | 0 |
| lyngbyatoxin a | 0 | low | 1 | 0 |
| delta-tocopherol | 0 | low | 1 | 0 |
| sarsasapogenin | 0 | low | 3 | 0 |
| tylophorine | 0 | low | 2 | 0 |
| lupenone | 0 | low | 1 | 0 |
| methylumbelliferyl-beta-d-xyloside | 0 | low | 1 | 0 |
| phenylacetylglutamine | 0 | low | 1 | 0 |
| 6,7-dihydro-1,1,2,3,3-pentamethyl-4-(5h)indanone | 0 | low | 1 | 0 |
| lopinavir | 0 | medium | 2 | 2 |
| gamma-tocopherol | 0 | low | 4 | 0 |
| allotetrahydrocortisol | 0 | low | 1 | 0 |
| propionyl-coenzyme a | 0 | low | 2 | 0 |
| alpha-eudesmol | 0 | low | 1 | 0 |
| methylarsine oxide | 0 | low | 1 | 0 |
| glycyltyrosine | 0 | low | 1 | 0 |
| norcantharidin | 0 | low | 42 | 0 |
| cortisol 21-mesylate | 0 | low | 1 | 0 |
| dithiobis(succinimidylpropionate) | 0 | low | 2 | 0 |
| dehydroabietic acid | 0 | low | 2 | 0 |
| malvidin 3-galactoside | 0 | low | 1 | 0 |
| alpha-tocopherol phosphate | 0 | low | 1 | 0 |
| glucuronic acid | 0 | low | 14 | 0 |
| 4-mercaptobenzoate | 0 | low | 1 | 0 |
| 2,2-dimethyl-beta-alanine | 0 | low | 4 | 0 |
| 6-ethylguanine | 0 | low | 1 | 0 |
| 4',5,6,7-tetramethoxyflavone | 0 | low | 1 | 0 |
| phosphoramide mustard | 0 | low | 1 | 0 |
| dipin | 0 | low | 1 | 0 |
| phosphazine | 0 | low | 1 | 0 |
| carbobenzoxyglycylphenylalanine amide | 0 | low | 1 | 0 |
| 5-iodotubercidin | 0 | low | 1 | 0 |
| 2-phenyl-5,5-dimethyltetrahydro-1,4-oxazine | 0 | low | 1 | 0 |
| 4-hydroxyantipyrine | 0 | low | 1 | 0 |
| cholest-5-ene-3 beta,26-diol | 0 | low | 2 | 0 |
| diosgenin | 0 | low | 12 | 0 |
| 4-methoxydalbergione | 0 | low | 2 | 0 |
| phorbolol myristate acetate | 0 | low | 1 | 0 |
| dianhydro-3,4-diacetylgalactitol | 0 | low | 2 | 0 |
| pyrimidin-2-one beta-ribofuranoside | 0 | low | 3 | 0 |
| nimbolide | 0 | low | 3 | 0 |
| foxes | 0 | low | 2 | 0 |
| kemptide | 0 | low | 1 | 0 |
| combretastatin | 0 | low | 3 | 0 |
| beta-hydroxyisovalerylshikonin | 0 | low | 1 | 0 |
| fangchinoline | 0 | low | 3 | 0 |
| 8-chloro-cyclic adenosine monophosphate | 0 | low | 1 | 0 |
| loliolide | 0 | low | 1 | 0 |
| coumarin 6 | 0 | low | 3 | 0 |
| arctiin | 0 | low | 3 | 0 |
| 7-amino-4-trifluoromethylcoumarin | 0 | low | 1 | 0 |
| n-hydroxysuccinimide suberic acid ester | 0 | low | 1 | 0 |
| n-succinimidyl 3-(2-pyridyldithio)propionate | 0 | low | 1 | 0 |
| tingenone | 0 | low | 1 | 0 |
| methyl mannoside, (alpha-d)-isomer | 0 | low | 1 | 0 |
| meldola blue | 0 | low | 1 | 0 |
| pregnanetriol | 0 | medium | 1 | 1 |
| n-methyladenosine | 0 | medium | 45 | 1 |
| 1,2-distearoylphosphatidylethanolamine | 0 | low | 2 | 0 |
| lanthionine | 0 | low | 1 | 0 |
| cobalt | 0 | low | 52 | 0 |
| p-methoxy-n-methylphenethylamine | 0 | low | 1 | 0 |
| fulvestrant | 0 | low | 4 | 0 |
| uftoral | 0 | medium | 10 | 1 |
| hydrogen sulfite | 0 | low | 9 | 0 |
| aflatoxin b1-2,3-oxide | 0 | low | 2 | 0 |
| yttrium radioisotopes | 0 | medium | 639 | 50 |
| chlorates | 0 | low | 2 | 0 |
| desethylamiodarone | 0 | low | 1 | 0 |
| u 73122 | 0 | low | 5 | 0 |
| fotemustine | 0 | low | 1 | 0 |
| arginyl-glycyl-aspartic acid | 0 | low | 25 | 0 |
| wr 1065 | 0 | medium | 1 | 1 |
| vitamin b 6 | 0 | medium | 9 | 1 |
| imipenem, anhydrous | 0 | low | 3 | 0 |
| cremophor el | 0 | low | 2 | 0 |
| 4-(methylnitrosamino)-1-(3-pyridyl)-1-butan-1-ol | 0 | low | 1 | 0 |
| s-nitrosoglutathione | 0 | low | 3 | 0 |
| bosentan anhydrous | 0 | low | 1 | 0 |
| ecgonine methyl ester | 0 | low | 1 | 0 |
| diacetyldichlorofluorescein | 0 | low | 1 | 0 |
| trimethylarsine oxide | 0 | low | 1 | 0 |
| 1-(2-(3-(4-methoxyphenyl)propoxy)-4-methoxyphenylethyl)-1h-imidazole | 0 | low | 2 | 0 |
| fluo-3 | 0 | low | 1 | 0 |
| 1,n(6)-ethenoadenine | 0 | medium | 2 | 2 |
| paxilline | 0 | low | 19 | 0 |
| prolinedithiocarbamate | 0 | low | 6 | 0 |
| beauvericin | 0 | low | 2 | 0 |
| benzo(a)pyrene-7,8-dione | 0 | low | 2 | 0 |
| artesunic acid | 0 | low | 15 | 0 |
| dihydrorhodamine 123 | 0 | low | 1 | 0 |
| cyanates | 0 | low | 7 | 0 |
| dehydroretronecine | 0 | low | 1 | 0 |
| pyridinoline | 0 | low | 1 | 0 |
| deoxypyridinoline | 0 | low | 1 | 0 |
| 1,n(6)-ethenodeoxyadenosine | 0 | low | 1 | 0 |
| thiamethoxam | 0 | medium | 2 | 2 |
| s-ethyl glutathione | 0 | low | 5 | 0 |
| 3-((3-cholamidopropyl)dimethylammonium)-1-propanesulfonate | 0 | low | 1 | 0 |
| pentoxyresorufin | 0 | low | 1 | 0 |
| cyproterone acetate, ethinyl estradiol drug combination | 0 | medium | 1 | 1 |
| sivelestat | 0 | medium | 1 | 1 |
| bismuth nitrate | 0 | low | 1 | 0 |
| 22-hydroxycholesterol | 0 | low | 4 | 0 |
| propionylcarnitine | 0 | low | 1 | 0 |
| aldophosphamide | 0 | low | 1 | 0 |
| inositol-1,3,4,5-tetrakisphosphate | 0 | low | 1 | 0 |
| dimyristoylphosphatidylglycerol | 0 | low | 1 | 0 |
| saikosaponin d | 0 | low | 17 | 0 |
| perindopril | 0 | medium | 8 | 2 |
| geniposide | 0 | low | 2 | 0 |
| phorbol-12-myristate | 0 | low | 1 | 0 |
| procyanidin | 0 | low | 10 | 0 |
| epicatechin gallate | 0 | low | 2 | 0 |
| deguelin | 0 | low | 2 | 0 |
| fingolimod hydrochloride | 0 | low | 14 | 0 |
| daidzin | 0 | low | 2 | 0 |
| parinaric acid | 0 | low | 1 | 0 |
| dihydrocapsaicin | 0 | low | 1 | 0 |
| n(g)-iminoethylornithine | 0 | low | 1 | 0 |
| triptolide | 0 | low | 13 | 0 |
| cobaltiprotoporphyrin | 0 | low | 3 | 0 |
| cafestol | 0 | low | 1 | 0 |
| asiaticoside | 0 | low | 1 | 0 |
| proanthocyanidin | 0 | low | 2 | 0 |
| diazan | 0 | low | 1 | 0 |
| parthenolide | 0 | low | 12 | 0 |
| rx 821002 | 0 | low | 1 | 0 |
| schizandrin b | 0 | low | 2 | 0 |
| tamibarotene | 0 | low | 2 | 0 |
| carboxyamido-triazole | 0 | low | 1 | 0 |
| ecteinascidin 743 | 0 | low | 1 | 0 |
| kt 5823 | 0 | low | 3 | 0 |
| 1-hexadecyl-2-acetyl-glycero-3-phosphocholine | 0 | medium | 5 | 1 |
| 3'-hydroxymethyl-4-(dimethylamino)azobenzene | 0 | low | 2 | 0 |
| bifendate | 0 | low | 3 | 0 |
| deoxyglucose | 0 | medium | 48 | 1 |
| tadalafil | 0 | low | 5 | 0 |
| bauerenol | 0 | low | 1 | 0 |
| precirol | 0 | low | 1 | 0 |
| 1-phenyl-2-decanoylamino-3-morpholino-1-propanol | 0 | low | 3 | 0 |
| 6-phenylhexyl isothiocyanate | 0 | low | 1 | 0 |
| 7-o-(2,6-dideoxy-2-fluoro-alpha-talopyranosyl)adriamycinone- 14-beta-alaniate hydrochloride | 0 | low | 1 | 0 |
| indolo(3,2-b)carbazole | 0 | low | 2 | 0 |
| 9-(2,3-dihydroxypropyl)adenine | 0 | low | 1 | 0 |
| homoorientin | 0 | medium | 2 | 1 |
| kahweol | 0 | low | 2 | 0 |
| monobromobimane | 0 | low | 1 | 0 |
| liquiritigenin | 0 | low | 4 | 0 |
| selenomethylselenocysteine | 0 | low | 4 | 0 |
| 3-deoxyglucosone | 0 | low | 1 | 0 |
| oxymatrine | 0 | low | 1 | 0 |
| 16-hydroxyestrone | 0 | low | 1 | 0 |
| n-(1-methyl-2-phenylethyl)adenosine | 0 | low | 1 | 0 |
| aluminum phthalocyanine | 0 | low | 2 | 0 |
| thromboxanes | 0 | low | 2 | 0 |
| monochlorobimane | 0 | low | 1 | 0 |
| 6-methyl-1,3,8-trichlorodibenzofuran | 0 | low | 1 | 0 |
| tanshinone | 0 | low | 30 | 0 |
| 1-(carboxymethylthio)tetradecane | 0 | low | 1 | 0 |
| protoberberine | 0 | low | 2 | 0 |
| soyasapogenol b | 0 | low | 1 | 0 |
| toosendanin | 0 | low | 5 | 0 |
| amarogentin | 0 | low | 1 | 0 |
| thymidine c5-hydrate | 0 | low | 1 | 0 |
| ifosfamide | 0 | low | 1 | 0 |
| 5-(tetradecyloxy)-2-furancarboxylic acid | 0 | low | 1 | 0 |
| metadoxine | 0 | low | 1 | 0 |
| 3'-o-(4-benzoyl)benzoyladenosine 5'-triphosphate | 0 | low | 1 | 0 |
| stachydrine | 0 | low | 2 | 0 |
| glycolithocholic acid | 0 | low | 1 | 0 |
| taraxasterol | 0 | low | 1 | 0 |
| 4'-phosphopantetheine | 0 | low | 1 | 0 |
| s-methyl glutathione | 0 | low | 1 | 0 |
| sophocarpine | 0 | low | 1 | 0 |
| 2-aminobicyclo(2,2,1)heptane-2-carboxylic acid | 0 | low | 1 | 0 |
| glycyl-arginyl-glycyl-aspartyl-seryl-proline | 0 | low | 1 | 0 |
| nitisinone | 0 | low | 17 | 0 |
| marimastat | 0 | low | 3 | 0 |
| asiatic acid | 0 | low | 2 | 0 |
| 1'-acetoxychavicol acetate | 0 | low | 2 | 0 |
| 2-pyrrolino-dox | 0 | low | 1 | 0 |
| 6-fluoromevalonolactone | 0 | low | 1 | 0 |
| dioscin | 0 | low | 3 | 0 |
| astilbin | 0 | low | 1 | 0 |
| 2-aminomethyl-4-t-butyl-6-iodophenol | 0 | low | 1 | 0 |
| cucurbitacins | 0 | low | 3 | 0 |
| benzo(a)pyrene-3,6-quinol | 0 | low | 1 | 0 |
| ginsenoside rh2 | 0 | low | 21 | 0 |
| ar 12463 | 0 | low | 1 | 0 |
| 5-fluoromethylornithine | 0 | low | 1 | 0 |
| elacridar | 0 | low | 2 | 0 |
| aminopentol | 0 | low | 1 | 0 |
| caprylates | 0 | low | 16 | 0 |
| 1,3,4-thiadiazole | 0 | low | 1 | 0 |
| pramipexole | 0 | low | 1 | 0 |
| parecoxib | 0 | medium | 6 | 4 |
| perimidine | 0 | low | 1 | 0 |
| 6-deoxy-6-fluoroglucose | 0 | low | 1 | 0 |
| disodium cantharidin | 0 | low | 1 | 0 |
| hydroquinidine | 0 | low | 1 | 0 |
| 1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acid | 0 | low | 3 | 0 |
| protoporphyrinogen | 0 | low | 1 | 0 |
| egta acetoxymethyl ester | 0 | low | 1 | 0 |
| (20s)-20-hydroxycholesterol | 0 | low | 2 | 0 |
| thymidine 3',5'-diphosphate | 0 | low | 1 | 0 |
| dl 111-it | 0 | low | 1 | 0 |
| 6-bromoconduritol | 0 | low | 1 | 0 |
| deoxyhypusine | 0 | low | 1 | 0 |
| soyasaponin bb | 0 | low | 1 | 0 |
| phytosphingosine | 0 | low | 1 | 0 |
| gadolinium 1,4,7,10-tetraazacyclododecane-n,n',n'',n'''-tetraacetate | 0 | low | 4 | 0 |
| benzoyl-coenzyme a | 0 | low | 1 | 0 |
| tryptophan methyl ester | 0 | low | 1 | 0 |
| san 58035 | 0 | low | 1 | 0 |
| saccharolactone | 0 | low | 1 | 0 |
| 3,7,12-trihydroxycholestan-26-oic acid | 0 | low | 1 | 0 |
| pd 128042 | 0 | low | 1 | 0 |
| astragaloside a | 0 | low | 9 | 0 |
| celastrol | 0 | low | 21 | 0 |
| bruceine d | 0 | low | 1 | 0 |
| aaptamine | 0 | low | 1 | 0 |
| carbene | 0 | low | 1 | 0 |
| peroxynitrous acid | 0 | medium | 9 | 2 |
| perchlorate | 0 | low | 1 | 0 |
| fullerene c60 | 0 | low | 11 | 0 |
| imatinib mesylate | 0 | medium | 32 | 5 |
| mk 0663 | 0 | low | 1 | 0 |
| tazobactam | 0 | low | 1 | 0 |
| ethylene glycolylbis(succinimidyl succinate) | 0 | low | 1 | 0 |
| cholesterol hydroperoxide | 0 | low | 1 | 0 |
| cdp ethanolamine | 0 | low | 1 | 0 |
| 7 alpha-hydroxy-4-cholesten-3-one | 0 | low | 1 | 0 |
| 4-carboxyfluorescein | 0 | low | 1 | 0 |
| galactosyl-(1-3)galactose | 0 | low | 2 | 0 |
| n(6)-carboxymethyllysine | 0 | low | 1 | 0 |
| technetium tc 99m hydroxymethylene diphosphonate | 0 | low | 7 | 0 |
| angiotensin ii, des-phe(8)- | 0 | low | 2 | 0 |
| glycyl-arginyl-glycyl-aspartyl-serine | 0 | low | 1 | 0 |
| n,n-dimethylarginine | 0 | low | 1 | 0 |
| htr composite | 0 | low | 2 | 0 |
| antibiotic g 418 | 0 | low | 2 | 0 |
| 4-iodoamphetamine | 0 | low | 2 | 0 |
| glycerophosphoethanolamine | 0 | low | 1 | 0 |
| f-chemotactic peptide | 0 | low | 1 | 0 |
| 1-((3,5-dichloro)-2,6-dihydroxy-4-methoxyphenyl)-1-hexanone | 0 | low | 1 | 0 |
| hydroxycitric acid | 0 | low | 2 | 0 |
| 3-hydroxymethylantipyrine | 0 | low | 1 | 0 |
| vadimezan | 0 | low | 1 | 0 |
| 27-hydroxycholesterol | 0 | low | 3 | 0 |
| tyrosyl-isoleucyl-glycyl-seryl-arginine | 0 | low | 1 | 0 |
| glabridin | 0 | low | 4 | 0 |
| soranjidiol | 0 | low | 1 | 0 |
| tetrahydrocurcumin | 0 | low | 1 | 0 |
| desloratadine | 0 | low | 1 | 0 |
| amdoxovir | 0 | low | 1 | 0 |
| genkwadaphnin | 0 | low | 1 | 0 |
| rubimaillin | 0 | low | 1 | 0 |
| 1,4,7-triazacyclononane-n,n',n''-triacetic acid | 0 | low | 1 | 0 |
| s-tubercidinylhomocysteine | 0 | low | 1 | 0 |
| nsc 224070 | 0 | low | 1 | 0 |
| 7-hydroxy-7'-methoxy-4,4'-bis(1,3-benzodioxole)-5,5'-dicarboxylic acid dimethyl ester | 0 | low | 1 | 0 |
| 6-methoxypurine arabinoside | 0 | low | 2 | 0 |
| glycerophosphoinositol 4,5-bisphosphate | 0 | low | 3 | 0 |
| n-acetylneuraminosyl(alpha2-6)lactosamine | 0 | low | 1 | 0 |
| dibutyryl cyclic-3',5'-cytidine monophosphate | 0 | low | 3 | 0 |
| adenosine triphosphate adenosine monophosphate adenosine monophosphate | 0 | low | 1 | 0 |
| n-(4-(2-chlorophenyl)-6,7-dimethyl-3-quinolyl)-n'-(2,4-difluorophenyl)urea | 0 | low | 1 | 0 |
| 502u83 | 0 | medium | 1 | 1 |
| 7-hydroxycoumarin glucuronide | 0 | low | 1 | 0 |
| anthglutin | 0 | low | 1 | 0 |
| neominophagen c | 0 | low | 3 | 0 |
| 7-(gamma-glutamyl)-4-methylcoumarylamide | 0 | low | 1 | 0 |
| panaxydol | 0 | low | 1 | 0 |
| disialosyl galactosyl globoside | 0 | low | 1 | 0 |
| 5-aza-2'-deoxycytidine-5'-triphosphate | 0 | low | 1 | 0 |
| methotrexate | 0 | medium | 109 | 6 |
| gsk peptide | 0 | low | 1 | 0 |
| ar 12456 | 0 | low | 1 | 0 |
| zm 189154 | 0 | low | 1 | 0 |
| schisanhenol b | 0 | low | 2 | 0 |
| 3-methyl-4',6-dihydroxy-3',5'-dibromoflavone | 0 | low | 1 | 0 |
| dihydroethidium | 0 | low | 1 | 0 |
| delphinidin | 0 | low | 3 | 0 |
| cyanidin | 0 | low | 1 | 0 |
| cki 7 | 0 | low | 1 | 0 |
| antiprimod | 0 | low | 2 | 0 |
| 4-hydroxy-25-desoxyneorollinicin | 0 | low | 3 | 0 |
| sekdel sequence | 0 | low | 1 | 0 |
| dioctadecylamidoglycylspermine | 0 | low | 1 | 0 |
| 7-benzylamino-6-chloro-2-piperazino-4-pyrrolidinopteridine | 0 | low | 1 | 0 |
| talotrexin | 0 | low | 1 | 0 |
| e 5880 | 0 | medium | 1 | 1 |
| mdl 29311 | 0 | low | 1 | 0 |
| 2-amino-1-(4-chlorophenyl)-3-fluoropropane | 0 | low | 1 | 0 |
| cercosporamide | 0 | low | 1 | 0 |
| umifenovir | 0 | low | 2 | 0 |
| 10-methyl spiro(4.5)dec-6-en-6-carboxylic acid | 0 | medium | 1 | 1 |
| sk&f 104976 | 0 | low | 2 | 0 |
| annomontacin | 0 | low | 1 | 0 |
| c 1311 | 0 | low | 1 | 0 |
| e 5324 | 0 | low | 1 | 0 |
| osw 1 | 0 | low | 2 | 0 |
| omega-n-methylarginine | 0 | low | 3 | 0 |
| kw 2189 | 0 | medium | 1 | 1 |
| 2,7,8-trimethyl-2-(beta-carboxyethyl)-6-hydroxychroman | 0 | low | 1 | 0 |
| carbapenems | 0 | medium | 2 | 1 |
| 1-(2-chloroethyl)-3-(1-oxyl-2,2,6,6-tetramethylpiperidinyl)-1-nitrosourea | 0 | low | 1 | 0 |
| calcium borate | 0 | medium | 2 | 2 |
| pomalidomide | 0 | low | 1 | 0 |
| xylose | 0 | low | 5 | 0 |
| d-apv | 0 | low | 1 | 0 |
| cd 437 | 0 | low | 3 | 0 |
| quinone methide | 0 | low | 1 | 0 |
| perrhenate | 0 | low | 1 | 0 |
| phytol | 0 | low | 1 | 0 |
| sinensetin | 0 | low | 2 | 0 |
| proline | 0 | medium | 55 | 1 |
| cucurbitaceae | 0 | low | 5 | 0 |
| escitalopram | 0 | low | 1 | 0 |
| procyanidin b3 | 0 | low | 1 | 0 |
| 5-(n-dodecanoyl)aminofluorescein | 0 | low | 1 | 0 |
| 8-chloroadenosine | 0 | low | 2 | 0 |
| docetaxel anhydrous | 0 | medium | 40 | 5 |
| perifosine | 0 | low | 2 | 0 |
| lonafarnib | 0 | low | 1 | 0 |
| peptide elongation factor 2 | 0 | low | 1 | 0 |
| levofloxacin | 0 | medium | 2 | 2 |
| aclacinomycin | 0 | low | 3 | 0 |
| ezetimibe | 0 | low | 1 | 0 |
| 4-boronophenylalanine | 0 | low | 1 | 0 |
| 2'-deoxycytidine diphosphate | 0 | low | 1 | 0 |
| vatalanib | 0 | medium | 5 | 1 |
| evodiamine | 0 | low | 14 | 0 |
| 3,3,5,5-tetramethyl-1-pyrroline n-oxide | 0 | low | 1 | 0 |
| copper bis(histidinate) | 0 | low | 1 | 0 |
| prolyl-tyrosine | 0 | low | 2 | 0 |
| moxifloxacin | 0 | low | 2 | 0 |
| tyramine o-sulfate | 0 | low | 1 | 0 |
| thiobenzyl benzyloxycarbonyl-l-lysinate | 0 | low | 1 | 0 |
| mn(iii) 5,10,15,20-tetrakis(n-methylpyridinium-2-yl)porphyrin | 0 | low | 1 | 0 |
| borneo | 0 | low | 1 | 0 |
| diamminebis(ursodeoxycholate(o,o'))platinum(ii) | 0 | low | 2 | 0 |
| 9-(4'-aminophenyl)-9h-pyrido(3,4-b)indole | 0 | low | 1 | 0 |
| bazedoxifene | 0 | low | 3 | 0 |
| phorbols | 0 | low | 3 | 0 |
| tomentosin | 0 | low | 1 | 0 |
| schizandrin a | 0 | low | 1 | 0 |
| omeprazole sulfide | 0 | low | 1 | 0 |
| 10-deacetyltaxol | 0 | low | 1 | 0 |
| atractylenolide iii | 0 | low | 1 | 0 |
| dehydrocrotonin | 0 | low | 1 | 0 |
| naproxen | 0 | medium | 2 | 1 |
| cinacalcet | 0 | low | 1 | 0 |
| hydroxyl radical | 0 | medium | 11 | 1 |
| 1-(2'-deoxy-2'-fluoro-beta-arabinofuranosyl)-5-methylcytosine triphosphate | 0 | low | 1 | 0 |
| gemcabene | 0 | low | 1 | 0 |
| gelsenicine | 0 | low | 1 | 0 |
| edotreotide | 0 | low | 1 | 0 |
| telbivudine | 0 | medium | 26 | 3 |
| jte 522 | 0 | low | 2 | 0 |
| rhodioloside | 0 | low | 4 | 0 |
| resiquimod | 0 | low | 1 | 0 |
| indium trichloride | 0 | low | 2 | 0 |
| singlet oxygen | 0 | low | 8 | 0 |
| justicidin a | 0 | low | 1 | 0 |
| aloesin | 0 | low | 1 | 0 |
| cryptotanshinone | 0 | low | 7 | 0 |
| fenton's reagent | 0 | low | 3 | 0 |
| cyc 202 | 0 | low | 5 | 0 |
| carbodiimides | 0 | low | 1 | 0 |
| matteucinol | 0 | low | 1 | 0 |
| cycloartane | 0 | low | 1 | 0 |
| abrine | 0 | low | 1 | 0 |
| ar-turmerone | 0 | low | 2 | 0 |
| oxypeucadanin | 0 | low | 1 | 0 |
| i-677 | 0 | low | 1 | 0 |
| isoflavanone | 0 | low | 1 | 0 |
| 2-deoxy-lyxo-hexose | 0 | low | 1 | 0 |
| nevadensin | 0 | low | 2 | 0 |
| sweroside | 0 | low | 1 | 0 |
| salvigenin | 0 | low | 1 | 0 |
| methanearsonous acid | 0 | low | 1 | 0 |
| maprounic acid | 0 | low | 1 | 0 |
| ampelopsin | 0 | low | 12 | 0 |
| methylselenic acid | 0 | low | 1 | 0 |
| myricanone | 0 | low | 1 | 0 |
| aloenin | 0 | low | 1 | 0 |
| isovitexin | 0 | low | 2 | 0 |
| 2-deoxy-2-fluorogalactose | 0 | low | 4 | 0 |
| lhrh, lys(6)- | 0 | low | 1 | 0 |
| platycodin d | 0 | low | 8 | 0 |
| isoindigotin | 0 | low | 1 | 0 |
| butrin | 0 | low | 1 | 0 |
| tanshinone ii a | 0 | low | 1 | 0 |
| enniatin b | 0 | low | 1 | 0 |
| calcium pyrophosphate | 0 | low | 1 | 0 |
| 2-phenyl-1,2-benzisothiazol-3-(2h)-one | 0 | low | 1 | 0 |
| technetium tc 99m pentetate | 0 | medium | 46 | 3 |
| metaperiodate | 0 | low | 1 | 0 |
| thiophosphoric acid | 0 | low | 1 | 0 |
| peiminine | 0 | low | 1 | 0 |
| ardisiacrispin a | 0 | low | 1 | 0 |
| nordihydrocapsaicin | 0 | low | 1 | 0 |
| boswellic acid | 0 | low | 2 | 0 |
| bisdechlorogeodin | 0 | low | 1 | 0 |
| beta-solamarine | 0 | low | 7 | 0 |
| isophorone diisocyanate | 0 | low | 1 | 0 |
| symmetric dimethylarginine | 0 | low | 1 | 0 |
| aminopterin | 0 | medium | 5 | 1 |
| 4-(2-aminoethyl)benzenesulfonamide | 0 | low | 1 | 0 |
| bradykinin, hydroxy-pro(3)- | 0 | low | 1 | 0 |
| 2-fluoro-2-deoxy-d-glucose | 0 | low | 1 | 0 |
| threonyl-lysyl-proline | 0 | low | 1 | 0 |
| angiotensin ii, sar(1)-val(5)- | 0 | low | 1 | 0 |
| copper tetrabenzo(b,f,j,n)-1,5,9,13-tetraazacyclohexadecine | 0 | low | 1 | 0 |
| 2-hydroxyhemopyrroline-5-one | 0 | low | 1 | 0 |
| methyl protodioscin | 0 | low | 1 | 0 |
| biotin | 0 | low | 34 | 0 |
| isofuranodiene | 0 | low | 2 | 0 |
| angiotensin ii | 0 | medium | 34 | 1 |
| campesterol | 0 | low | 3 | 0 |
| carboline-3-carboxylic acid | 0 | low | 1 | 0 |
| 1-nitrohydroxyphenyl-n-benzoylalanine | 0 | low | 1 | 0 |
| atropine | 0 | medium | 3 | 1 |
| stronger neominophagen c | 0 | low | 2 | 0 |
| anemodeanin a | 0 | low | 1 | 0 |
| lignin | 0 | medium | 5 | 1 |
| ropivacaine | 0 | medium | 4 | 1 |
| oleanolic acid 3-o-monoglucuronide | 0 | low | 1 | 0 |
| dendrophenol | 0 | low | 1 | 0 |
| sb 203580 | 0 | low | 24 | 0 |
| sb 216763 | 0 | low | 1 | 0 |
| enzastaurin | 0 | low | 2 | 0 |
| 4'-o-methylepigallocatechin | 0 | low | 1 | 0 |
| organophosphonates | 0 | medium | 66 | 6 |
| ly 353381 | 0 | low | 1 | 0 |
| limonin | 0 | low | 2 | 0 |
| nickel monoxide | 0 | low | 1 | 0 |
| psyllium | 0 | low | 1 | 0 |
| scutellarin | 0 | low | 4 | 0 |
| dimethylarsinous acid | 0 | low | 2 | 0 |
| aflatoxin b1 | 0 | medium | 261 | 3 |
| santamarine | 0 | low | 1 | 0 |
| 5'-deoxy-5'-iodouridine | 0 | low | 1 | 0 |
| o-(4-ethoxybutyl)berbamine | 0 | low | 2 | 0 |
| mk 912 | 0 | low | 1 | 0 |
| deflazacort | 0 | low | 1 | 0 |
| eudesmane | 0 | low | 1 | 0 |
| indigoidine | 0 | low | 1 | 0 |
| n-acetylgalactosamine 6-sulfate | 0 | low | 1 | 0 |
| isobavachin | 0 | low | 1 | 0 |
| cohumulone | 0 | low | 1 | 0 |
| araloside a | 0 | low | 1 | 0 |
| troleandomycin | 0 | low | 3 | 0 |
| purine n-oxide | 0 | low | 1 | 0 |
| lapatinib | 0 | medium | 7 | 2 |
| 2-(4-morpholinoanilino)-6-cyclohexylaminopurine | 0 | low | 1 | 0 |
| darunavir | 0 | low | 1 | 0 |
| deferasirox | 0 | medium | 7 | 1 |
| taspine | 0 | low | 3 | 0 |
| dabigatran | 0 | low | 2 | 0 |
| tolvaptan | 0 | low | 4 | 0 |
| 1-methylpropyl-2-imidazolyl disulfide | 0 | low | 1 | 0 |
| demecolcine | 0 | low | 5 | 0 |
| cholic acid | 0 | low | 14 | 0 |
| deoxycholic acid | 0 | low | 20 | 0 |
| cortisone | 0 | low | 33 | 0 |
| vacquinol-1 | 0 | low | 1 | 0 |
| 3-nitrotyrosine | 0 | low | 8 | 0 |
| stigmastanol | 0 | low | 1 | 0 |
| lanosterol | 0 | low | 5 | 0 |
| 2-hydroxyestradiol | 0 | low | 2 | 0 |
| vincristine sulfate | 0 | low | 1 | 0 |
| mitopodozide | 0 | low | 1 | 0 |
| nsc 74859 | 0 | low | 8 | 0 |
| pheophorbide a | 0 | low | 9 | 0 |
| anisomycin | 0 | low | 6 | 0 |
| benzofurans | 0 | medium | 40 | 1 |
| chondocurine (1beta)-(+-)-isomer | 0 | low | 1 | 0 |
| potassium bromide | 0 | low | 1 | 0 |
| 1,3,6,8-tetrabromocarbazole | 0 | low | 1 | 0 |
| hellebrigenin | 0 | low | 1 | 0 |
| cinobufotalin | 0 | low | 6 | 0 |
| Gamabufogenin | 0 | low | 1 | 0 |
| lupeol | 0 | low | 10 | 0 |
| cyclovirobuxine d | 0 | low | 1 | 0 |
| metribolone | 0 | low | 2 | 0 |
| solanine | 0 | low | 4 | 0 |
| withaferin a | 0 | low | 4 | 0 |
| 6-methylpurine 2'-deoxyriboside | 0 | low | 1 | 0 |
| noscapine | 0 | low | 1 | 0 |
| Harringtonine | 0 | low | 2 | 0 |
| glaucarubinone | 0 | low | 1 | 0 |
| homoharringtonine | 0 | low | 5 | 0 |
| acivicin | 0 | medium | 4 | 1 |
| elesclomol | 0 | low | 4 | 0 |
| wortmannin | 0 | low | 29 | 0 |
| a-130a | 0 | low | 1 | 0 |
| menogaril | 0 | medium | 1 | 1 |
| 2-oxindole | 0 | low | 1 | 0 |
| 2,2-bis(hydroxymethyl)-1-azabicyclo(2,2,2,)octan-3-one | 0 | low | 1 | 0 |
| withanolides | 0 | low | 5 | 0 |
| rocaglamide | 0 | low | 1 | 0 |
| lariciresinol | 0 | low | 1 | 0 |
| nsc 348884 | 0 | low | 1 | 0 |
| 2'-fluorothymidine | 0 | low | 8 | 0 |
| erianin | 0 | low | 6 | 0 |
| trimethoprim, sulfamethoxazole drug combination | 0 | low | 1 | 0 |
| demethyleneberberine | 0 | low | 1 | 0 |
| o-(chloroacetylcarbamoyl)fumagillol | 0 | low | 13 | 0 |
| colupulone | 0 | low | 1 | 0 |
| pomolic acid | 0 | low | 1 | 0 |
| taurochenodeoxycholic acid | 0 | low | 5 | 0 |
| 2-(2-nitro-1h-imidazol-1-yl)-n-(2,2,3,3,3-pentafluoropropyl)acetamide | 0 | low | 1 | 0 |
| chamaejasmin | 0 | low | 1 | 0 |
| neocryptolepine | 0 | low | 1 | 0 |
| ritonavir | 0 | medium | 13 | 3 |
| acetogenins | 0 | low | 6 | 0 |
| cap1-6d | 0 | low | 1 | 0 |
| Bardoxolone | 0 | low | 1 | 0 |
| bardoxolone methyl | 0 | low | 1 | 0 |
| fluorocholine | 0 | medium | 10 | 3 |
| n,n-dimethyl-n-(18f)fluoromethyl-2-hydroxyethylammonium | 0 | low | 7 | 0 |
| dihydropyridines | 0 | low | 3 | 0 |
| lanatosides | 0 | low | 2 | 0 |
| gant 61 | 0 | low | 5 | 0 |
| permanganate | 0 | medium | 2 | 2 |
| secalonic acid | 0 | low | 3 | 0 |
| leupeptins | 0 | low | 38 | 0 |
| carboplatin | 0 | medium | 49 | 12 |
| lithium chloride | 0 | low | 6 | 0 |
| leptomycin b | 0 | low | 1 | 0 |
| s-adenosylhomocysteine | 0 | low | 13 | 0 |
| 5'-methylthioadenosine | 0 | low | 6 | 0 |
| glycogen | 0 | low | 114 | 0 |
| arabinose | 0 | low | 3 | 0 |
| n-acetylneuraminic acid | 0 | medium | 33 | 1 |
| mannose-6-phosphate | 0 | low | 7 | 0 |
| fibrin | 0 | low | 10 | 0 |
| bradykinin | 0 | low | 9 | 0 |
| canavanine | 0 | low | 8 | 0 |
| glucosamine | 0 | low | 48 | 0 |
| elastin | 0 | low | 6 | 0 |
| carnosine | 0 | low | 4 | 0 |
| mevalonic acid | 0 | medium | 46 | 1 |
| ribose 1-phosphate | 0 | low | 1 | 0 |
| raffinose | 0 | low | 3 | 0 |
| naringenin | 0 | low | 13 | 0 |
| epiglucan | 0 | low | 9 | 0 |
| pantetheine | 0 | low | 1 | 0 |
| theanine | 0 | low | 1 | 0 |
| inositol 1,4,5-trisphosphate | 0 | low | 8 | 0 |
| cysteinylglycine | 0 | low | 1 | 0 |
| ouabain | 0 | low | 16 | 0 |
| allose | 0 | low | 2 | 0 |
| scopolin | 0 | low | 1 | 0 |
| puromycin | 0 | low | 40 | 0 |
| taxifolin | 0 | low | 2 | 0 |
| desmosterol | 0 | low | 1 | 0 |
| tosylphenylalanyl chloromethyl ketone | 0 | low | 1 | 0 |
| tartaric acid | 0 | low | 1 | 0 |
| n-formylmethionine | 0 | low | 1 | 0 |
| taurolithocholic acid | 0 | low | 2 | 0 |
| n-glycolylneuraminic acid | 0 | low | 3 | 0 |
| nitroarginine | 0 | low | 1 | 0 |
| 3,7-dihydroxycholestan-26-oic acid | 0 | low | 1 | 0 |
| dehydroascorbic acid | 0 | low | 2 | 0 |
| nivalenol | 0 | low | 1 | 0 |
| arbutin | 0 | low | 1 | 0 |
| strychnine | 0 | low | 7 | 0 |
| quinidine | 0 | low | 3 | 0 |
| meropenem | 0 | medium | 1 | 1 |
| griseofulvin | 0 | low | 8 | 0 |
| monensin | 0 | low | 17 | 0 |
| digitoxin | 0 | low | 3 | 0 |
| saquinavir | 0 | low | 1 | 0 |
| pentazocine | 0 | medium | 3 | 1 |
| rocuronium | 0 | low | 1 | 0 |
| hyperforin | 0 | low | 1 | 0 |
| miglitol | 0 | low | 1 | 0 |
| phalloidine | 0 | low | 5 | 0 |
| taccalonolide a | 0 | low | 1 | 0 |
| neriifolin | 0 | low | 1 | 0 |
| ruscogenin | 0 | low | 1 | 0 |
| ginsenoside rg1 | 0 | low | 4 | 0 |
| notoginsenoside r1 | 0 | low | 1 | 0 |
| brucine | 0 | low | 7 | 0 |
| ferruginol | 0 | low | 1 | 0 |
| ingenol | 0 | low | 1 | 0 |
| decursin | 0 | low | 1 | 0 |
| genipin | 0 | low | 7 | 0 |
| naringin | 0 | low | 5 | 0 |
| swertiamarin | 0 | low | 1 | 0 |
| ochratoxin a | 0 | low | 7 | 0 |
| theasinensin a | 0 | low | 1 | 0 |
| vicenin ii | 0 | low | 1 | 0 |
| Hircinol | 0 | low | 1 | 0 |
| gingerol | 0 | low | 3 | 0 |
| alpha-toxicarol | 0 | low | 1 | 0 |
| alpha bitter acid | 0 | low | 1 | 0 |
| cyclopamine | 0 | low | 9 | 0 |
| ecgonine | 0 | low | 1 | 0 |
| lignans | 0 | low | 33 | 0 |
| acriflavine | 0 | low | 1 | 0 |
| acetylleucyl-leucyl-norleucinal | 0 | low | 7 | 0 |
| bq 123 | 0 | low | 1 | 0 |
| n-formylmethionine leucyl-phenylalanine | 0 | low | 2 | 0 |
| sodium arsenite | 0 | low | 10 | 0 |
| soyasaponin ii | 0 | low | 1 | 0 |
| petunidin-3-glucoside | 0 | low | 1 | 0 |
| malvidin-3-glucoside | 0 | low | 1 | 0 |
| sultamicillin | 0 | medium | 1 | 1 |
| betadex | 0 | low | 14 | 0 |
| maleic acid | 0 | low | 1 | 0 |
| acetyl coenzyme a | 0 | low | 21 | 0 |
| e-z cinnamic acid | 0 | low | 1 | 0 |
| ergosterol | 0 | low | 5 | 0 |
| trichostatin a | 0 | low | 51 | 0 |
| tretinoin | 0 | medium | 196 | 8 |
| equilenin | 0 | low | 2 | 0 |
| arachidonic acid | 0 | medium | 51 | 2 |
| fumaric acid | 0 | low | 1 | 0 |
| farnesol | 0 | low | 10 | 0 |
| 3-hydroxy-3-methylglutaryl-coenzyme a | 0 | low | 1 | 0 |
| resveratrol | 0 | medium | 74 | 1 |
| retinol | 0 | low | 53 | 0 |
| latrunculin a | 0 | low | 5 | 0 |
| cyanoginosin lr | 0 | low | 21 | 0 |
| palmitoleic acid | 0 | low | 1 | 0 |
| oleic acid | 0 | low | 78 | 0 |
| ferulic acid | 0 | low | 6 | 0 |
| pectins | 0 | low | 6 | 0 |
| (3R,5S)-fluvastatin | 0 | low | 2 | 0 |
| cerivastatin | 0 | low | 1 | 0 |
| cocaine | 0 | low | 2 | 0 |
| eicosapentaenoic acid | 0 | low | 14 | 0 |
| sr 12813 | 0 | low | 1 | 0 |
| thapsigargin | 0 | low | 36 | 0 |
| mycophenolic acid | 0 | medium | 20 | 1 |
| keratan sulfate | 0 | low | 1 | 0 |
| gw 6471 | 0 | low | 1 | 0 |
| lycopene | 0 | medium | 19 | 1 |
| zithromax | 0 | low | 2 | 0 |
| adenylosuccinate | 0 | low | 1 | 0 |
| cefoxitin | 0 | low | 3 | 0 |
| obeticholic acid | 0 | low | 5 | 0 |
| gw 3965 | 0 | low | 3 | 0 |
| t0901317 | 0 | low | 7 | 0 |
| n-(4-methoxybenzyl)-n'-(5-nitro-1,3-thiazol-2-yl)urea | 0 | low | 1 | 0 |
| y 27632 | 0 | low | 10 | 0 |
| cytidine monophosphate n-acetylneuraminic acid | 0 | low | 2 | 0 |
| adenosine-5'-(n-ethylcarboxamide) | 0 | low | 2 | 0 |
| benzoylecgonine | 0 | low | 1 | 0 |
| n(1)-guanyl-1,7-diaminoheptane | 0 | low | 3 | 0 |
| prostaglandin d2 | 0 | low | 14 | 0 |
| diethylstilbestrol | 0 | low | 26 | 0 |
| epothilone a | 0 | low | 6 | 0 |
| alitretinoin | 0 | low | 10 | 0 |
| h 89 | 0 | low | 4 | 0 |
| afimoxifene | 0 | low | 5 | 0 |
| imidazolidines | 0 | medium | 2 | 1 |
| fluciclovine f-18 | 0 | low | 1 | 0 |
| n-succinimidyl-4-fluorobenzoate | 0 | low | 1 | 0 |
| aclarubicin | 0 | medium | 14 | 1 |
| taribavirin | 0 | low | 3 | 0 |
| decitabine | 0 | medium | 78 | 1 |
| colfosceril palmitate | 0 | low | 1 | 0 |
| phorbol-12,13-didecanoate | 0 | low | 1 | 0 |
| iridoids | 0 | low | 16 | 0 |
| lamivudine triphosphate | 0 | low | 1 | 0 |
| troxacitabine | 0 | low | 2 | 0 |
| dactinomycin | 0 | low | 195 | 0 |
| gamma-sitosterol | 0 | low | 9 | 0 |
| aphidicolin | 0 | low | 2 | 0 |
| 3-(1-deoxyribofuranosyl)benzamide | 0 | low | 1 | 0 |
| azaserine | 0 | low | 5 | 0 |
| melphalan | 0 | medium | 19 | 1 |
| benzyloxycarbonylleucyl-leucyl-leucine aldehyde | 0 | low | 25 | 0 |
| posaconazole | 0 | low | 1 | 0 |
| ganoderiol f | 0 | low | 1 | 0 |
| 5-ethynyl-2'-deoxyuridine | 0 | low | 1 | 0 |
| bromodeoxycytidine | 0 | low | 1 | 0 |
| rubitecan | 0 | low | 3 | 0 |
| terameprocol | 0 | low | 1 | 0 |
| micafungin | 0 | low | 2 | 0 |
| acetylshikonin | 0 | low | 3 | 0 |
| shikonin | 0 | low | 16 | 0 |
| reynosin | 0 | low | 1 | 0 |
| riboflavin | 0 | low | 25 | 0 |
| n-nonyl-1-deoxynojirimycin | 0 | low | 1 | 0 |
| likviriton | 0 | low | 1 | 0 |
| evp 4593 | 0 | low | 3 | 0 |
| 2,3-bis(bromomethyl)quinoxaline-1,4-dioxide | 0 | medium | 2 | 2 |
| tyrosine o-sulfate | 0 | low | 4 | 0 |
| sodium bicarbonate | 0 | low | 1 | 0 |
| sodium benzoate | 0 | low | 1 | 0 |
| ammonium acetate | 0 | low | 1 | 0 |
| zn(ii)-phthalocyanine | 0 | low | 6 | 0 |
| spathulenol | 0 | low | 1 | 0 |
| bromochloroacetic acid | 0 | medium | 172 | 1 |
| calix(4)arene | 0 | low | 1 | 0 |
| tolfenamic acid | 0 | low | 1 | 0 |
| artemisin | 0 | low | 1 | 0 |
| carbenoxolone sodium | 0 | low | 1 | 0 |
| hectochlorin | 0 | low | 1 | 0 |
| alpha-asarone | 0 | low | 1 | 0 |
| nemorosone | 0 | low | 1 | 0 |
| rhapontin | 0 | low | 1 | 0 |
| cinnamaldehyde | 0 | low | 4 | 0 |
| elaidic acid | 0 | low | 3 | 0 |
| anethole | 0 | low | 1 | 0 |
| geraniol | 0 | low | 4 | 0 |
| glycosides | 0 | low | 36 | 0 |
| benzylideneacetone | 0 | low | 1 | 0 |
| chalcone | 0 | low | 23 | 0 |
| isomethyleugenol | 0 | medium | 265 | 2 |
| piplartine | 0 | low | 3 | 0 |
| citral | 0 | low | 2 | 0 |
| beta-ionone | 0 | low | 9 | 0 |
| retinaldehyde | 0 | low | 1 | 0 |
| piperine | 0 | low | 4 | 0 |
| squalene | 0 | low | 4 | 0 |
| stilbenes | 0 | low | 88 | 0 |
| isoliquiritigenin | 0 | low | 2 | 0 |
| phenyl-n-tert-butylnitrone | 0 | low | 2 | 0 |
| xanthohumol | 0 | low | 6 | 0 |
| picibanil | 0 | medium | 50 | 7 |
| 2-methoxycinnamaldehyde | 0 | low | 2 | 0 |
| cardamonin | 0 | low | 1 | 0 |
| hirsutanol a | 0 | low | 1 | 0 |
| xanthoangelol | 0 | low | 2 | 0 |
| floxuridine | 0 | low | 2 | 0 |
| flavin-adenine dinucleotide | 0 | low | 4 | 0 |
| cannabidiol | 0 | low | 1 | 0 |
| malonyl coenzyme a | 0 | low | 1 | 0 |
| buprenorphine | 0 | low | 1 | 0 |
| lypressin | 0 | medium | 1 | 1 |
| arginine vasopressin | 0 | low | 1 | 0 |
| pyrophosphate | 0 | low | 15 | 0 |
| palmitoyl coenzyme a | 0 | low | 2 | 0 |
| gw9662 | 0 | low | 7 | 0 |
| s 1033 | 0 | low | 3 | 0 |
| dihydrosphingosine 1-phosphate | 0 | low | 1 | 0 |
| acetyl-aspartyl-glutamyl-valyl-aspartal | 0 | low | 1 | 0 |
| azidopine | 0 | low | 1 | 0 |
| amygdalin | 0 | low | 5 | 0 |
| trilostane | 0 | low | 1 | 0 |
| bucillamine | 0 | low | 1 | 0 |
| lanatoside c | 0 | low | 2 | 0 |
| polidocanol | 0 | low | 3 | 0 |
| iothalamate meglumine | 0 | low | 4 | 0 |
| sodium metabisulfite | 0 | medium | 1 | 1 |
| tram 34 | 0 | low | 2 | 0 |
| isopropyl thiogalactoside | 0 | low | 4 | 0 |
| leuprolide | 0 | medium | 3 | 2 |
| fludarabine | 0 | low | 5 | 0 |
| nsc 4347 | 0 | low | 2 | 0 |
| n(6)-cyclopentyladenosine | 0 | low | 1 | 0 |
| sesquiterpenes | 0 | low | 80 | 0 |
| chlorprothixene | 0 | low | 1 | 0 |
| dienestrol | 0 | low | 1 | 0 |
| etomidate | 0 | low | 1 | 0 |
| mercaptopurine | 0 | low | 21 | 0 |
| methylthiouracil | 0 | low | 4 | 0 |
| ag-213 | 0 | low | 2 | 0 |
| 3,3',4,5'-tetrahydroxystilbene | 0 | low | 4 | 0 |
| thioinosine | 0 | low | 2 | 0 |
| jrf 12 | 0 | low | 1 | 0 |
| thiobenzamide | 0 | low | 2 | 0 |
| caffeic acid | 0 | low | 7 | 0 |
| 1-(2-hydroxy-5-methylphenyl)-3-phenyl-1,3-propanedione | 0 | low | 1 | 0 |
| urocanic acid | 0 | low | 1 | 0 |
| parthenolide, (1ar-(1ar*,4e,7as*,10as*,10br*))-isomer | 0 | low | 1 | 0 |
| tetrahydropalmatine | 0 | low | 3 | 0 |
| dieldrin | 0 | low | 2 | 0 |
| curcumin | 0 | low | 167 | 0 |
| hypocrellin b | 0 | low | 3 | 0 |
| ptc-209 | 0 | low | 1 | 0 |
| thiouracil | 0 | low | 3 | 0 |
| 5-(4-ethylbenzylidene)-2-thioxothiazolidin-4-one | 0 | low | 1 | 0 |
| thiohydantoins | 0 | medium | 1 | 1 |
| methimazole | 0 | low | 3 | 0 |
| sulindac | 0 | low | 4 | 0 |
| capsaicin | 0 | low | 17 | 0 |
| enclomiphene | 0 | low | 3 | 0 |
| terbinafine | 0 | low | 1 | 0 |
| aurapten | 0 | low | 2 | 0 |
| caryophyllene oxide | 0 | low | 2 | 0 |
| chlorogenic acid | 0 | medium | 17 | 1 |
| fatostatin | 0 | low | 1 | 0 |
| thioguanine anhydrous | 0 | low | 3 | 0 |
| neotetrazolium | 0 | low | 2 | 0 |
| thiobarbituric acid | 0 | low | 2 | 0 |
| thiourea | 0 | medium | 8 | 1 |
| indigo carmine | 0 | medium | 7 | 1 |
| D-fructopyranose | 0 | low | 45 | 0 |
| thioacetamide | 0 | low | 49 | 0 |
| tempo | 0 | low | 1 | 0 |
| ferric ferrocyanide | 0 | low | 6 | 0 |
| succimer | 0 | low | 2 | 0 |
| digoxin | 0 | low | 5 | 0 |
| fumonisin b1 | 0 | medium | 10 | 1 |
| fumonisin b2 | 0 | low | 1 | 0 |
| tamoxifen | 0 | medium | 130 | 34 |
| sodium taurodeoxycholate | 0 | low | 5 | 0 |
| 1-dodecyl-3-methylimidazolium | 0 | low | 1 | 0 |
| nadp | 0 | low | 56 | 0 |
| 1,1-diphenyl-2-picrylhydrazyl | 0 | low | 5 | 0 |
| yoda 1 | 0 | low | 1 | 0 |
| 5-cyano-2,3-ditolyltetrazolium chloride | 0 | low | 2 | 0 |
| 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2h-tetrazolium | 0 | low | 2 | 0 |
| t 0070907 | 0 | low | 3 | 0 |
| stattic | 0 | low | 5 | 0 |
| nitrobenzanthrone | 0 | low | 3 | 0 |
| krn 7000 | 0 | low | 3 | 0 |
| sirtinol | 0 | low | 2 | 0 |
| methyl-thiohydantoin-tryptophan | 0 | low | 3 | 0 |
| 10074-g5 | 0 | low | 1 | 0 |
| hlm006474 | 0 | low | 1 | 0 |
| monastrol | 0 | low | 2 | 0 |
| zeranol | 0 | low | 2 | 0 |
| rhyncophylline | 0 | low | 1 | 0 |
| valinomycin | 0 | low | 6 | 0 |
| thiopental | 0 | low | 4 | 0 |
| ranitidine | 0 | low | 3 | 0 |
| maraviroc | 0 | low | 2 | 0 |
| toremifene | 0 | low | 2 | 0 |
| u 0126 | 0 | low | 29 | 0 |
| rwj 67657 | 0 | low | 1 | 0 |
| dieckol | 0 | low | 2 | 0 |
| telaprevir | 0 | medium | 14 | 1 |
| laccase | 0 | low | 1 | 0 |
| pica | 0 | low | 1 | 0 |
| 5-hydroxycytosine | 0 | low | 1 | 0 |
| 3,7,11,15-tetramethyl-1,2,3-hexadecanetriol | 0 | low | 3 | 0 |
| 6-methyl-2-(phenylethynyl)pyridine | 0 | low | 1 | 0 |
| bms 387032 | 0 | low | 1 | 0 |
| lithium | 0 | low | 14 | 0 |
| fosfestrol | 0 | low | 1 | 0 |
| deacylcortivazol | 0 | low | 1 | 0 |
| cobaltous chloride | 0 | low | 26 | 0 |
| nitrogen dioxide | 0 | medium | 5 | 3 |
| dermatan sulfate | 0 | low | 5 | 0 |
| dezocine | 0 | medium | 1 | 1 |
| nizatidine | 0 | low | 1 | 0 |
| orlistat | 0 | low | 6 | 0 |
| kaurenoic acid | 0 | low | 2 | 0 |
| 1,2-bis(2-aminophenoxy)ethane n,n,n',n'-tetraacetic acid acetoxymethyl ester | 0 | low | 5 | 0 |
| 15,16-dihydro-11-methylcyclopenta(a)phenanthren-17-one | 0 | low | 1 | 0 |
| indium oxine | 0 | low | 2 | 0 |
| rtki cpd | 0 | low | 6 | 0 |
| didimethylsulfoxide dichloroplatinum(ii) | 0 | low | 1 | 0 |
| muricatacin | 0 | low | 1 | 0 |
| glutathione glycylethyl ester | 0 | low | 1 | 0 |
| cystine | 0 | low | 20 | 0 |
| 1-palmitoyl-2-(10-(4-((trifluoromethyl)diazirinyl)phenyl)-8-oxadecanoyl)-sn-glycero-3-phosphocholine | 0 | low | 1 | 0 |
| diethylstilbestrol monophosphate | 0 | low | 2 | 0 |
| 3-aminolevamisole | 0 | low | 2 | 0 |
| byakangelicol | 0 | low | 1 | 0 |
| safingol | 0 | low | 4 | 0 |
| erysolin | 0 | low | 1 | 0 |
| bigelovin | 0 | low | 1 | 0 |
| ct 2584 | 0 | low | 1 | 0 |
| dicyclanil | 0 | low | 3 | 0 |
| glutaryl-coenzyme a | 0 | low | 2 | 0 |
| ascorbigen | 0 | low | 1 | 0 |
| 2-fluoro-2-deoxyglucose-6-phosphate | 0 | low | 1 | 0 |
| nitinol | 0 | low | 3 | 0 |
| calixarenes | 0 | low | 2 | 0 |
| dryocrassin | 0 | low | 1 | 0 |
| bakuchicin | 0 | low | 1 | 0 |
| heparin | 0 | low | 1 | 0 |
| cactinomycin | 0 | low | 1 | 0 |
| amanitins | 0 | low | 8 | 0 |
| cytellin | 0 | low | 13 | 0 |
| verticillins | 0 | low | 1 | 0 |
| phosphonic acid | 0 | low | 1 | 0 |
| n-(2-naphthalene)sulfonyl-dl-tryptophan | 0 | low | 1 | 0 |
| salinomycin | 0 | low | 11 | 0 |
| gnidimacrin | 0 | low | 1 | 0 |
| gigantol | 0 | low | 3 | 0 |
| ginsenosides | 0 | medium | 64 | 2 |
| 2-(4-(2-carboxyethyl)phenethylamino)-5'-n-ethylcarboxamidoadenosine | 0 | low | 2 | 0 |
| compound 968 | 0 | low | 1 | 0 |
| chromeceptin | 0 | low | 1 | 0 |
| phosphothreonine | 0 | low | 7 | 0 |
| cambinol | 0 | low | 4 | 0 |
| ovalbumin | 0 | low | 7 | 0 |
| n-acetylgalactosaminyl-1-4-n-acetylglucosamine | 0 | low | 1 | 0 |
| sodium dodecyl sulfate | 0 | low | 22 | 0 |
| fh535 | 0 | low | 6 | 0 |
| blister | 0 | low | 2 | 0 |
| bromohydrin pyrophosphate | 0 | low | 1 | 0 |
| crocin | 0 | low | 4 | 0 |
| galactomannan | 0 | low | 2 | 0 |
| mtt formazan | 0 | low | 13 | 0 |
| l 663536 | 0 | low | 5 | 0 |
| 6-hydrazinopyridine-3-carboxylic acid | 0 | low | 1 | 0 |
| zinc protoporphyrin ix | 0 | low | 2 | 0 |
| 3-(2,4-dichloro-5-methoxyphenyl)-2-sulfanyl-4(3h)-quinazolinone | 0 | low | 4 | 0 |
| ocotillol | 0 | low | 1 | 0 |
| metanil yellow | 0 | low | 1 | 0 |
| alpha-chymotrypsin | 0 | low | 18 | 0 |
| alpinetin | 0 | low | 1 | 0 |
| ferrostatin-1 | 0 | low | 3 | 0 |
| tetramethylrhodamine isothiocyanate | 0 | low | 2 | 0 |
| sb 415286 | 0 | low | 1 | 0 |
| 17-ketosteroids | 0 | low | 3 | 0 |
| naphthoquinones | 0 | medium | 58 | 1 |
| d 609 | 0 | low | 1 | 0 |
| jhw 015 | 0 | low | 2 | 0 |
| sc 560 | 0 | low | 2 | 0 |
| sodium borohydride | 0 | low | 1 | 0 |
| alpha-carotene | 0 | medium | 5 | 1 |
| digitoxigenin | 0 | low | 1 | 0 |
| osteoprotegerin | 0 | low | 5 | 0 |
| 1,1-dimethyl-4-acetylpiperazinium | 0 | low | 1 | 0 |
| 4-mercaptophenylboronic acid | 0 | low | 1 | 0 |
| 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1h-imidazol-2-yl)benzamide | 0 | low | 3 | 0 |
| rhodamine 123 | 0 | low | 24 | 0 |
| myelin basic protein | 0 | low | 2 | 0 |
| tx 402 | 0 | low | 1 | 0 |
| merbarone | 0 | medium | 1 | 1 |
| imd 0354 | 0 | low | 1 | 0 |
| ex 527 | 0 | low | 2 | 0 |
| iodoazomycin arabinoside | 0 | low | 1 | 0 |
| tetrathiomolybdate | 0 | low | 1 | 0 |
| diethyl maleate | 0 | low | 1 | 0 |
| ginkgetin | 0 | low | 1 | 0 |
| resveratrol-4'-o-glucuronide | 0 | low | 1 | 0 |
| cinnamamide | 0 | low | 1 | 0 |
| eupatilin | 0 | low | 1 | 0 |
| isoliensinine | 0 | low | 2 | 0 |
| farnesoic acid | 0 | low | 1 | 0 |
| geranylgeranic acid | 0 | low | 6 | 0 |
| catechin gallate | 0 | low | 1 | 0 |
| ku 55933 | 0 | low | 2 | 0 |
| sphingosine | 0 | low | 51 | 0 |
| quercetin | 0 | low | 85 | 0 |
| ubiquinone q2 | 0 | low | 1 | 0 |
| bilirubin | 0 | medium | 547 | 35 |
| dinoprostone | 0 | medium | 87 | 1 |
| dinoprost | 0 | low | 3 | 0 |
| biochanin a | 0 | low | 2 | 0 |
| formononetin | 0 | low | 2 | 0 |
| sterigmatocystin | 0 | low | 7 | 0 |
| vitexin | 0 | low | 7 | 0 |
| acacetin | 0 | low | 2 | 0 |
| apigenin | 0 | low | 41 | 0 |
| luteolin | 0 | medium | 23 | 1 |
| 7,3'-dihydroxy-4'-methoxyisoflavone | 0 | low | 5 | 0 |
| linoleic acid | 0 | low | 30 | 0 |
| calcitriol | 0 | medium | 27 | 1 |
| pinosylvin | 0 | low | 1 | 0 |
| scopoletin | 0 | low | 1 | 0 |
| ubiquinone 9 | 0 | low | 1 | 0 |
| vitamin k semiquinone radical | 0 | medium | 95 | 2 |
| beta carotene | 0 | medium | 23 | 1 |
| leukotriene b4 | 0 | low | 7 | 0 |
| leukotriene c4 | 0 | low | 1 | 0 |
| retinol palmitate | 0 | low | 1 | 0 |
| coniferaldehyde | 0 | low | 1 | 0 |
| feruloyltyramine | 0 | low | 2 | 0 |
| hymecromone | 0 | low | 13 | 0 |
| daphnetin | 0 | low | 2 | 0 |
| 8,11,14-eicosatrienoic acid | 0 | low | 4 | 0 |
| luteolin-7-glucoside | 0 | low | 1 | 0 |
| chrysoeriol | 0 | low | 1 | 0 |
| apigetrin | 0 | low | 2 | 0 |
| 15-ketoprostaglandin e2 | 0 | low | 1 | 0 |
| alprostadil | 0 | medium | 21 | 2 |
| vitamin d 2 | 0 | low | 4 | 0 |
| stigmasterol | 0 | low | 3 | 0 |
| cholecalciferol | 0 | medium | 11 | 2 |
| rutin | 0 | low | 11 | 0 |
| vitamin k1 oxide | 0 | low | 1 | 0 |
| kaempferol | 0 | low | 7 | 0 |
| leukotriene d4 | 0 | low | 1 | 0 |
| leukotriene e4 | 0 | low | 1 | 0 |
| prostaglandin a2 | 0 | low | 1 | 0 |
| 9-deoxy-delta-9-prostaglandin d2 | 0 | low | 4 | 0 |
| 9-deoxy-9,10-didehydro-12,13-didehydro-13,14-dihydroprostaglandin d2 | 0 | low | 1 | 0 |
| 6-ketoprostaglandin f1 alpha | 0 | low | 3 | 0 |
| zeaxanthin | 0 | low | 2 | 0 |
| lipoxin a4 | 0 | low | 4 | 0 |
| gamma-linolenic acid | 0 | medium | 7 | 2 |
| alpha-linolenic acid | 0 | low | 12 | 0 |
| harmine | 0 | low | 4 | 0 |
| naringenin chalcone | 0 | low | 1 | 0 |
| genistein | 0 | low | 64 | 0 |
| amphotericin b | 0 | low | 10 | 0 |
| pulmicort | 0 | low | 1 | 0 |
| oxymetholone | 0 | low | 23 | 0 |
| mivacurium | 0 | low | 1 | 0 |
| kava | 0 | low | 1 | 0 |
| paricalcitol | 0 | low | 1 | 0 |
| trovafloxacin | 0 | low | 1 | 0 |
| 2-hexenal, z-isomer | 0 | low | 2 | 0 |
| butein | 0 | low | 9 | 0 |
| astaxanthine | 0 | low | 3 | 0 |
| canthaxanthin | 0 | low | 1 | 0 |
| cryptoxanthins | 0 | medium | 3 | 1 |
| fucoxanthin | 0 | low | 3 | 0 |
| lutein | 0 | low | 3 | 0 |
| cucurbitacin b | 0 | low | 5 | 0 |
| cucurbitacin c | 0 | low | 1 | 0 |
| cucurbitacin d | 0 | low | 2 | 0 |
| nsc 106399 | 0 | low | 3 | 0 |
| cucurbitacin i | 0 | low | 4 | 0 |
| geranylgeraniol | 0 | low | 3 | 0 |
| mezerein | 0 | low | 1 | 0 |
| strigol | 0 | low | 1 | 0 |
| esculetin | 0 | low | 1 | 0 |
| esculin | 0 | low | 1 | 0 |
| 7-hydroxycoumarin | 0 | low | 3 | 0 |
| costunolide | 0 | low | 1 | 0 |
| trilobolide | 0 | low | 1 | 0 |
| xanthatin | 0 | low | 3 | 0 |
| humulene | 0 | medium | 5 | 2 |
| oleuropein | 0 | low | 3 | 0 |
| garcinol | 0 | low | 3 | 0 |
| zearalenone | 0 | low | 5 | 0 |
| amentoflavone | 0 | low | 4 | 0 |
| baicalein | 0 | medium | 28 | 2 |
| chrysin | 0 | low | 14 | 0 |
| diosmetin | 0 | low | 3 | 0 |
| diosmin | 0 | low | 2 | 0 |
| fisetin | 0 | low | 5 | 0 |
| galangin | 0 | low | 9 | 0 |
| hinokiflavone | 0 | low | 1 | 0 |
| hispidulin | 0 | low | 4 | 0 |
| euxanthone | 0 | low | 1 | 0 |
| mangiferin | 0 | low | 3 | 0 |
| mangostin | 0 | low | 7 | 0 |
| 3-methylquercetin | 0 | low | 4 | 0 |
| norathyriol | 0 | low | 1 | 0 |
| kaempferide | 0 | low | 2 | 0 |
| morin | 0 | low | 6 | 0 |
| morusin | 0 | low | 2 | 0 |
| myricetin | 0 | low | 8 | 0 |
| orientin | 0 | low | 1 | 0 |
| rhamnetin | 0 | low | 4 | 0 |
| scutellarein | 0 | low | 1 | 0 |
| tricetin | 0 | low | 1 | 0 |
| wogonin | 0 | low | 8 | 0 |
| daidzein | 0 | low | 11 | 0 |
| trans-2,3',4,5'-tetrahydroxystilbene | 0 | low | 1 | 0 |
| pterostilbene | 0 | low | 8 | 0 |
| epsilon-viniferin | 0 | low | 1 | 0 |
| petasitenine | 0 | low | 1 | 0 |
| retrorsine | 0 | low | 2 | 0 |
| riddelliine | 0 | low | 1 | 0 |
| echinacoside | 0 | low | 2 | 0 |
| caffeic acid phenethyl ester | 0 | low | 6 | 0 |
| plantamajoside | 0 | low | 1 | 0 |
| rosmarinic acid | 0 | low | 5 | 0 |
| salvianolic acid a | 0 | low | 1 | 0 |
| shogaol | 0 | low | 7 | 0 |
| acteoside | 0 | low | 5 | 0 |
| 4'-methoxy-3',5,7-trihydroxyisoflavone | 0 | low | 1 | 0 |
| prunetin | 0 | low | 1 | 0 |
| wedelolactone | 0 | low | 2 | 0 |
| maytansine | 0 | low | 2 | 0 |
| rottlerin | 0 | low | 2 | 0 |
| ellagic acid | 0 | low | 9 | 0 |
| sdz psc 833 | 0 | low | 4 | 0 |
| l 660,711 | 0 | low | 1 | 0 |
| rutamycin | 0 | low | 1 | 0 |
| astragalin | 0 | low | 1 | 0 |
| geranylgeranylacetone | 0 | low | 2 | 0 |
| 8-epi-prostaglandin f2alpha | 0 | low | 2 | 0 |
| n,n-dimethylsphingenine | 0 | low | 2 | 0 |
| tocotrienol, alpha | 0 | low | 2 | 0 |
| tocotrienol, delta | 0 | low | 4 | 0 |
| 4-hydroxyestradiol | 0 | low | 1 | 0 |
| isotretinoin | 0 | medium | 4 | 1 |
| ozagrel | 0 | medium | 1 | 1 |
| pitavastatin | 0 | low | 7 | 0 |
| zinostatin | 0 | medium | 85 | 11 |
| ethamolin | 0 | medium | 5 | 2 |
| trans-10,cis-12-conjugated linoleic acid | 0 | low | 1 | 0 |
| 13-hydroxy-9,11-octadecadienoic acid | 0 | low | 2 | 0 |
| 17-phenyltrinorprostaglandin e2 | 0 | low | 1 | 0 |
| thromboxane b2 | 0 | low | 5 | 0 |
| 20-hydroxy-5,8,11,14-eicosatetraenoic acid | 0 | low | 1 | 0 |
| 4-hydroxy-2-nonenal | 0 | low | 20 | 0 |
| oleylamide | 0 | low | 3 | 0 |
| n-oleoylethanolamine | 0 | low | 2 | 0 |
| menaquinone 6 | 0 | medium | 48 | 7 |
| sphingosine 1-phosphate | 0 | low | 21 | 0 |
| n-palmitoylsphingosine | 0 | low | 1 | 0 |
| ceramide 1-phosphate | 0 | low | 1 | 0 |
| cholesteryl oleate | 0 | low | 1 | 0 |
| purmorphamine | 0 | low | 1 | 0 |
| cinnamyl anthranilate | 0 | low | 1 | 0 |
| codeine | 0 | low | 1 | 0 |
| mitolactol | 0 | low | 1 | 0 |
| phenylephrine hydrochloride | 0 | low | 2 | 0 |
| 3-amino-1,4-dimethyl-5h-pyrido(4,3-b)indole | 0 | low | 2 | 0 |
| 3-amino-1-methyl-5h-pyrido(4,3-b)indole | 0 | low | 1 | 0 |
| cyproterone | 0 | low | 6 | 0 |
| granisetron | 0 | medium | 1 | 1 |
| naloxone | 0 | low | 2 | 0 |
| oxycodone | 0 | low | 2 | 0 |
| vitamin k 1 | 0 | medium | 14 | 1 |
| proscillaridin | 0 | low | 1 | 0 |
| topiramate | 0 | low | 1 | 0 |
| menaquinone 7 | 0 | medium | 2 | 2 |
| brefeldin a | 0 | low | 18 | 0 |
| alvocidib | 0 | low | 3 | 0 |
| fenretinide | 0 | low | 13 | 0 |
| ic 261 | 0 | low | 1 | 0 |
| 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin | 0 | low | 6 | 0 |
| morphine | 0 | medium | 16 | 3 |
| pactamycin | 0 | low | 2 | 0 |
| su 5402 | 0 | low | 1 | 0 |
| 4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid | 0 | medium | 2 | 1 |
| arachidonyl-2-chloroethylamide | 0 | low | 1 | 0 |
| 4-amino-5-chloro-N-[(3R,4S)-1-[3-(4-fluorophenoxy)propyl]-3-methoxy-4-piperidinyl]-2-methoxybenzamide | 0 | low | 1 | 0 |
| clobetasol | 0 | low | 3 | 0 |
| deamino arginine vasopressin | 0 | low | 1 | 0 |
| desoximetasone | 0 | low | 1 | 0 |
| dexmedetomidine | 0 | medium | 6 | 1 |
| fluticasone | 0 | medium | 1 | 1 |
| herbimycin | 0 | low | 3 | 0 |
| goserelin | 0 | medium | 1 | 1 |
| iloprost | 0 | low | 2 | 0 |
| 15-deoxy-delta(12,14)-prostaglandin j2 | 0 | low | 6 | 0 |
| ono-di-004 | 0 | low | 3 | 0 |
| lysophosphatidic acid | 0 | low | 19 | 0 |
| lysophosphatidylcholines | 0 | low | 24 | 0 |
| n-(n-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester | 0 | low | 4 | 0 |
| cytochalasin b | 0 | low | 18 | 0 |
| calyculin a | 0 | low | 2 | 0 |
| (3r)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone | 0 | low | 1 | 0 |
| kn 93 | 0 | low | 1 | 0 |
| sulprostone | 0 | low | 1 | 0 |
| casticin | 0 | low | 3 | 0 |
| biliverdine | 0 | low | 3 | 0 |
| bisdemethoxycurcumin | 0 | low | 2 | 0 |
| bufothionine | 0 | low | 1 | 0 |
| corylin | 0 | low | 2 | 0 |
| glycycoumarin | 0 | low | 2 | 0 |
| hydroxygenkwanin | 0 | low | 1 | 0 |
| andrographolide | 0 | low | 14 | 0 |
| isoegomaketone | 0 | low | 1 | 0 |
| isofraxidin | 0 | low | 2 | 0 |
| isoginkgetin | 0 | low | 1 | 0 |
| koumine | 0 | low | 2 | 0 |
| dehydrocrenatidine | 0 | low | 2 | 0 |
| icariin | 0 | low | 3 | 0 |
| licochalcone a | 0 | low | 5 | 0 |
| licochalcone b | 0 | low | 1 | 0 |
| neobavaisoflavone | 0 | low | 1 | 0 |
| nerolidol | 0 | low | 1 | 0 |
| notopterol | 0 | low | 1 | 0 |
| 5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one | 0 | low | 13 | 0 |
| artemetin | 0 | low | 1 | 0 |
| tiliroside | 0 | low | 1 | 0 |
| rhamnazin | 0 | low | 1 | 0 |
| caryophyllene | 0 | low | 1 | 0 |
| 1-(4-(6-bromobenzo(1,3)dioxol-5-yl)-3a,4,5,9b-tetrahydro-3h-cyclopenta(c)quinolin-8-yl)ethanone | 0 | low | 1 | 0 |
| malealdehyde | 0 | low | 1 | 0 |
| fluvoxamine | 0 | low | 2 | 0 |
| 7,8-dimethylalloxazine | 0 | low | 1 | 0 |
| globo-h | 0 | low | 2 | 0 |
| casein kinase ii | 0 | low | 18 | 0 |
| erbstatin | 0 | low | 1 | 0 |
| ag-490 | 0 | low | 8 | 0 |
| semaxinib | 0 | low | 1 | 0 |
| nifuroxazide | 0 | low | 2 | 0 |
| mitoguazone | 0 | low | 1 | 0 |
| fosbretabulin | 0 | low | 2 | 0 |
| fosbretabulin | 0 | low | 15 | 0 |
| ergosterol-5,8-peroxide | 0 | low | 3 | 0 |
| spectinabilin | 0 | low | 1 | 0 |
| heteronemin | 0 | low | 1 | 0 |
| hemiasterlin | 0 | low | 1 | 0 |
| lead | 0 | medium | 18 | 3 |
| tin | 0 | low | 13 | 0 |
| butylidenephthalide | 0 | medium | 3 | 1 |
| 12-hydroxy-5,8,10,14-eicosatetraenoic acid | 0 | low | 4 | 0 |
| 13-hydroperoxy-9,11-octadecadienoic acid | 0 | low | 1 | 0 |
| 15-hydroxy-5,8,11,13-eicosatetraenoic acid | 0 | low | 1 | 0 |
| bay 11-7082 | 0 | medium | 6 | 2 |
| bay 11-7085 | 0 | low | 1 | 0 |
| 5,5',6,6'-tetrachloro-1,1',3,3'-tetraethylbenzimidazolocarbocyanine | 0 | low | 1 | 0 |
| diamide | 0 | low | 7 | 0 |
| antimony | 0 | low | 3 | 0 |
| cesium | 0 | low | 6 | 0 |
| barium | 0 | low | 4 | 0 |
| flavokawain a | 0 | low | 1 | 0 |
| flavokawain b | 0 | low | 2 | 0 |
| rubidium | 0 | low | 5 | 0 |
| sinulariolide | 0 | low | 4 | 0 |
| aluminum | 0 | low | 8 | 0 |
| 6-chloropurine | 0 | low | 1 | 0 |
| strontium | 0 | medium | 3 | 1 |
| bismuth | 0 | medium | 10 | 2 |
| thallium | 0 | low | 5 | 0 |
| alternariol | 0 | low | 4 | 0 |
| arsenic | 0 | medium | 131 | 9 |
| indium | 0 | low | 23 | 0 |
| 4-hydroxyaminoquinoline-1-oxide | 0 | low | 1 | 0 |
| naltrexone | 0 | low | 2 | 0 |
| dextromethorphan | 0 | low | 1 | 0 |
| alternariol monomethyl ether | 0 | low | 2 | 0 |
| gallium | 0 | low | 26 | 0 |
| butorphanol | 0 | low | 1 | 0 |
| methylnaltrexone | 0 | low | 1 | 0 |
| batimastat | 0 | medium | 3 | 1 |
| indinavir sulfate | 0 | low | 4 | 0 |
| sulfur | 0 | medium | 50 | 1 |
| methylazoxymethanol acetate | 0 | low | 6 | 0 |
| ethyl oleate | 0 | low | 1 | 0 |
| geldanamycin | 0 | low | 6 | 0 |
| musk | 0 | low | 2 | 0 |
| costunolide | 0 | low | 5 | 0 |
| diphenylhexatriene | 0 | low | 1 | 0 |
| 2',4'-dihydroxychalcone | 0 | low | 1 | 0 |
| urolithin b | 0 | low | 1 | 0 |
| puerarin | 0 | low | 3 | 0 |
| ajoene | 0 | low | 1 | 0 |
| suillin | 0 | low | 1 | 0 |
| 3,4',5-trimethoxystilbene | 0 | low | 1 | 0 |
| sanglifehrin a | 0 | low | 1 | 0 |
| enalapril | 0 | low | 1 | 0 |
| 3,3'-diethyloxacarbocyanine | 0 | low | 1 | 0 |
| artocarpin lectin | 0 | low | 1 | 0 |
| 3-acetyldeoxynivalenol | 0 | low | 1 | 0 |
| hispanolone | 0 | low | 1 | 0 |
| nsc 600032 | 0 | low | 1 | 0 |
| sinomenine | 0 | low | 6 | 0 |
| dimyristoylphosphatidylcholine | 0 | low | 6 | 0 |
| ecdysterone | 0 | low | 1 | 0 |
| sedoheptulose | 0 | low | 1 | 0 |
| deoxyribose | 0 | low | 1 | 0 |
| fumarates | 0 | low | 3 | 0 |
| beryllium | 0 | medium | 2 | 1 |
| cysteine | 0 | medium | 79 | 1 |
| thyronines | 0 | low | 1 | 0 |
| silicon | 0 | low | 9 | 0 |
| phosphorus | 0 | medium | 26 | 2 |
| boron | 0 | low | 10 | 0 |
| 2,3-dehydrosilybin | 0 | low | 1 | 0 |
| concanamycin b | 0 | low | 1 | 0 |
| bakuchiol | 0 | low | 1 | 0 |
| s-trans,trans-farnesylthiosalicylic acid | 0 | low | 8 | 0 |
| zerumbone | 0 | low | 3 | 0 |
| sulindac sulfone | 0 | low | 1 | 0 |
| sinularin | 0 | low | 1 | 0 |
| 1,5-bis(2-methoxy-4-nitro-5-sulfophenyl)-3-((phenylamino)carbonyl)formazan | 0 | low | 1 | 0 |
| pepstatin | 0 | low | 2 | 0 |
| ximelagatran | 0 | low | 1 | 0 |
| phytochlorin | 0 | low | 10 | 0 |
| cefepime | 0 | medium | 1 | 1 |
| l 685458 | 0 | low | 1 | 0 |
| morusinol | 0 | low | 1 | 0 |
| baohuoside ii | 0 | low | 1 | 0 |
| ici 118551 | 0 | low | 1 | 0 |
| benzoporphyrin d | 0 | low | 1 | 0 |
| strontium radioisotopes | 0 | low | 1 | 0 |
| troxerutin | 0 | low | 2 | 0 |
| talaporfin | 0 | low | 4 | 0 |
| pregabalin | 0 | medium | 2 | 1 |
| citrusinine i | 0 | low | 1 | 0 |
| 3,8-dihydroxy-6h-dibenzo(b,d)pyran-6-one | 0 | low | 2 | 0 |
| baohuoside i | 0 | low | 3 | 0 |
| chlorin p6 | 0 | low | 1 | 0 |
| avicularin | 0 | low | 1 | 0 |
| alpinumisoflavone | 0 | low | 1 | 0 |
| vx680 | 0 | low | 2 | 0 |
| n-acetylsphingosine | 0 | low | 3 | 0 |
| lysophosphatidic acid | 0 | low | 1 | 0 |
| triolein | 0 | low | 2 | 0 |
| docosapentaenoic acid | 0 | low | 1 | 0 |
| bafilomycin a | 0 | low | 2 | 0 |
| n-caproylsphingosine | 0 | low | 8 | 0 |
| 3,3'-dioctadecylindocarbocyanine | 0 | low | 3 | 0 |
| carbocyanines | 0 | low | 18 | 0 |
| salubrinal | 0 | low | 5 | 0 |
| cefotaxime | 0 | medium | 1 | 1 |
| epimedin c | 0 | low | 1 | 0 |
| quercetin-3'-o-beta-d-glucopyranoside | 0 | low | 2 | 0 |
| 1,2-dielaidoylphosphatidylethanolamine | 0 | low | 4 | 0 |
| zearalenol | 0 | low | 1 | 0 |
| ammonium sulfate | 0 | low | 21 | 0 |
| 4,4'-diisothiocyanostilbene-2,2'-disulfonic acid | 0 | low | 5 | 0 |
| ma-1 | 0 | medium | 1 | 1 |
| coomassie brilliant blue | 0 | low | 1 | 0 |
| mastoparan | 0 | low | 1 | 0 |
| deoxyelephantopin | 0 | low | 3 | 0 |
| lasiocarpine | 0 | low | 1 | 0 |
| selenium | 0 | medium | 99 | 2 |
| selenocysteine | 0 | low | 6 | 0 |
| tellurium | 0 | low | 13 | 0 |
| radium | 0 | low | 3 | 0 |
| thorium x | 0 | low | 1 | 0 |
| oxalates | 0 | low | 3 | 0 |
| palonosetron | 0 | low | 3 | 0 |
| (3S,5S,6E)-7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid | 0 | low | 11 | 0 |
| maxacalcitol | 0 | low | 1 | 0 |
| mevalonolactone | 0 | low | 1 | 0 |
| dizocilpine maleate | 0 | low | 1 | 0 |
| antimycin a | 0 | low | 7 | 0 |
| pregnanediol | 0 | low | 2 | 0 |
| gamma-eudesmol | 0 | low | 1 | 0 |
| 5-aminolevulinic acid hexyl ester | 0 | low | 1 | 0 |
| methylazoxymethanol | 0 | low | 1 | 0 |
| s-(1,2-dichlorovinyl)cysteine | 0 | low | 1 | 0 |
| dolichols | 0 | low | 9 | 0 |
| hygromycin a | 0 | low | 2 | 0 |
| bongkrekic acid | 0 | low | 1 | 0 |
| cilastatin | 0 | low | 3 | 0 |
| sclerotiorin | 0 | low | 1 | 0 |
| bafilomycin a1 | 0 | low | 9 | 0 |
| germacrone | 0 | low | 1 | 0 |
| dehydroergosterol | 0 | low | 1 | 0 |
| sarcophine | 0 | low | 1 | 0 |
| 1-oleoyl-2-acetylglycerol | 0 | low | 3 | 0 |
| brl 28500 | 0 | low | 1 | 0 |
| ro 13-6298 | 0 | low | 1 | 0 |
| 1,2-dioleoyloxy-3-(trimethylammonium)propane | 0 | low | 6 | 0 |
| pectenotoxin 2 | 0 | low | 1 | 0 |
| dioleoyl phosphatidylethanolamine | 0 | low | 1 | 0 |
| (2e,4e,6e,10e)-3,7,11,15-tetramethyl-2,4,6,10,14-hexadecapentaenoic acid | 0 | medium | 51 | 5 |
| concanamycin a | 0 | low | 1 | 0 |
| manumycin | 0 | low | 6 | 0 |
| plastochromanol 8 | 0 | low | 7 | 0 |
| thermozymocidin | 0 | low | 1 | 0 |
| neo-gambogic acid | 0 | low | 3 | 0 |
| rooperol | 0 | low | 1 | 0 |
| 4-o-carboxymethylascochlorin | 0 | low | 1 | 0 |
| 17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid | 0 | low | 1 | 0 |
| e 3330 | 0 | low | 2 | 0 |
| erucylphosphocholine | 0 | low | 1 | 0 |
| n-(n-(7-nitro-2,1,3-benzoxadiazol-4-yl)-epsilon-aminohexanoyl)sphingosylphosphorylcholine | 0 | low | 3 | 0 |
| pregna-4,17-diene-3,16-dione | 0 | low | 4 | 0 |
| echinacin | 0 | low | 1 | 0 |
| feruloyltyramine, (z)-isomer | 0 | low | 1 | 0 |
| goniothalamin | 0 | low | 1 | 0 |
| antibiotic 1233a | 0 | low | 1 | 0 |
| 1,2-linoleoylphosphatidylcholine | 0 | low | 1 | 0 |
| menahydroquinone-4 | 0 | low | 2 | 0 |
| bafilomycin c1 | 0 | low | 1 | 0 |
| n(4)-oleylcytosine arabinoside | 0 | low | 1 | 0 |
| ergosta-4,6,8(14),22-tetraen-3-one | 0 | low | 2 | 0 |
| isoobtusilactone a | 0 | low | 1 | 0 |
| emerin | 0 | low | 1 | 0 |
| meso-zeaxanthin | 0 | low | 1 | 0 |
| 13(S)-HODE | 0 | low | 1 | 0 |
| nb 598 | 0 | low | 1 | 0 |
| hydroxysafflor yellow a | 0 | low | 3 | 0 |
| mkt 077 | 0 | low | 1 | 0 |
| ixabepilone | 0 | low | 1 | 0 |
| ekb 569 | 0 | low | 2 | 0 |
| n-solanesyl-n,n'-bis(3,4-dimethoxybenzyl)ethylenediamine | 0 | low | 1 | 0 |
| 16-(2'-o-glucopyranosylglucopyranosyloxy)hexadecanoic acid 1',4''-lactone 6',6''-diacetate | 0 | low | 1 | 0 |
| cdw17 antigen | 0 | low | 1 | 0 |
| asialo gm1 ganglioside | 0 | low | 3 | 0 |
| sialosylparagloboside | 0 | low | 1 | 0 |
| idb 1016 | 0 | medium | 1 | 1 |
| ovatodiolide | 0 | low | 3 | 0 |
| salvianolic acid B | 0 | low | 1 | 0 |
| i(3)so3-galactosylceramide | 0 | low | 8 | 0 |
| abt-100 | 0 | low | 1 | 0 |
| trilobatin | 0 | low | 1 | 0 |
| technetium tc 99m pyrophosphate | 0 | low | 1 | 0 |
| glucuronyl glucosamine glycan sulfate | 0 | low | 1 | 0 |
| brazilein | 0 | low | 1 | 0 |
| indigo carmine | 0 | low | 1 | 0 |
| cyclosporin g | 0 | low | 1 | 0 |
| beta-escin | 0 | low | 3 | 0 |
| isoacteoside | 0 | low | 1 | 0 |
| scy-635 | 0 | medium | 1 | 1 |
| panduratin a | 0 | low | 1 | 0 |
| Uvangoletin | 0 | low | 1 | 0 |
| tanespimycin | 0 | low | 12 | 0 |
| verlukast | 0 | low | 2 | 0 |
| beta-escin | 0 | low | 125 | 0 |
| glucoraphanin | 0 | low | 1 | 0 |
| stigmasterol 3-o-beta-d-glucopyranoside | 0 | low | 1 | 0 |
| s-nitroso-n-acetylpenicillamine | 0 | low | 5 | 0 |
| nitrofurantoin | 0 | low | 1 | 0 |
| sb 269970 | 0 | low | 1 | 0 |
| cgk 733 | 0 | low | 1 | 0 |
| lactacystin | 0 | low | 3 | 0 |
| echinocystic acid | 0 | low | 1 | 0 |
| ispinesib | 0 | medium | 1 | 1 |
| gsk5182 | 0 | low | 1 | 0 |
| peplomycin | 0 | low | 4 | 0 |
| 6 beta-hydroxycortisol | 0 | low | 1 | 0 |
| gadolinium dtpa | 0 | medium | 877 | 36 |
| morphinans | 0 | low | 6 | 0 |
| androstane | 0 | low | 2 | 0 |
| carboxyl radical | 0 | low | 1 | 0 |
| 2-(quinolin-2-ylmethylene)hydrazinecarbothioamide | 0 | low | 1 | 0 |
| sq-23377 | 0 | low | 9 | 0 |
| fostriecin | 0 | low | 2 | 0 |
| fk 866 | 0 | low | 3 | 0 |
| fumagillin | 0 | low | 3 | 0 |
| teroxirone | 0 | low | 1 | 0 |
| edatrexate | 0 | medium | 1 | 1 |
| bufogenin | 0 | low | 1 | 0 |
| etoposide phosphate | 0 | low | 1 | 0 |
| vorozole | 0 | low | 1 | 0 |
| perfosfamide | 0 | low | 1 | 0 |
| d-phenylalanyl-cysteinyl-tyrosyl-tryptophyl-lysyl-cysteinyl-threoninamide | 0 | low | 1 | 0 |
| combretastatin a-4 disodium phosphate | 0 | low | 1 | 0 |
| vilazodone hydrochloride | 0 | low | 1 | 0 |
| cvt 313 | 0 | low | 1 | 0 |
| beta-elemene | 0 | low | 3 | 0 |
| brostallicin | 0 | low | 1 | 0 |
| pd 184352 | 0 | low | 1 | 0 |
| jwh-133 | 0 | low | 1 | 0 |
| vildagliptin | 0 | low | 2 | 0 |
| hti-286 | 0 | low | 1 | 0 |
| on 01910 | 0 | low | 2 | 0 |
| corosolic acid | 0 | low | 7 | 0 |
| 5-((4-prop-2-ynylpiperazin-1-yl)methyl)quinolin-8-ol | 0 | low | 1 | 0 |
| isoborneol | 0 | low | 2 | 0 |
| bromopyruvate | 0 | low | 21 | 0 |
| staurosporine | 0 | low | 36 | 0 |
| bufalin | 0 | low | 25 | 0 |
| shu 508 | 0 | medium | 84 | 13 |
| hypericum | 0 | low | 3 | 0 |
| phosphocreatine | 0 | low | 1 | 0 |
| guaiane | 0 | low | 1 | 0 |
| cholanic acid | 0 | low | 1 | 0 |
| mannich bases | 0 | low | 1 | 0 |
| formazans | 0 | low | 16 | 0 |
| gs-7340 | 0 | low | 10 | 0 |
| triacsin c | 0 | low | 5 | 0 |
| triacsin d | 0 | low | 1 | 0 |
| sabcomeline | 0 | low | 1 | 0 |
| vacuolin-1 | 0 | low | 1 | 0 |
| s-allylcysteine | 0 | low | 3 | 0 |
| s-allylmercaptocysteine | 0 | low | 1 | 0 |
| clasto-lactacystin beta-lactone | 0 | low | 2 | 0 |
| iniparib | 0 | low | 1 | 0 |
| am 555s | 0 | medium | 5 | 2 |
| gw 501516 | 0 | low | 3 | 0 |
| amoxicillin-potassium clavulanate combination | 0 | low | 2 | 0 |
| dolastatin 10 | 0 | medium | 1 | 1 |
| 6-methylsulfinylhexyl isothiocyanate | 0 | low | 1 | 0 |
| 6-(7-nitro-2,1,3-benzoxadiazol-4-ylthio)hexanol | 0 | low | 1 | 0 |
| bicyclol | 0 | low | 4 | 0 |
| ono 8711 | 0 | low | 2 | 0 |
| andarine | 0 | low | 1 | 0 |
| pd 0325901 | 0 | low | 2 | 0 |
| midostaurin | 0 | low | 2 | 0 |
| pd 176252 | 0 | low | 1 | 0 |
| jasplakinolide | 0 | low | 1 | 0 |
| sincalide | 0 | low | 13 | 0 |
| racivir | 0 | low | 1 | 0 |
| tapentadol | 0 | low | 1 | 0 |
| technetium tc 99m diphosphonate | 0 | low | 1 | 0 |
| reparixin | 0 | low | 1 | 0 |
| etomoxir | 0 | low | 4 | 0 |
| n(6)-cyclohexyladenosine | 0 | low | 3 | 0 |
| cp 91149 | 0 | low | 1 | 0 |
| gallium maltolate | 0 | low | 1 | 0 |
| pr-104a | 0 | low | 1 | 0 |
| ursodoxicoltaurine | 0 | low | 5 | 0 |
| ginsenoside m1 | 0 | low | 10 | 0 |
| gambogic acid | 0 | low | 14 | 0 |
| 4-anisyltetrazolium blue | 0 | low | 1 | 0 |
| conophylline | 0 | low | 1 | 0 |
| flag peptide | 0 | low | 1 | 0 |
| kla peptide | 0 | low | 1 | 0 |
| nu 7026 | 0 | low | 1 | 0 |
| gc 1 compound | 0 | low | 3 | 0 |
| agn 194204 | 0 | low | 1 | 0 |
| mocetinostat | 0 | medium | 19 | 1 |
| sc 236 | 0 | low | 1 | 0 |
| alloin | 0 | low | 1 | 0 |
| practolol | 0 | low | 1 | 0 |
| carbobenzoxy-leucyl-leucyl-norvalinal | 0 | low | 3 | 0 |
| k 7174 | 0 | low | 1 | 0 |
| bleomycin a6 | 0 | low | 3 | 0 |
| lipid a | 0 | low | 3 | 0 |
| 4-methylene-2-octyl-5-oxofuran-3-carboxylic acid | 0 | low | 3 | 0 |
| dehydroxymethylepoxyquinomicin | 0 | low | 5 | 0 |
| pi103 | 0 | low | 6 | 0 |
| 3,5-bis(2-fluorobenzylidene)piperidin-4-one | 0 | low | 4 | 0 |
| ru24858 | 0 | low | 1 | 0 |
| dapagliflozin | 0 | medium | 3 | 1 |
| mk 386 | 0 | low | 1 | 0 |
| xestospongin a | 0 | low | 1 | 0 |
| gw 4064 | 0 | low | 8 | 0 |
| mart-1 antigen | 0 | low | 4 | 0 |
| ginsenoside rb1 | 0 | low | 1 | 0 |
| g(m2) ganglioside | 0 | low | 3 | 0 |
| gentamicin sulfate | 0 | low | 1 | 0 |
| plomestane | 0 | low | 1 | 0 |
| ginsenoside f2 | 0 | low | 1 | 0 |
| ginsenoside rg3 | 0 | medium | 14 | 1 |
| sorbitan monooleate | 0 | medium | 2 | 2 |
| bibr 1532 | 0 | low | 1 | 0 |
| tocotrienols | 0 | low | 6 | 0 |
| rucaparib | 0 | low | 1 | 0 |
| vulm 1457 | 0 | low | 1 | 0 |
| cediranib | 0 | medium | 4 | 2 |
| tae226 | 0 | low | 1 | 0 |
| pd 184161 | 0 | low | 2 | 0 |
| pasireotide | 0 | medium | 3 | 1 |
| zeolites | 0 | medium | 3 | 1 |
| pitolisant | 0 | medium | 2 | 2 |
| 3,4-dihydro-5-(4-(1-piperidinyl)butoxy)-1(2h)-isoquinolinone | 0 | low | 1 | 0 |
| npi 2358 | 0 | low | 1 | 0 |
| cp 31398 | 0 | low | 2 | 0 |
| tetramethylrhodamine | 0 | low | 1 | 0 |
| u 18666a | 0 | low | 8 | 0 |
| 1-(3,4-dimethoxyphenethyl)-4-(3-phenylpropyl)piperazine dihydrochloride | 0 | low | 1 | 0 |
| aq4n | 0 | low | 1 | 0 |
| pd 198306 | 0 | low | 1 | 0 |
| ubiquinol | 0 | low | 4 | 0 |
| g(m1) ganglioside | 0 | low | 9 | 0 |
| ganu | 0 | low | 1 | 0 |
| sr 11302 | 0 | low | 1 | 0 |
| aluminum oxide | 0 | medium | 1 | 1 |
| isojacareubin | 0 | low | 1 | 0 |
| cgp 20712a | 0 | low | 1 | 0 |
| way-362450 | 0 | low | 1 | 0 |
| osu 03012 | 0 | low | 1 | 0 |
| actein | 0 | low | 1 | 0 |
| cholest-8(14)-en-3-ol-15-one | 0 | low | 1 | 0 |
| methionine sulfoxide | 0 | low | 1 | 0 |
| isopanduratin a | 0 | low | 1 | 0 |
| metapristone | 0 | low | 1 | 0 |
| methyl 3,5-di-o-caffeoyl quinate | 0 | low | 1 | 0 |
| baicalein-7-o-diglucoside | 0 | low | 1 | 0 |
| eclalbasaponin i | 0 | low | 1 | 0 |
| hispolon | 0 | low | 2 | 0 |
| avenanthramide b | 0 | low | 1 | 0 |
| givinostat hydrochloride | 0 | low | 3 | 0 |
| linagliptin | 0 | low | 1 | 0 |
| 2-methoxyjuglone | 0 | low | 1 | 0 |
| cystathionine | 0 | low | 5 | 0 |
| sepantronium | 0 | low | 3 | 0 |
| cuprous sulfide | 0 | low | 2 | 0 |
| betulin-3-caffeate | 0 | low | 1 | 0 |
| n-acetylcysteinamide | 0 | low | 1 | 0 |
| dimethylarginine | 0 | low | 1 | 0 |
| apixaban | 0 | low | 2 | 0 |
| bibw 2992 | 0 | low | 2 | 0 |
| gw 799388 | 0 | low | 1 | 0 |
| artenimol | 0 | low | 15 | 0 |
| jte 013 | 0 | low | 1 | 0 |
| papuamine | 0 | low | 1 | 0 |
| trans-sodium crocetinate | 0 | low | 1 | 0 |
| aee 788 | 0 | low | 2 | 0 |
| garcinone e | 0 | low | 1 | 0 |
| saracatinib | 0 | low | 3 | 0 |
| alpha-synuclein | 0 | low | 2 | 0 |
| haliclonadiamine | 0 | low | 1 | 0 |
| demethylzeylasteral | 0 | low | 1 | 0 |
| nymphaeol c | 0 | low | 1 | 0 |
| thonningianin a | 0 | low | 1 | 0 |
| 7-aminoactinomycin d | 0 | low | 1 | 0 |
| ccx282-b | 0 | low | 1 | 0 |
| ngr peptide | 0 | medium | 4 | 1 |
| crenolanib | 0 | low | 1 | 0 |
| azd3965 | 0 | low | 1 | 0 |
| 15-acetyldeoxynivalenol | 0 | low | 1 | 0 |
| (1,2-bis(1,2-benzisoselenazolone-3(2h)-ketone))ethane | 0 | low | 1 | 0 |
| cgs 24012 | 0 | low | 1 | 0 |
| 2-furoyl-ligrlo-amide | 0 | low | 1 | 0 |
| alpha-cadinol | 0 | low | 1 | 0 |
| erinacine a | 0 | low | 1 | 0 |
| 2',4'-dihydroxy-6'-methoxy-3',5'-dimethylchalcone | 0 | low | 3 | 0 |
| cay 10404 | 0 | low | 1 | 0 |
| homatropine methylbromide | 0 | low | 1 | 0 |
| manassantin b | 0 | low | 1 | 0 |
| volasertib | 0 | low | 2 | 0 |
| 2'-benzoyloxycinnamaldehyde | 0 | low | 1 | 0 |
| glaucocalyxin a | 0 | low | 1 | 0 |
| 3-dihydroxy-6-methyl-7-(phenylmethyl)-4-propylnaphthalene-1-carboxylic acid | 0 | low | 1 | 0 |
| oxadiazoles | 0 | low | 13 | 0 |
| homocamptothecin | 0 | low | 2 | 0 |
| cytosporone b | 0 | low | 1 | 0 |
| aloperine | 0 | low | 1 | 0 |
| 1,7-bis(4-hydroxy-3-methoxyphenyl)-1,4,6-heptatrien-3-one | 0 | low | 2 | 0 |
| trienomycin a | 0 | low | 1 | 0 |
| ucn 1028 c | 0 | low | 4 | 0 |
| 5-methoxy-8,8-dimethyl-2-phenyl-4H,8H-pyrano[2,3-h]chromen-4-one | 0 | low | 1 | 0 |
| ribose | 0 | low | 13 | 0 |
| 5-formylcytosine | 0 | low | 2 | 0 |
| acebutolol | 0 | medium | 4 | 1 |
| lactulose | 0 | medium | 8 | 1 |
| phakellistatin 13 | 0 | low | 1 | 0 |
| cyclic diadenosine phosphate | 0 | low | 1 | 0 |
| acetyl-11-ketoboswellic acid | 0 | low | 2 | 0 |
| wp1066 | 0 | low | 1 | 0 |
| erastin | 0 | low | 9 | 0 |
| degrasyn | 0 | low | 1 | 0 |
| epoxomicin | 0 | low | 3 | 0 |
| abt-737 | 0 | low | 11 | 0 |
| brimonidine tartrate | 0 | low | 1 | 0 |
| procyanidin b1 | 0 | low | 1 | 0 |
| ascochlorin | 0 | low | 2 | 0 |
| nystatin a1 | 0 | low | 2 | 0 |
| withanolide a | 0 | low | 1 | 0 |
| nu 7441 | 0 | low | 3 | 0 |
| bms-690514 | 0 | low | 1 | 0 |
| cyt997 | 0 | low | 1 | 0 |
| bi 2536 | 0 | low | 3 | 0 |
| karwinskia toxin t-514 | 0 | low | 1 | 0 |
| mitoquinone | 0 | low | 1 | 0 |
| sodium selenosulfate | 0 | low | 2 | 0 |
| Dihydrotanshinone I | 0 | low | 5 | 0 |
| technetium tc 99m disofenin | 0 | low | 13 | 0 |
| technetium tc 99m mebrofenin | 0 | low | 5 | 0 |
| nutlin-3a | 0 | low | 11 | 0 |
| danusertib | 0 | low | 3 | 0 |
| alogliptin | 0 | low | 1 | 0 |
| pr-104 | 0 | medium | 1 | 1 |
| nvp-aew541 | 0 | low | 3 | 0 |
| irc-110160 | 0 | low | 1 | 0 |
| 5-(2,2-difluorobenzo(1,3)dioxol-5-ylmethylene)thiazolidine-2,4-dione | 0 | low | 1 | 0 |
| ginsenoside rk1 | 0 | low | 3 | 0 |
| dorsomorphin | 0 | low | 1 | 0 |
| quisinostat | 0 | low | 1 | 0 |
| ro 31-8425 | 0 | low | 1 | 0 |
| 2,5-dimethylcelecoxib | 0 | low | 3 | 0 |
| carfilzomib | 0 | medium | 4 | 1 |
| sitagliptin phosphate | 0 | low | 4 | 0 |
| gw 2580 | 0 | low | 1 | 0 |
| idelalisib | 0 | low | 3 | 0 |
| crizotinib | 0 | low | 4 | 0 |
| zstk474 | 0 | low | 1 | 0 |
| 2,4,3',5'-tetrahydroxystilbene | 0 | low | 2 | 0 |
| ly2109761 | 0 | low | 7 | 0 |
| ginsenoside rd | 0 | low | 1 | 0 |
| pf-562,271 | 0 | low | 1 | 0 |
| pha 767491 | 0 | low | 1 | 0 |
| sauchinone | 0 | low | 1 | 0 |
| losartan potassium | 0 | medium | 136 | 2 |
| excisanin a | 0 | low | 1 | 0 |
| guluronic acid | 0 | low | 1 | 0 |
| alpha-Neup5Ac-(2->3)-beta-D-Galp-(1->4)-[alpha-L-Fucp-(1->3)]-D-GlcpNAc | 0 | low | 18 | 0 |
| 2-(n-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino)-2-deoxyglucose | 0 | low | 1 | 0 |
| empagliflozin | 0 | medium | 2 | 1 |
| moxestrol | 0 | low | 4 | 0 |
| technetium tc 99m exametazime | 0 | low | 2 | 0 |
| calcimycin | 0 | low | 11 | 0 |
| dextrothyroxine | 0 | low | 2 | 0 |
| delta-1-pyrroline-5-carboxylate | 0 | low | 1 | 0 |
| sepharose | 0 | low | 15 | 0 |
| indocyanine green | 0 | medium | 240 | 6 |
| scopolamine hydrobromide | 0 | low | 1 | 0 |
| cinobufagin | 0 | low | 11 | 0 |
| dactolisib | 0 | low | 9 | 0 |
| pituitrin | 0 | low | 8 | 0 |
| podophyllin | 0 | low | 3 | 0 |
| th 302 | 0 | low | 1 | 0 |
| n-monoacetylcystine | 0 | low | 1 | 0 |
| arabinofuranosyluracil | 0 | low | 8 | 0 |
| demethylcantharidin | 0 | low | 5 | 0 |
| bufotalin | 0 | low | 2 | 0 |
| phytosterols | 0 | low | 7 | 0 |
| arenobufagin | 0 | low | 4 | 0 |
| glycoursodeoxycholic acid | 0 | low | 1 | 0 |
| grandiflorenic acid | 0 | low | 1 | 0 |
| dihydrotachysterol | 0 | low | 2 | 0 |
| tirucallane | 0 | low | 1 | 0 |
| oplodiol | 0 | low | 1 | 0 |
| rifamycins | 0 | low | 2 | 0 |
| silidianin | 0 | low | 1 | 0 |
| soyasapogenol a | 0 | low | 1 | 0 |
| eudesmanolide | 0 | low | 2 | 0 |
| clove | 0 | low | 7 | 0 |
| acid phosphatase | 0 | low | 66 | 0 |
| esorubicin | 0 | medium | 1 | 1 |
| mefloquine | 0 | low | 1 | 0 |
| 3-aminobenzanthrone | 0 | low | 1 | 0 |
| aminoethyl-isothiourea | 0 | low | 1 | 0 |
| bleomycetin | 0 | low | 1 | 0 |
| 1-arabinofuranosylcytosine-5'-stearylphosphate | 0 | medium | 2 | 2 |
| medicagenic acid-3-o-glucopyranoside | 0 | low | 1 | 0 |
| 4-amino-1-(3,4-dihydroxy-5-(hydroxymethyl)-3-methyltetrahydrofuran-2-yl)pyrimidin-2(1h)-one | 0 | low | 1 | 0 |
| aflatoxin g1 | 0 | low | 2 | 0 |
| chikusetsu saponin iva | 0 | low | 1 | 0 |
| bisdesmoside | 0 | low | 1 | 0 |
| astragaloside ii | 0 | low | 2 | 0 |
| alisol b monoacetate | 0 | low | 1 | 0 |
| lucidenic acid a | 0 | low | 1 | 0 |
| riccardin d | 0 | low | 1 | 0 |
| nodularin | 0 | low | 2 | 0 |
| 3-methylcytidine | 0 | low | 1 | 0 |
| curcumol | 0 | medium | 4 | 1 |
| butaprost | 0 | low | 1 | 0 |
| peonidin 3-glucoside | 0 | low | 2 | 0 |
| periplocin | 0 | low | 1 | 0 |
| britannin | 0 | low | 1 | 0 |
| hypocrellin a | 0 | low | 1 | 0 |
| lyoniside | 0 | low | 3 | 0 |
| oroxylin a-7-o-glucuronide | 0 | low | 1 | 0 |
| icatibant | 0 | low | 1 | 0 |
| obtusallene | 0 | low | 1 | 0 |
| 6-methoxydihydrosanguinarine | 0 | low | 1 | 0 |
| jaw | 0 | low | 1 | 0 |
| adenanthin | 0 | low | 2 | 0 |
| ankaflavin | 0 | low | 1 | 0 |
| aflatoxin m1 | 0 | low | 7 | 0 |
| cyanidin-3-o-beta-glucopyranoside | 0 | low | 2 | 0 |
| vibsanin b | 0 | low | 1 | 0 |
| nad | 0 | medium | 70 | 3 |
| dianhydrogalactitol | 0 | low | 2 | 0 |
| n-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide | 0 | medium | 6 | 2 |
| macitentan | 0 | low | 1 | 0 |
| toceranib phosphate | 0 | low | 1 | 0 |
| cytochrome c-t | 0 | low | 137 | 0 |
| bms-650032 | 0 | low | 9 | 0 |
| gw 4869 | 0 | low | 1 | 0 |
| rg 7128 | 0 | low | 1 | 0 |
| melitten | 0 | low | 21 | 0 |
| cholecystokinin | 0 | low | 2 | 0 |
| ceruletide | 0 | low | 2 | 0 |
| atrial natriuretic factor | 0 | low | 7 | 0 |
| tachyplesin peptide, tachypleus tridentatus | 0 | low | 3 | 0 |
| tannins | 0 | medium | 1 | 1 |
| cecropin b protein, insecta | 0 | low | 3 | 0 |
| (dtpa-phe(1))-octreotide | 0 | low | 2 | 0 |
| rpl41 protein, human | 0 | low | 1 | 0 |
| hes1 protein, human | 0 | low | 13 | 0 |
| glycoprotein e2, hepatitis c virus | 0 | low | 27 | 0 |
| nociceptin | 0 | low | 3 | 0 |
| alamethicin | 0 | low | 2 | 0 |
| protein kinase inhibitor peptide | 0 | low | 1 | 0 |
| galanin (1-13)-spantide amide | 0 | low | 1 | 0 |
| gastrins | 0 | low | 4 | 0 |
| gramicidin a | 0 | low | 1 | 0 |
| glucagon | 0 | medium | 73 | 3 |
| beta-endorphin | 0 | low | 2 | 0 |
| emerimicins | 0 | low | 1 | 0 |
| thymosin beta(4) | 0 | low | 2 | 0 |
| ceca1 protein, drosophila | 0 | low | 1 | 0 |
| neuropeptide y | 0 | low | 3 | 0 |
| pancreastatin | 0 | low | 3 | 0 |
| lactoferricin b | 0 | low | 1 | 0 |
| angiotensinogen | 0 | low | 26 | 0 |
| cortistatin 14 | 0 | low | 1 | 0 |
| tannins | 0 | medium | 16 | 2 |
| oligonucleotides | 0 | medium | 72 | 1 |
| liraglutide | 0 | low | 3 | 0 |
| glucagon-like peptide 1 | 0 | low | 5 | 0 |
| th9507 | 0 | medium | 1 | 1 |
| incretins | 0 | low | 2 | 0 |
| c-peptide | 0 | low | 8 | 0 |
| natriuretic peptide, c-type | 0 | low | 1 | 0 |
| an 207 | 0 | low | 1 | 0 |
| pr 39 | 0 | low | 2 | 0 |
| eriocalyxin b | 0 | low | 1 | 0 |
| tbe 31 | 0 | low | 1 | 0 |
| cellulose | 0 | medium | 36 | 3 |
| endothelin-1 | 0 | medium | 10 | 2 |
| phosphatidylcholines | 0 | medium | 77 | 1 |
| guttiferone k | 0 | low | 1 | 0 |
| barium ferrite | 0 | low | 1 | 0 |
| diethylumbelliferyl phosphate | 0 | low | 2 | 0 |
| n-(7-(4-nitrobenzo-2-oxa-1,3-diazole))-6-aminocaproyl sphingosine | 0 | low | 2 | 0 |
| gdc-0973 | 0 | low | 1 | 0 |
| buparlisib | 0 | low | 4 | 0 |
| chlorophyll a | 0 | low | 13 | 0 |
| archazolid a | 0 | low | 1 | 0 |
| phenylmercuric acetate | 0 | low | 1 | 0 |
| 4-aminophenylmercuriacetate | 0 | low | 1 | 0 |
| snwo4 | 0 | low | 1 | 0 |
| tg101209 | 0 | low | 1 | 0 |
| cay10566 | 0 | low | 1 | 0 |
| ku 0063794 | 0 | low | 2 | 0 |
| dihydroceramide | 0 | low | 2 | 0 |
| pravastatin sodium | 0 | low | 1 | 0 |
| didymin | 0 | low | 1 | 0 |
| adenosine kinase | 0 | low | 2 | 0 |
| xu 62-320 | 0 | low | 2 | 0 |
| hoe 33342 | 0 | low | 2 | 0 |
| jsh 23 | 0 | low | 1 | 0 |
| sodium salicylate | 0 | low | 3 | 0 |
| sphingosine kinase | 0 | low | 17 | 0 |
| ubiquinone | 0 | medium | 22 | 1 |
| pinoresinol | 0 | low | 1 | 0 |
| gdc 0941 | 0 | low | 1 | 0 |
| sm 164 | 0 | low | 1 | 0 |
| cilastatin, imipenem drug combination | 0 | low | 1 | 0 |
| rhenium(v)dimercaptosuccinic acid | 0 | low | 1 | 0 |
| calpain | 0 | low | 31 | 0 |
| 4,1-benzoxazepine | 0 | low | 1 | 0 |
| tetronic 701 | 0 | low | 1 | 0 |
| cholesteryl ester hydroperoxide | 0 | low | 1 | 0 |
| lucifer yellow | 0 | low | 3 | 0 |
| tetracosapentaenoic acid | 0 | low | 1 | 0 |
| non-ovlon | 0 | low | 1 | 0 |
| sapogenins | 0 | low | 9 | 0 |
| asparanin a | 0 | low | 1 | 0 |
| drupacine | 0 | low | 1 | 0 |
| lucidenic acid n | 0 | low | 2 | 0 |
| cathestatin b | 0 | low | 1 | 0 |
| ginsenoside rh4 | 0 | low | 1 | 0 |
| caudatin | 0 | low | 2 | 0 |
| scalaradial | 0 | low | 1 | 0 |
| ilexgenin a | 0 | low | 1 | 0 |
| 23-hydroxybetulinic acid | 0 | low | 5 | 0 |
| 13-acetoxysarcocrassolide | 0 | low | 3 | 0 |
| monanchorin | 0 | low | 1 | 0 |
| biotinyltyramide | 0 | low | 2 | 0 |
| menotropins | 0 | low | 1 | 0 |
| chitosan | 0 | medium | 131 | 4 |
| technetium tc 99m sestamibi | 0 | medium | 10 | 1 |
| 15-deoxyprostaglandin j2 | 0 | low | 2 | 0 |
| s-nitro-n-acetylpenicillamine | 0 | low | 4 | 0 |
| kx-01 | 0 | low | 1 | 0 |
| bucladesine | 0 | low | 54 | 0 |
| osteum | 0 | low | 1 | 0 |
| sodium bisulfite | 0 | low | 4 | 0 |
| sodium tetradecyl sulfate | 0 | medium | 1 | 1 |
| bmy 21950 | 0 | low | 1 | 0 |
| urografin 76 | 0 | low | 1 | 0 |
| sodium nitrite | 0 | low | 6 | 0 |
| amphotericin b, deoxycholate drug combination | 0 | low | 1 | 0 |
| stearates | 0 | low | 2 | 0 |
| sodium glutamate | 0 | low | 1 | 0 |
| ro13-9904 | 0 | medium | 3 | 1 |
| sodium pertechnetate tc 99m | 0 | medium | 10 | 1 |
| sodium ethylxanthate | 0 | low | 9 | 0 |
| chiniofon | 0 | low | 9 | 0 |
| arginine | 0 | medium | 6 | 1 |
| gadofosveset trisodium | 0 | low | 1 | 0 |
| olaparib | 0 | low | 6 | 0 |
| thiostrepton | 0 | low | 2 | 0 |
| hygromycin b | 0 | low | 5 | 0 |
| gelsemine | 0 | low | 1 | 0 |
| n-trans-feruloyloctopamine | 0 | low | 2 | 0 |
| plx 4720 | 0 | low | 1 | 0 |
| methyl jasmonate | 0 | low | 4 | 0 |
| lcl161 | 0 | low | 4 | 0 |
| pci 34051 | 0 | low | 1 | 0 |
| phosphatidylinositol 4-phosphate | 0 | low | 1 | 0 |
| s-adenosylmethionine | 0 | low | 61 | 0 |
| mk-7009 | 0 | low | 1 | 0 |
| mln 8237 | 0 | low | 4 | 0 |
| snx 2112 | 0 | low | 1 | 0 |
| nsc 177223 | 0 | low | 1 | 0 |
| gdc 0449 | 0 | low | 5 | 0 |
| gdc-0068 | 0 | low | 1 | 0 |
| sgi 1776 | 0 | low | 1 | 0 |
| st2825 | 0 | low | 1 | 0 |
| canagliflozin | 0 | low | 8 | 0 |
| pci 32765 | 0 | low | 2 | 0 |
| madecassoside | 0 | low | 1 | 0 |
| ponatinib | 0 | low | 2 | 0 |
| ethyl cellulose | 0 | low | 2 | 0 |
| arabinogalactan | 0 | low | 4 | 0 |
| intrinsic factor | 0 | low | 2 | 0 |
| mk-1775 | 0 | low | 2 | 0 |
| tak-875 | 0 | low | 1 | 0 |
| oxymatrine | 0 | low | 3 | 0 |
| antroquinonol d | 0 | low | 1 | 0 |
| dolichol monophosphate | 0 | low | 3 | 0 |
| PP121 | 0 | low | 1 | 0 |
| niraparib | 0 | medium | 2 | 1 |
| navitoclax | 0 | low | 7 | 0 |
| pervanadate | 0 | low | 1 | 0 |
| sns 314 | 0 | low | 1 | 0 |
| jzl 184 | 0 | low | 1 | 0 |
| 4,4-difluoro-4-bora-3a,4a-diaza-s-indacene | 0 | low | 4 | 0 |
| quetiapine fumarate | 0 | low | 3 | 0 |
| chlorin e4 | 0 | low | 2 | 0 |
| cardiovascular agents | 0 | low | 4 | 0 |
| pnd 1186 | 0 | low | 1 | 0 |
| trelstar | 0 | medium | 4 | 2 |
| neurotensin | 0 | low | 15 | 0 |
| peptide 31d | 0 | low | 1 | 0 |
| lhrh, n-ac-(4-cl-phe)(1)-(4-clphe)(2)-(3-benzo(b)thi-ala)(3)-lys(6)-alanh2(10)- | 0 | low | 1 | 0 |
| defactinib | 0 | low | 1 | 0 |
| incb-018424 | 0 | low | 4 | 0 |
| mannans | 0 | low | 8 | 0 |
| pexidartinib | 0 | low | 4 | 0 |
| bms-790052 | 0 | low | 22 | 0 |
| gsk 2126458 | 0 | low | 1 | 0 |
| gsk 1838705a | 0 | low | 1 | 0 |
| ixazomib | 0 | low | 1 | 0 |
| (1-(4-(naphthalen-2-yl)pyrimidin-2-yl)piperidin-4-yl)methanamine | 0 | low | 1 | 0 |
| (2-phenylthiazol-4-yl)-(3,4,5-trimethoxyphenyl)methanone | 0 | low | 1 | 0 |
| azd2014 | 0 | low | 2 | 0 |
| mahanine | 0 | low | 1 | 0 |
| 9r-(9alpha(z),10alpha) of 3'-angeloyloxy-4'-acetoxy-3',4'-dihydroseselin | 0 | low | 1 | 0 |
| 4'-geranyloxyferulic acid | 0 | low | 1 | 0 |
| lysophosphatidylserine | 0 | low | 1 | 0 |
| plx4032 | 0 | medium | 2 | 1 |
| 2,3-bis(2-hydroxyethylsulfanyl)-(1,4)naphthoquinone | 0 | low | 1 | 0 |
| triiodothyronine, reverse | 0 | low | 4 | 0 |
| urushiol | 0 | low | 1 | 0 |
| 2-cyano-3,12-dioxooleana-1,9(11)-dien-28-oic acid ethyl amide | 0 | low | 1 | 0 |
| glycolipids | 0 | medium | 74 | 2 |
| pki 402 | 0 | low | 1 | 0 |
| elafin | 0 | low | 4 | 0 |
| piperidines | 0 | medium | 68 | 8 |
| resolvin d1 | 0 | low | 1 | 0 |
| bryostatin 1 | 0 | low | 1 | 0 |
| thymosin | 0 | medium | 18 | 4 |
| manassantin a | 0 | low | 1 | 0 |
| interleukin-8 | 0 | medium | 126 | 8 |
| anagliptin | 0 | low | 2 | 0 |
| pki 587 | 0 | low | 3 | 0 |
| cblc137 | 0 | low | 3 | 0 |
| sd 1029 | 0 | low | 1 | 0 |
| salpichrolide g | 0 | low | 1 | 0 |
| kurarinol | 0 | low | 1 | 0 |
| avicin d | 0 | low | 1 | 0 |
| hamamelitannin | 0 | low | 1 | 0 |
| kahalalide f | 0 | low | 1 | 0 |
| saquayamycin b | 0 | low | 1 | 0 |
| leachianone a | 0 | low | 1 | 0 |
| streptochlorin | 0 | low | 1 | 0 |
| isosilybin | 0 | low | 1 | 0 |
| 4-fluoroglutamine | 0 | low | 1 | 0 |
| lb-100 | 0 | low | 2 | 0 |
| abt-450 | 0 | medium | 10 | 1 |
| scutebarbatine a | 0 | low | 1 | 0 |
| formylchromone | 0 | low | 1 | 0 |
| gx 15-070 | 0 | low | 3 | 0 |
| colistin | 0 | medium | 1 | 1 |
| fosinopril | 0 | low | 1 | 0 |
| sofosbuvir | 0 | medium | 69 | 5 |
| exenatide | 0 | medium | 2 | 1 |
| aplysiatoxin | 0 | low | 1 | 0 |
| 14-o-phosphonooxymethyltriptolide | 0 | low | 1 | 0 |
| pf 3084014 | 0 | low | 2 | 0 |
| gypenoside ix | 0 | low | 1 | 0 |
| gsk923295 | 0 | low | 1 | 0 |
| vs-5584 | 0 | low | 1 | 0 |
| dinaciclib | 0 | low | 1 | 0 |
| diphthamide | 0 | low | 1 | 0 |
| fructose-1,6-diphosphate | 0 | low | 5 | 0 |
| gyy 4137 | 0 | low | 1 | 0 |
| ly2874455 | 0 | low | 2 | 0 |
| bix 01294 | 0 | low | 5 | 0 |
| technetium tc 99m gluceptate | 0 | low | 1 | 0 |
| calcipotriene | 0 | low | 2 | 0 |
| birinapant | 0 | low | 2 | 0 |
| lusutrombopag | 0 | medium | 5 | 1 |
| abt-199 | 0 | low | 1 | 0 |
| pracinostat | 0 | low | 1 | 0 |
| spautin-1 | 0 | low | 1 | 0 |
| azd4547 | 0 | low | 3 | 0 |
| methylcellulose | 0 | low | 4 | 0 |
| armillaridin | 0 | low | 1 | 0 |
| sphaeropsidin a | 0 | low | 1 | 0 |
| isoquercitrin | 0 | low | 2 | 0 |
| dimethylaminomicheliolide | 0 | low | 1 | 0 |
| coronarin d | 0 | low | 1 | 0 |
| osu-2s | 0 | low | 2 | 0 |
| 3-(2,6-dichloro-3,5-dimethoxyphenyl)-1-(6-(4-(4-ethylpiperazin-1-yl)-phenylamino)pyrimidin-4-yl)-1-methylurea | 0 | low | 7 | 0 |
| vasoactive intestinal peptide | 0 | low | 5 | 0 |
| phosphomannopentaose sulfate | 0 | medium | 5 | 2 |
| antcin k | 0 | low | 2 | 0 |
| natriuretic peptide, brain | 0 | low | 3 | 0 |
| ysk05 | 0 | low | 1 | 0 |
| heme | 0 | medium | 36 | 2 |
| antrocin | 0 | low | 1 | 0 |
| chondroitin | 0 | low | 14 | 0 |
| heparitin sulfate | 0 | low | 36 | 0 |
| cudc-907 | 0 | low | 1 | 0 |
| ascorbic acid | 0 | medium | 76 | 1 |
| novobiocin | 0 | low | 4 | 0 |
| tetracycline | 0 | low | 27 | 0 |
| chlortetracycline | 0 | low | 1 | 0 |
| oxytetracycline, anhydrous | 0 | low | 2 | 0 |
| minocycline | 0 | low | 4 | 0 |
| salicylates | 0 | low | 10 | 0 |
| dicumarol | 0 | low | 3 | 0 |
| acenocoumarol | 0 | medium | 1 | 1 |
| mobic | 0 | medium | 13 | 1 |
| warfarin | 0 | low | 79 | 0 |
| dihydroxyfumarate | 0 | low | 1 | 0 |
| bromfenacoum | 0 | low | 1 | 0 |
| phenprocoumon | 0 | low | 1 | 0 |
| tipranavir | 0 | low | 1 | 0 |
| 4-hydroxycoumarin | 0 | low | 1 | 0 |
| rolitetracycline | 0 | low | 1 | 0 |
| 2-o-octadecylascorbic acid | 0 | low | 1 | 0 |
| teriflunomide | 0 | low | 1 | 0 |
| 3-deazauridine | 0 | low | 1 | 0 |
| tigecycline | 0 | low | 4 | 0 |
| ilicicolin h | 0 | low | 2 | 0 |
| s 1 (combination) | 0 | medium | 43 | 6 |
| potassium ascorbyl tocopheryl phosphate | 0 | low | 1 | 0 |
| ew-7197 | 0 | low | 1 | 0 |
| abt-267 | 0 | medium | 10 | 1 |
| grn163 | 0 | low | 1 | 0 |
| abt-333 | 0 | medium | 10 | 1 |
| byl719 | 0 | medium | 2 | 1 |
| rgfp966 | 0 | low | 2 | 0 |
| n,n'-bis(pyridoxal-5-phosphate)ethylenediamine-n,n'-diacetic acid | 0 | medium | 25 | 13 |
| epidermal growth factor | 0 | medium | 197 | 1 |
| zhengguangmycin | 0 | low | 4 | 0 |
| microcystin | 0 | low | 2 | 0 |
| gastrin-releasing peptide | 0 | low | 2 | 0 |
| calca protein, human | 0 | low | 1 | 0 |
| clay | 0 | low | 3 | 0 |
| charybdotoxin | 0 | low | 1 | 0 |
| rhodostomin | 0 | low | 1 | 0 |
| transforming growth factor beta | 0 | medium | 554 | 4 |
| phytoestrogens | 0 | low | 12 | 0 |
| miravirsen | 0 | low | 1 | 0 |
| okadaic acid | 0 | low | 18 | 0 |
| methylglyoxal bis(cyclopentylamidinohydrazone) | 0 | low | 1 | 0 |
| ceritinib | 0 | low | 2 | 0 |
| sybr green i | 0 | low | 2 | 0 |
| cc-223 | 0 | low | 1 | 0 |
| rki-1447 | 0 | low | 1 | 0 |
| xl 888 | 0 | low | 1 | 0 |
| saroglitazar | 0 | low | 1 | 0 |
| pyrethrins | 0 | low | 1 | 0 |
| epz-6438 | 0 | low | 1 | 0 |
| gsk2879552 | 0 | low | 1 | 0 |
| millepachine | 0 | low | 3 | 0 |
| vo-ohpic | 0 | low | 1 | 0 |
| ledipasvir | 0 | low | 12 | 0 |
| gs-5816 | 0 | low | 8 | 0 |
| g007-lk | 0 | low | 2 | 0 |
| gsk-2816126 | 0 | low | 2 | 0 |
| 3-(6-isobutyl-9-methoxy-1,4-dioxo-1,2,3,4,6,7,12,12a-octahydropyrazino(1',2'-1,6)pyrido(3,4-b)indol-3-yl)propionic acid tert-butyl ester | 0 | low | 1 | 0 |
| n2-(1h-indazole-5-yl)-n6-methyl-3-nitropyridine-2,6-diamine | 0 | low | 1 | 0 |
| longikaurin a | 0 | low | 1 | 0 |
| ponicidin | 0 | low | 1 | 0 |
| ML355 | 0 | low | 1 | 0 |
| gsk343 | 0 | low | 1 | 0 |
| cucurbitane | 0 | low | 1 | 0 |
| kiss1 protein, human | 0 | low | 8 | 0 |
| timosaponin aiii | 0 | low | 3 | 0 |
| fti 277 | 0 | low | 1 | 0 |
| leu-ser-lys-leu peptide | 0 | low | 1 | 0 |
| rome | 0 | low | 5 | 0 |
| eupalinolide a | 0 | low | 2 | 0 |
| osimertinib | 0 | low | 1 | 0 |
| hunanamycin a | 0 | low | 1 | 0 |
| agar | 0 | low | 13 | 0 |
| arsenic trisulfide | 0 | low | 1 | 0 |
| meglumine ioglicinate | 0 | low | 1 | 0 |
| technetium tc 99m lidofenin | 0 | low | 14 | 0 |
| 3-(4-chlorophenyl)-adamantane-1-carboxylic acid (pyridin-4-ylmethyl)amide | 0 | low | 1 | 0 |
| 5-nitro-gamma-tocopherol | 0 | low | 1 | 0 |
| 1-[(1R)-1-(1-ethylsulfonyl-4-piperidinyl)ethyl]-N-[(4-methoxy-6-methyl-2-oxo-1H-pyridin-3-yl)methyl]-2-methyl-3-indolecarboxamide | 0 | low | 1 | 0 |
| gsk-j4 | 0 | low | 1 | 0 |
| ziyuglycoside ii | 0 | low | 1 | 0 |
| sar405 | 0 | low | 1 | 0 |
| hirudin | 0 | low | 2 | 0 |
| ephrin-a5 | 0 | low | 2 | 0 |
| imetelstat | 0 | low | 1 | 0 |
| glutaminase | 0 | low | 34 | 0 |
| ginsenoside rg5 | 0 | low | 1 | 0 |
| cyclin d1 | 0 | medium | 325 | 1 |
| ganoderic acid | 0 | low | 1 | 0 |
| onc201 | 0 | low | 1 | 0 |
| caseins | 0 | low | 17 | 0 |
| ckd732 | 0 | low | 1 | 0 |
| nattokinase | 0 | low | 1 | 0 |
| ginsenoside rk3 | 0 | low | 1 | 0 |
| technetium tc 99m sulfur colloid | 0 | low | 30 | 0 |
| azd3759 | 0 | low | 1 | 0 |
| oligomycins | 0 | low | 9 | 0 |
| ellagitannin | 0 | low | 1 | 0 |
| phthalocyanine | 0 | low | 4 | 0 |
| carubicin | 0 | low | 1 | 0 |
| g(m3) ganglioside | 0 | low | 5 | 0 |
| benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone | 0 | low | 28 | 0 |
| 2,3-dibromopropyl-2,4,6-tribromophenyl ether | 0 | low | 1 | 0 |
| nitrophenols | 0 | low | 29 | 0 |
| glaucarubin | 0 | low | 1 | 0 |
| brevinin-1 protein, rana | 0 | low | 1 | 0 |
| lewis x antigen | 0 | low | 13 | 0 |
| angiotensin i | 0 | low | 3 | 0 |
| ferric oxide, saccharated | 0 | low | 1 | 0 |
| contrast agent p792 | 0 | low | 1 | 0 |
| germacranolide | 0 | low | 1 | 0 |
| gadoxetic acid disodium | 0 | medium | 638 | 28 |
| cobamamide | 0 | low | 2 | 0 |
| hyaluronoglucosaminidase | 0 | low | 19 | 0 |
| adrenomedullin | 0 | low | 5 | 0 |
| mica | 0 | low | 1 | 0 |
| bacoside a | 0 | low | 1 | 0 |
| epoetin alfa | 0 | low | 1 | 0 |
| lipofectamine | 0 | low | 5 | 0 |
| trichokonin vi | 0 | low | 2 | 0 |
| diospyros | 0 | low | 4 | 0 |
| ginkgolide b | 0 | low | 2 | 0 |
| ginkgolide c | 0 | low | 1 | 0 |
| neferine | 0 | low | 3 | 0 |
| sodium aescinate | 0 | low | 1 | 0 |
| oridonin | 0 | low | 12 | 0 |
| ailanthone | 0 | low | 1 | 0 |
| chebulagic acid | 0 | low | 1 | 0 |
| ganoderic acid a | 0 | low | 1 | 0 |
| isomurisolenin | 0 | low | 1 | 0 |
| t-2 toxin | 0 | low | 3 | 0 |
| 4-acetylantroquinonol b | 0 | low | 2 | 0 |
| THZ531 | 0 | low | 1 | 0 |
| aldrin | 0 | low | 3 | 0 |
| ivalin | 0 | low | 1 | 0 |
| nonactin | 0 | low | 1 | 0 |
| 7-deoxynarciclasine | 0 | low | 1 | 0 |
| sanggenone c | 0 | low | 1 | 0 |
| peoniflorin | 0 | low | 4 | 0 |
| vitamin b 12 | 0 | medium | 40 | 1 |
| aconitine | 0 | low | 3 | 0 |
| ferric ammonium citrate | 0 | low | 4 | 0 |
| oblimersen | 0 | medium | 1 | 1 |
| norgestrel | 0 | low | 13 | 0 |
| transforming growth factor alpha | 0 | low | 98 | 0 |
| as 1411 | 0 | low | 2 | 0 |
| dehydrotomatine | 0 | low | 1 | 0 |
| psma-617 | 0 | low | 2 | 0 |
| insulin, 3-iodo-tyr(a14)- | 0 | low | 1 | 0 |
| cyclosporine | 0 | medium | 67 | 1 |
| flavin mononucleotide | 0 | low | 3 | 0 |
| tetrazanbigen | 0 | low | 3 | 0 |
| silybin | 0 | medium | 19 | 1 |
| triciribine | 0 | low | 2 | 0 |
| cytochalasin d | 0 | low | 10 | 0 |
| antipain | 0 | low | 1 | 0 |
| apicidin | 0 | low | 4 | 0 |
| peptide yy | 0 | low | 1 | 0 |
| siomycin a | 0 | low | 1 | 0 |
| lactoferrin | 0 | medium | 12 | 1 |
| danoprevir | 0 | low | 1 | 0 |
| digitonin | 0 | low | 12 | 0 |
| protopanaxadiol | 0 | low | 2 | 0 |
| catalpol | 0 | medium | 4 | 2 |
| peimisine | 0 | low | 1 | 0 |
| oxysophocarpine | 0 | low | 1 | 0 |
| edetic acid | 0 | low | 2 | 0 |
| icg 001 | 0 | low | 3 | 0 |
| neohesperidin | 0 | low | 1 | 0 |
| alpha-solanine | 0 | low | 2 | 0 |
| phenanthroindolizidine | 0 | low | 1 | 0 |
| 2,5-diaziridinyl-3-(hydroxymethyl)-6-methyl-1,4-benzoquinone | 0 | low | 1 | 0 |
| gallium ga 68 dotatate | 0 | low | 2 | 0 |
| orabase | 0 | low | 10 | 0 |
| technetium tc 99m medronate | 0 | medium | 30 | 1 |
| technetium tc-99m tetrofosmin | 0 | medium | 1 | 1 |
| apyrase | 0 | low | 7 | 0 |
| thromboplastin | 0 | low | 28 | 0 |
| muramidase | 0 | low | 11 | 0 |
| cord factors | 0 | low | 2 | 0 |
| chromomycins | 0 | low | 2 | 0 |
| nedaplatin | 0 | low | 3 | 0 |
| lewis y antigen | 0 | low | 3 | 0 |
| sc002 | 0 | low | 1 | 0 |
| amyloid beta-peptides | 0 | low | 1 | 0 |
| cyclooctatin | 0 | low | 1 | 0 |
| khasianine | 0 | low | 1 | 0 |
| chondroitin sulfates | 0 | low | 13 | 0 |
| iminoquinone | 0 | low | 1 | 0 |
| exudates | 0 | low | 31 | 0 |
| angiogenin | 0 | low | 12 | 0 |
| plicamycin | 0 | low | 3 | 0 |
| clivorine | 0 | low | 1 | 0 |
| protopanaxatriol | 0 | low | 1 | 0 |
| technetium tc 99m dimercaptosuccinic acid | 0 | low | 2 | 0 |
| fucosyl gm1 ganglioside | 0 | low | 2 | 0 |
| 68ga-dotanoc | 0 | low | 1 | 0 |
| akt-i-1,2 compound | 0 | low | 4 | 0 |
| acyclovir | 0 | low | 9 | 0 |
| osi 027 | 0 | low | 2 | 0 |
| levoleucovorin | 0 | medium | 84 | 22 |
| cyclic gmp | 0 | low | 44 | 0 |
| sepiapterin | 0 | low | 1 | 0 |
| deoxyguanosine | 0 | medium | 57 | 1 |
| guanosine diphosphate | 0 | low | 3 | 0 |
| guanosine diphosphate mannose | 0 | low | 2 | 0 |
| guanosine monophosphate | 0 | low | 3 | 0 |
| guanosine triphosphate | 0 | low | 17 | 0 |
| guanine | 0 | medium | 331 | 13 |
| guanosine | 0 | low | 23 | 0 |
| hypoxanthine | 0 | low | 8 | 0 |
| inosinic acid | 0 | low | 2 | 0 |
| inosine | 0 | medium | 11 | 1 |
| sapropterin | 0 | low | 4 | 0 |
| folic acid | 0 | medium | 83 | 1 |
| 3-methyladenine | 0 | low | 33 | 0 |
| cyclic imp | 0 | low | 1 | 0 |
| guanosine 5'-o-(3-thiotriphosphate) | 0 | medium | 6 | 1 |
| neopterin | 0 | medium | 10 | 1 |
| rifampin | 0 | medium | 26 | 1 |
| dacarbazine | 0 | medium | 8 | 1 |
| didanosine | 0 | low | 1 | 0 |
| penciclovir | 0 | low | 3 | 0 |
| raltitrexed | 0 | medium | 13 | 3 |
| nolatrexed | 0 | medium | 4 | 4 |
| ici 198583 | 0 | low | 1 | 0 |
| 8-azaxanthine | 0 | low | 1 | 0 |
| ro 3306 | 0 | low | 1 | 0 |
| 2-aminopurine dioxolane | 0 | low | 1 | 0 |
| inosine dialdehyde | 0 | low | 1 | 0 |
| allopurinol | 0 | low | 30 | 0 |
| n-(4(n-((2-amino-4-hydroxy-6-quinazolinyl)methyl)prop-2-ynylamino)benzoyl)-l-glutamic acid | 0 | low | 1 | 0 |
| 2,2'-(hydroxynitrosohydrazono)bis-ethanamine | 0 | low | 2 | 0 |
| azaguanine | 0 | low | 8 | 0 |
| guanylyl imidodiphosphate | 0 | low | 2 | 0 |
| mrs 2211 | 0 | low | 1 | 0 |
| diazeniumdiolate | 0 | low | 6 | 0 |
| 8-hydroxyguanosine | 0 | low | 1 | 0 |
| 2,4-diaminohypoxanthine | 0 | low | 1 | 0 |
| noc 18 | 0 | low | 1 | 0 |
| alanosine | 0 | low | 1 | 0 |
| 2-amino-4-hydroxy-6-formylpteridine | 0 | low | 1 | 0 |
| 9-((2-phosphonylmethoxy)ethyl)guanine | 0 | low | 1 | 0 |
| pyridoxal isonicotinoyl hydrazone | 0 | low | 1 | 0 |
| guanosine 5'-o-(2-thiodiphosphate) | 0 | low | 1 | 0 |
| pemetrexed | 0 | medium | 4 | 1 |
| cytarabine | 0 | low | 6 | 0 |
| lobucavir | 0 | low | 2 | 0 |
| sildenafil citrate | 0 | low | 2 | 0 |
| aprepitant | 0 | low | 3 | 0 |
| pyrazofurin | 0 | low | 2 | 0 |
| vardenafil dihydrochloride | 0 | low | 1 | 0 |
| azilsartan | 0 | low | 1 | 0 |
| xav939 | 0 | low | 4 | 0 |
| 8-bromocyclic gmp | 0 | low | 9 | 0 |
| 8-hydroxyguanine | 0 | medium | 5 | 1 |
| hesperadin | 0 | low | 1 | 0 |
| trypan blue | 0 | low | 21 | 0 |
| 2-azahypoxanthine | 0 | low | 1 | 0 |
| nintedanib | 0 | medium | 9 | 3 |
| lomofungin | 0 | low | 1 | 0 |
| heliomycin | 0 | low | 1 | 0 |
| 3'-fluoro-2',3'-dideoxyguanosine | 0 | low | 2 | 0 |
| methylnitronitrosoguanidine | 0 | low | 8 | 0 |
| 8-hydroxy-2'-deoxyguanosine | 0 | medium | 56 | 1 |
| bms 536924 | 0 | low | 1 | 0 |
| 7-methylguanosine | 0 | low | 1 | 0 |
| amg531 | 0 | low | 1 | 0 |
| prodigiosin | 0 | low | 3 | 0 |
| 8-methylguanosine | 0 | low | 3 | 0 |
| 8-nitroguanine | 0 | low | 1 | 0 |
| galloflavin | 0 | low | 1 | 0 |
| 5-methyltetrahydrofolate | 0 | low | 2 | 0 |
| n(7)-hydroxyethylguanine | 0 | low | 1 | 0 |
| 9-(4-fluoro-3-hydroxymethylbutyl)guanine | 0 | medium | 1 | 1 |
| hydrazinocurcumin | 0 | low | 3 | 0 |
| cytidylyl-3'-5'-guanosine | 0 | low | 6 | 0 |
| apogossypolone | 0 | low | 2 | 0 |
| ganciclovir triphosphate | 0 | low | 1 | 0 |
| alpha-(4-pyridyl-1-oxide)-n-tert-butylnitrone | 0 | low | 1 | 0 |
| 2,3-dihydro-2-(n(7)-guanyl)-3-hydroxyaflatoxin b1 | 0 | medium | 6 | 2 |
| heme arginate | 0 | low | 1 | 0 |
| bmn 673 | 0 | low | 1 | 0 |
| 7-methyl-2-deoxyguanosine | 0 | low | 1 | 0 |
| 2'-carbodeoxyguanosine | 0 | low | 1 | 0 |
| liproxstatin-1 | 0 | low | 1 | 0 |
| aflatoxin b1-formamidopyrimidine | 0 | low | 3 | 0 |
| brucine n-oxide | 0 | low | 3 | 0 |
| sp2509 | 0 | low | 1 | 0 |
| cyanine dye 3 | 0 | low | 4 | 0 |
| alcian blue | 0 | low | 1 | 0 |
| pitstop 2 | 0 | low | 2 | 0 |
| cycloprodigiosin | 0 | low | 1 | 0 |
| lipoteichoic acid | 0 | low | 4 | 0 |
| cholestyramine resin | 0 | low | 6 | 0 |
| eye | 0 | low | 2 | 0 |
| swinholide a | 0 | low | 1 | 0 |
| manganese-zinc ferrite | 0 | low | 4 | 0 |
| zinc(ii) phthalocyanine trisulfonic acid | 0 | low | 2 | 0 |
| chromomycin a3 | 0 | low | 1 | 0 |
| maltodextrin | 0 | low | 2 | 0 |
| acetylcellulose | 0 | medium | 3 | 2 |
| carbidopa | 0 | low | 1 | 0 |
| ganodermanontriol | 0 | low | 1 | 0 |
| curcumenol | 0 | low | 1 | 0 |
| chaetocin | 0 | low | 2 | 0 |
| ganoderic acid b | 0 | low | 1 | 0 |
| pseudolaric acid b | 0 | low | 4 | 0 |
| concanavalin a | 0 | medium | 104 | 1 |
| chlorotoxin | 0 | low | 1 | 0 |
| trypsinogen | 0 | low | 3 | 0 |
| metallothionein | 0 | low | 88 | 0 |
| antimony sodium gluconate | 0 | low | 1 | 0 |
| beta, beta-dimethylacrylshikonin | 0 | low | 1 | 0 |
| dinitrobenzenes | 0 | low | 6 | 0 |
| aluminum tetrasulfophthalocyanine | 0 | low | 1 | 0 |
| aluminum phthalocyanine disulfonate | 0 | low | 1 | 0 |
| 2',7'-bis(carboxyethyl)-5(6)-carboxyfluorescein | 0 | low | 2 | 0 |
| phosphorus radioisotopes | 0 | medium | 60 | 3 |
| 1,24-dihydroxyvitamin d2 | 0 | low | 1 | 0 |
| leptin | 0 | medium | 53 | 1 |
| pkh 26 | 0 | low | 1 | 0 |
| pyrimidinones | 0 | medium | 25 | 2 |
| destruxin b | 0 | low | 2 | 0 |
| sc-2001 | 0 | low | 5 | 0 |
| sinoporphyrin sodium | 0 | low | 1 | 0 |
| filipin | 0 | low | 2 | 0 |
| phenanthrenes | 0 | medium | 42 | 1 |
| sybr green ii | 0 | low | 1 | 0 |